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The opioid crisis is an ongoing serious public health challenge in the United States. 
Starting in the late 1990s, increases in prescriptions for opioid pharmaceuticals led to increases 
in nonmedical prescription opioid use and, in some cases, subsequent heroin use. These changes 
have had significant impacts on public health. Drug overdose mortality quadrupled between 
1999 and 2016 and increases in injection drug use have led to a rise in bloodborne viral 
infections. Improving substance use disorder treatment outcomes is a major public health 
priority; 40-60% treated for a substance use disorder relapse within a year of completing 
treatment. 
This dissertation explored three public health priorities related to the opioid crisis: injury, 
infection, and recovery. In chapter 2, we focused on injury prevention by examining overdose 
experiences, naloxone knowledge, attitudes towards overdose risk, and justice involvement 
among a sample of adults who used opioids in a justice diversion addiction treatment program in 
Michigan. We used latent class analysis to identify two general justice involvement patterns that 
occurred prior to treatment: the first was characterized by many recent arrests and little 
incarceration time, and the second involved incarceration prior to diversion. Only 56.2% of 
participants had heard of naloxone and identified it as an overdose treatment, yet 68.1% had 
experienced and 79.2% had witnessed an overdose. These results highlighted the universal need 
for overdose education and naloxone distribution in the justice diversion addiction treatment 
setting.  
 xv 
In chapter 3, we characterized the potential impact of interventions to combat the 
growing incidence of hepatitis C virus (HCV) infection among young people who inject drugs 
(PWID). We developed an age-stratified ordinary differential equation HCV transmission model 
fit to surveillance data from Michigan. We predicted that treating 10% of PWID per year in 
Michigan could reduce HCV cases by over half. Coupling HCV treatment with behavioral 
interventions could further reduce HCV incidence and prevalence. 
In chapter 4, we explored a potential new target for adjunctive treatments to promote 
recovery from opioid use disorders by examining how substance use impacts the gut microbiota. 
The gut microbiota is the community of living bacteria in the human gut. It is increasingly 
recognized as an important communicator along the gut-brain axis, the crosstalk pathways 
between the gut and brain, and may also modify psychopathology. We studied 46 patients 
receiving outpatient addiction treatment in Michigan who were exposed to opioid agonists 
(prescription opioids and heroin) and antagonists (naltrexone or naloxone). We found that opioid 
agonist exposure tended to decrease bacterial community diversity and was associated with 
lower abundance of Roseburia, a butyrate producer, and Bilophila, a microbe important in bile 
acid metabolism. We did not find these changes in participants who were concurrently or singly 
exposed to opioid antagonists. These findings were consistent with those from murine models of 
morphine exposure and highlighted directions for future work that further explores whether 
psycho-adjunctive treatments that promote gut health could improve opioid use disorder 
treatment outcomes. 
In chapter 5, I close by highlighting some of the lessons I learned through my dissertation 
work, and propose new research avenues within the areas of injury, infection, and recovery, that 
focus on mitigating the negative impacts of the opioid crisis on public health. 
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Chapter 1 Introduction 
 
This dissertation explores several public health challenges related to the opioid crisis, 
including injury prevention, bloodborne viral infections, and recovery. In this chapter, I discuss 
the changing epidemiology of opioid use and opioid use disorders (OUDs) in the United States 
(US) over the past two decades. I introduce three public health priorities related to the opioid 
crisis: reducing accidental overdose fatalities through overdose education and naloxone 
distribution, minimizing the growing incidence and prevalence of hepatitis C virus (HCV) 
infections, and developing new strategies to support recovery from OUDs. I explore each of 
these topics further in the remainder of the dissertation.  
 
1.1 Changing Epidemiology of Opioid Use in the United States 
In 2016, at least 2.1 million Americans aged 12 years and older had an OUD; only 21.1% 
received treatment.1,2 OUDs, as described further below, are formally defined by the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) as medical illnesses related to opioid use or 
misuse.3,4 Opioids are a class of drugs that include both licit prescription pain relievers (e.g. 
oxycodone, hydrocodone, and morphine) and illicit substances (e.g. heroin).1 Opioid drugs bind 
to receptors that control nociception in the brain, spinal cord, and gut; licit opioids are therefore 
commonly prescribed to treat pain.5 The 2016 Centers for Disease Control and Prevention (CDC) 
Guidelines highlight the need for judicious opioid prescribing practices given the potential harms 
associated with opioids, including risk for developing OUDs.5 At high doses, both licit and illicit 
opioids can cause overdose, respiratory depression, or death.5 
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Formal diagnosis with an OUD involves meeting two or more diagnostic criteria in the 
past 12 months; these criteria capture a spectrum of impairments to a person’s social functioning, 
health, and control over using opioids (Figure 1.1).3,4 OUDs can include several physiologic 
symptoms, such as tolerance (the need to increase the dose of opioids used to achieve the same 
physiologic effect or ‘high’), cravings to use opioids, and withdrawal (a syndrome occurring 
upon the removal of opioids often involving nausea, vomiting, diarrhea, chills, depression, and 
cravings to use opioids).3 In addition, several cognitive and behavioral symptoms capture 
behavioral patterns of continued use despite social, personal, or health consequences.3 
Over the past two decades, growing morbidity and mortality from OUDs and related 
health problems in the US led to recognition of the opioid crisis and the declaration of a national 
emergency in 2017.6,7 Opioid pharmaceuticals were increasingly prescribed for the treatment of 
pain beginning in the mid- to late-1990s; these increases coincided with the introduction of 
OxyContin by Purdue Pharma in 1995 and the adoption of pain as the fifth “vital sign,” akin to 
blood pressure, heart rate, etc.8 Opioid prescribing rates rose steadily from 61.9 prescriptions per 
100 Americans in 2000 to a high of 81.3 prescriptions per 100 Americans in 2012.8–10 
Accordingly, past 30 day use of prescription opioids rose from 5% of Americans aged ≥20 years 
in 1999 to 6.9% in 2003, and remained stable through 2011.11 During this period, prescription of 
high strength opioids also increased.11 Among adults who used prescription opioids in 2011, 
37% used prescription opioids more potent than morphine compared to 17% in 1999.11 Opioids 
more potent than morphine include fentanyl, hydromorphone, methadone, oxycodone, and 
oxymorphone, as a smaller dosage amount (i.e. milligrams) of these opioids would provide the 
same pain relief that could be obtained with a standard dose of morphine.12 In 2012, an analysis 
of US prescribing patterns showed that medical practitioners specializing in family practice 
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prescribed the highest share of total opioid prescriptions (18.2% of opioid prescription), followed 
by internal medicine (15.1%), nurse practitioners or physician’s assistants (11.2%), and general 
practice (11.2%).13 Not surprisingly, opioid prescribing rates were highest in pain medicine, 
surgery, and physical medicine and rehabilitation specialties.13  
Changes in opioid prescribing practices were accompanied by a 75% increase in chronic 
nonmedical prescription opioid use (i.e. nonmedical use for 200 or more days of the year).14 
Nonmedical prescription opioid use is defined as use beyond the prescribed purpose, use of a 
greater amount of opioids, and/or use without a prescription.1 In 2010, approximately 5% of 
Americans aged ≥12 years misused prescription opioids, and 0.4% chronically misused 
prescription opioids.14 Long-term opioid use and nonmedical prescription opioid use are risk 
factors for developing an OUD.5,15,16 Becker et al. found that nearly 13% of adults who used 
prescription opioids nonmedically met diagnostic criteria for an OUD.15 Prevalence of OUD is 
even higher among young adults; 24% of adults aged 26-34 years who used prescription opioids 
nonmedically in the past year had an OUD in 2014.16 Risk of developing an OUD is lower for 
people who use opioids as prescribed, but increases with duration of opioid prescription.17,18 
Edlund et al. conducted a longitudinal study of 568,640 individuals to detect incident OUD in 
the 18-months after an opioid prescription and noted that 0.12% of people prescribed opioids for 
≤90 days developed an OUD whereas 6.1% of people prescribed opioids for >90 days at an 
average daily dose of ≥120 morphine equivalent milligrams (a standardized opioid dosage unit to 
account for differences in prescription opioid strengths) developed an OUD.18 By comparison, 
0.004% of people not prescribed opioids developed an OUD during the period of study.18 
Opioid prescribing rates have declined since 2012; there were 66.5 opioid prescriptions 
per 100 Americans in 2016.10 These declines may, in part, be attributable to policies that curb 
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nonmedical prescription opioid use, such as prescription drug monitoring programs, which track 
physician prescribing patterns and patient prescription dispensing (i.e. the number and type of 
opioids prescribed) to identify patient diversion (e.g. patients seeking prescriptions from multiple 
physicians).19 However, increases in heroin use starting in the late 2000s suggest that the current 
opioid crisis cannot be curbed with measures solely focused on prescribing practices.8,16,19–21 
Prevalence of past year heroin use more than doubled during 2002-2016; 948,000 US adults used 
heroin in 2016.2 Muhuri et al. estimated that 3.6% of people who use opioids nonmedically 
initiate heroin use within 5 years, suggesting that nonmedical prescription opioid use may lead to 
heroin use.22 More than three-quarters of people who use heroin report using prescription opioids 
nonmedically beforehand.20,22 The higher availability and lower cost of heroin relative to 
prescription opioids may further influence the transition from prescription opioid to heroin use.19 
A more recent change in the opioid crisis is the introduction of illicitly manufactured fentanyl, a 
synthetic opioid that is 50-100 times more potent than morphine, into the heroin supply.23 As I 
discuss further below, the introduction of this more potent opioid contributed to the recent sharp 
increases in overdose mortality in the US.23,24  
In 2013, prescription OUDs and prescription opioid overdose were estimated to cost 
$78.5 billion in health care, OUD treatment, criminal justice system expenses, and lost 
productivity.25 US life expectancy decreased in the US for two consecutive years (i.e. 2015 and 
2016) related to increasing rates of opioid overdose.26–28 Mitigating these negative consequences 
to health and mortality are major and immediate public health priorities.7 In the remainder of this 
chapter, I introduce three public health priorities related to the opioid crisis. Each is further 
explored chapters 2-5.  
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1.2 Increases in Overdose Mortality 
Opioid overdose deaths in the US have more than quadrupled since 2000.24,29 In 2016, 
there were 42,249 opioid overdose deaths.24 The number of deaths from opioid overdose 
outnumbered deaths from motor vehicle crashes for the first time in 2016.24,30 An average of 115 
people die from an opioid overdose in the US each day.31  
The CDC has characterized three distinct periods of the opioid overdose epidemic.31 
First, prescription opioid overdose deaths, such as those from oxycodone, rose steadily during 
the period 1999-2009.31 The second period began in 2010, when deaths from heroin overdose 
increased sharply.31 By 2015, heroin overdose deaths outnumbered those due to prescription 
opioids.31 The third period began in 2013 with the introduction of illicitly manufactured fentanyl 
and fentanyl analogs into supplies of heroin and other illicit drugs.31 Deaths due to synthetic 
opioids, most of which involve fentanyl or fentanyl analogs, now outnumber heroin and 
prescription opioid overdose deaths and were involved in 45.9% of all opioid overdose deaths in 
2016.23,31  
Continued increases in opioid overdose deaths through 2016 highlight the need for 
immediate responses to reduce fatal and nonfatal overdose deaths. One response is to distribute 
naloxone to people who use opioids.32–34 Naloxone is an opioid antagonist that can reverse life-
threatening respiratory depression caused by an opioid overdose. In chapter 2, I describe the 
potential benefits of overdose education and naloxone distribution in the justice diversion 





1.3 Injection Drug Use and Bloodborne Viral Infections 
In 2012, 1.9% of people who used prescription opioids nonmedically and 47.8% of 
people who used heroin injected substances (e.g. heroin and prescription opioids).35 Sharing 
syringes while injecting drugs can lead to bloodborne viral infections, including HCV and human 
immunodeficiency virus (HIV).36 Injection drug use is the most common risk factor for new 
HCV infections in the US.36 The number of new HCV infections more than tripled during 2010-
2016, and increases were especially sharp among young adults aged 20-29 years.36 HCV 
infection can cause life-threatening liver damage during years of chronic, asymptomatic 
infection.37 More than half of people who inject drugs (PWID) in the US are infected with 
HCV.38  
Newly approved, highly effective direct-acting antivirals made HCV curable in 2012.39 
However, treatment uptake among PWID is low.40,41 Modeling studies support that increasing 
rates of HCV treatment could decrease HCV prevalence and interrupt transmission.42 In chapter 
3, I quantify the potential impact of HCV treatment and behavioral interventions on HCV 
prevalence and incidence among young PWID in Michigan.  
 
1.4 Recovery from Opioid Use Disorders 
Unmet need for the treatment of OUDs is high: only 37.5% of people with a heroin use 
disorder and 17.5% of people with a prescription OUD received OUD treatment in 2016.2 
Effective treatments for OUDs include medication assisted treatments such as methadone, 
buprenorphine, and naltrexone, which should be provided alongside behavioral counseling.43 
Relapse rates after SUD treatment are high; 40-60% of people with SUDs relapse within one 
year of treatment.44,45 Return to use may be even higher among people who use opioids without 
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medication assisted treatment.46,47 These statistics highlight the need for both increasing uptake 
of effective OUD treatments and the identification of adjunctive treatments that support OUD 
recovery. In chapter 4, I summarize results from a pilot study of one potential target for future 
adjunctive treatments that is increasingly recognized for its role in psychopathology: the gut 
microbiota.48 
 
1.5 Dissertation Aims 
The overall goal of this dissertation is to examine three inter-related public health 
priorities connected to the opioid crisis. In chapter 2, we characterize justice involvement 
characteristics, overdose experiences, naloxone knowledge, and overdose attitudes among a 
sample of people who use opioids receiving treatment in a justice diversion residential addiction 
treatment program. Further, we examine whether overdose experiences differ by justice 
involvement and how overdose experiences and justice involvement are associated with 
naloxone knowledge, overdose risk reduction attitudes, and confidence in overdose response. We 
use these results to highlight the need for overdose education and naloxone distribution in the 
justice diversion addiction treatment setting.  
In chapter 3, we review the development of a hepatitis C virus transmission model among 
young people who inject drugs. We fit the model to hepatitis C virus surveillance data from 
Michigan for a set of 10,000 scenarios generated through stratified random sampling of 
parameter ranges that were identified through literature review. We then simulate the potential 
impact of several interventions, including HCV treatment, decreased injection drug use initiation, 
and several other interventions. We discuss how these results could inform public health 
strategies to reduce hepatitis C infections among young people who inject drugs in Michigan. 
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In chapter 4, we focus on the area of recovery. Increasingly, the gut microbiota is 
explored as a modifier of health and disease, including psychopathology. We examine how 
opioids influence the gut microbiota among a sample of 46 patients receiving outpatient 
substance use disorder treatment. We note how differences in diversity, enterotypes, and genera 
may reflect the negative impact of opioids on gut health, and discuss how these results could 
inform future, more comprehensive studies of OUD recovery.  
In the final chapter, I reflect on some of the defining events in my PhD, the skills they 
helped me gain, and the challenges I faced while conducting interdisciplinary research. I close 
with an outline of future directions for research on injury, infection, and recovery from opioid 
use disorders. 
 9 
Figure 1.1 DSM-5* Criteria for Diagnosis with an Opioid Use Disorder (OUD) 
 
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) defines 
OUDs by the presence of two or more of the above criteria in the past 12 months.3,4 These 
criteria are meant to encompass the cognitive, physiologic, and behavioral consequences of 
opioid use.3,4 The severity of an OUD is defined by the number of criteria endorsed, with 2-3 
criteria indicating a mild OUD, 4-5 criteria indicating a moderate OUD, and 6 or more criteria 
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Chapter 2 Justice Involvement Patterns, Overdose Experiences, and Naloxone 
Knowledge among Men and Women in Criminal Justice Diversion Addiction 
Treatment 
 
In preparation for publication in a peer reviewed journal 
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2.1 Author Summary 
One response to the four-fold increase in opioid overdose mortality in the US between 
1999-2016 has focused on training people who use opioids (PWUO) to reduce their own 
overdose risk and respond to witnessed overdoses by providing naloxone.1,2 While community 
access to naloxone increased in Michigan after state officials approved a 2017 standing order for 
pharmacy-based distribution, addiction treatment services, the correctional system, and justice 
diversion programs are an underutilized mechanism for overdose education and naloxone 
distribution.3–5 We characterized justice involvement, overdose experiences, naloxone 
knowledge, and overdose risk reduction and response attitudes among a sample of 514 PWUO in 
a justice diversion residential addiction treatment program in Michigan. Most participants had 
experienced (68.1%) or witnessed (79.2%) an overdose. However, only 56.2% had heard of 
naloxone and correctly identified it as an overdose treatment. History or type of justice 
involvement was not associated with overdose experience, suggesting a universal need for 
overdose education and naloxone distribution independent of justice involvement prior to 
treatment. Participants with more overdose experience were more likely to know about naloxone. 
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Our results suggest that all PWUO in justice diversion addiction treatment programs should be 
educated about reducing their overdose risk, responding to an overdose with effective actions, 
and be provided naloxone before treatment completion.  
 
2.2 Abstract 
Criminal justice diversion programs are one major pathway to addiction treatment that 
could provide overdose education and distribute naloxone to people who use opioids (PWUO). 
Pre-treatment justice involvement patterns, overdose experiences, naloxone knowledge, and 
overdose risk reduction and response attitudes may help identify current needs for overdose 
education and naloxone distribution (OEND) occurring during justice diversion addiction 
treatment. PWUO are at high risk for overdose post-treatment and post-incarceration and 
commonly witness overdoses. OEND among PWUO is cost-effective and reduces overdose 
mortality in community settings.  
We characterized the demographic characteristics, overdose experiences, naloxone 
knowledge, and overdose attitudes among a sample of 514 PWUO in a justice diversion 
residential addiction treatment program during 2014-2016. We conducted a latent class analysis, 
stratified by gender, to characterize justice involvement given the complexity of pre-treatment 
patterns. We used quasi-Poisson regression models with robust standard errors to examine 
prevalence of naloxone knowledge and overdose attitudes by overdose experiences and justice 
involvement. 
Most participants had personally experienced (68.1%) and/or witnessed another person 
(79.2%) experience an overdose. Only 56.2% had heard of naloxone and correctly identified it as 
an opioid overdose treatment. Two justice involvement groups were identified, and these differed 
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by gender: low involvement (20.3% of men and 46.5% of women), characterized by older age at 
first arrest, more arrests in the past year, and less time incarcerated; and high involvement 
(79.7% of men and 53.5% of women), characterized by younger age at first arrest and more 
lifetime arrests and time incarcerated. Men and women who had personally experienced an 
overdose were more likely to have heard of naloxone and to correctly identify it as an overdose 
treatment after adjustment for age and race (Prevalence Ratio, PR [95% Confidence Interval, 
CI]: Men 2.1 [1.6-2.9], Women 2.0 [1.3-3.1]). Among women without naloxone knowledge, 
those who had witnessed an overdose felt more ready and confident about responding to an 
overdose than women who had not witnessed an overdose (PR [95% CI]: 2.1 [1.0-4.3]). This 
association was attenuated among men (PR [95% CI]: 1.3 [0.98-1.7]).  
All PWUO in criminal justice diversion addiction treatment programs would benefit from 
OEND given the high propensity to experience and witness overdoses and low knowledge of 
naloxone across justice involvement backgrounds and genders. Among those who did not know 
about naloxone, discrepancies between perceived ability to respond to an overdose and 
knowledge may need to be resolved during overdose education programming. 
 
2.3 Introduction 
Mortality from opioid overdose increased more than 4-fold from 1999 to 2016 in the 
United States (US); more than 42,000 people died from an opioid overdose in 2016.1,2 Training 
witnesses to identify and respond to an opioid overdose and equipping them with naloxone, an 
opioid antagonist that reverses the respiratory depression caused by high doses of opioids, 
reduces opioid overdose mortality.6 However, a challenge of existing overdose education and 
naloxone distribution (OEND) programs is to identify appropriate candidates for training, that is, 
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people who are highly likely to personally experience and/or witness an overdose.7 Several 
characteristics increase risk for experiencing or witnessing an overdose. People who have 
experienced an overdose in the past are more likely to witness or experience a future overdose.8–
11 Overdose risk is heightened in the period immediately following incarceration or addiction 
treatment.10,11 Men are more likely to witness overdoses while women and non-Hispanic white 
individuals are more likely to experience overdoses.8,10,11 The relationship of age and overdose 
risk varies by study.10,11 
PWUO are targeted for OEND programs due to their high propensity to experience and 
witness overdoses; they are both potential overdose victims and bystanders who could respond.7–
9,12–20 Approximately 50-96% of people who use illicit drugs witness an overdose, and 17-68% 
personally experience an overdose.10 Naloxone distribution to PWUO is cost-effective, 
especially when combined with addiction treatment, and reduces opioid overdose mortality.6,21–23 
Further, PWUO are willing to administer naloxone to other PWUO.15,24  
There are several key elements of OEND programs. First, participants are trained to 
recognize the signs and symptoms of an overdose (e.g. loss of consciousness, shallow breathing, 
pale, blue, or cold skin, small pupils, or a limp body) and educated about behaviors that increase 
overdose risk.18,25 Second, they are provided naloxone and trained to effectively respond using 
naloxone, cardiopulmonary resuscitation (CPR), rescue breathing, or by involving professional 
medical services.25 Naloxone is an opioid antagonist that reverses the respiratory depressive 
effects caused by high doses of opioids.3 It is currently available in injectable and intranasal 
formulations.3 Some OEND programs include other education components. For instance, one 
program educated PWUO about Good Samaritan Laws, which protect overdose witnesses and 
victims against legal prosecution for illegal activities discovered when witnesses involve 
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professional medical help.25,26 The authors found that correct knowledge of the law increased the 
odds of 911 calling 3.6-fold in instances of overdose.26  
To jointly maximize the number of PWUO who are well-positioned to respond to an 
overdose or benefit from receipt of naloxone and the cost-effectiveness of training, OEND 
should occur in settings where opioid use disorders (OUDs) are prevalent.7 In the US, this 
includes jails, prisons, and addiction treatment services; these settings converge in justice 
diversion addiction treatment programs, which provide PWUO facing legal prosecution with 
addiction treatment to avoid criminal charges or to reduce incarceration time.5,7,27,28 PWUO are 
referred to justice diversion programs by law enforcement, drug courts, or the correctional 
system.5,29–32 Justice diversion addiction treatment programs can be categorized into two types 
by the time at which people are diverted.33 Pre-booking programs divert individuals to treatment 
directly after arrest to avoid criminal charges.5,33 Individuals in pre-booking programs often 
avoid incarceration altogether.5,33 Alternatively, post-booking programs provide treatment to 
individuals awaiting charges or sentencing or who have already been charged and sentenced to 
attend treatment; these individuals often spend time in jail while awaiting sentencing.33 
Individuals could also be diverted after violating parole or probationary agreements and may or 
may not have been incarcerated prior to parole or probation.33  
The post-incarceration and post-treatment periods are marked by high rates of return to 
opioid misuse and elevated overdose and overdose mortality rates.28,34–37 These highlight the 
need to incorporate OEND and maintenance medications (i.e. methadone, buprenorphine, and 
naltrexone) in justice diversion and related settings.5,28,34–43 Binswanger et al. showed that risk of 
drug overdose death was 129-fold higher during the first two weeks following release from 
incarceration (jail or prison) among a sample of former inmates in Washington relative to the 
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non-incarcerated population.34 In the treatment setting, Davoli et al. showed that mortality in the 
post-treatment period was 21-fold higher than mortality in the general population using a sample 
of >10,000 Italians who used heroin.44 Most of this elevated risk of death occurred in the first 
four weeks post-treatment.44 Similarly, Ravndal and Amundsen suggested that mortality rates 
were nearly 16-fold higher in the four weeks post-treatment compared to >4 weeks.45 A loss of 
physiologic tolerance (i.e. the need to use more of a drug to achieve the same effect) during the 
period of non-use during incarceration or treatment, in the context of relapse to drug use, is the 
likely reason that the first month post-treatment is a critical period for overdose risk.34,44–48  
Providing naloxone before community re-entry after incarceration could reduce overdose 
risk for both the released individual and their substance use network in this critical period.49,50 At 
the population level, Bird et al. found that opioid overdose mortality rates were reduced by 36% 
after implementation of a Scottish policy that provided all released individuals with naloxone.49 
Parmar et al. attempted to assess whether providing naloxone prior to community re-entry 
reduced the risk of opioid overdose death after release by conducting a randomized controlled 
trial of naloxone on release for >1600 individuals incarcerated in England.50 However, their trial 
was unable to compare the risk of post-release overdose death for participants who received and 
did not receive naloxone because participants who received and used their naloxone most often 
used it to respond to an overdose they witnessed.50 While not the intended purpose of this study, 
these results highlight the potential for naloxone to benefit both PWUO and their network.  
PWUO become involved with justice diversion addiction treatment programs at various 
stages of justice involvement.5,33 Alongside these variable pathways to treatment, the aspects of 
justice involvement preceding diversion (e.g. arrest history, age at first arrest, cumulative 
incarceration time), history of overdose experiences and witnessed overdose, naloxone 
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knowledge, overdose risk reduction and response attitudes, and demographic characteristics are 
not thoroughly described. However, high prevalence of witnessed overdose and experienced 
overdose in related settings (e.g. jail, prison, and community corrections) support investigating 
the justice diversion setting further. For example, a study of PWUO in community corrections 
found that 40% experienced an opioid overdose and that 78% of PWUO who experienced an 
overdose had also witnessed an overdose.51 Because previous overdose experience is a risk factor 
for future overdose experience and for witnessing an overdose, identifying correlates of overdose 
experience among PWUO could help with targeting of OEND.8,52 In addition, aspects of justice 
involvement, including multiple incarcerations and property and drug crimes are associated with 
elevated overdose risk and mortality, suggesting that the way PWUO are referred to justice 
diversion programs is important in their overdose risk.30,53,54 Taken together, this research 
supports describing overlaps in justice involvement, overdose experiences, and naloxone 
knowledge to inform planning of OEND in the justice diversion context.  
Describing attitudes towards overdose risk and responses may also help determine the 
potential impact of OEND and identify barriers to behavior change. Recent overdose education 
interventions have incorporated motivational interviewing theory, which identifies discrepancies 
between beliefs and behaviors to motivate behavior change.55–57 Attitudes, beliefs, and intentions 
are believed to be important predictors of behavior change.55 PWUO in justice diversion 
addiction treatment may have varying motivations to change overdose risk behaviors given that 
their primary motivation for enrolling in treatment may have been to avoid legal repercussions 
(rather than a desire to stop using substances). Studying motivations to change overdose risk 
behaviors is therefore important for intervention planning. In addition, ineffective responses to 
overdose (e.g. causing pain to wake an overdose victim or injecting an overdose victim with 
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something) are highly prevalent among PWUO.8,16 While OEND increases confidence in 
responding to an overdose among people with initially low confidence, it is unknown whether 
uptake of effective overdose responses is modified by false beliefs (i.e. high baseline confidence 
regarding empirically ineffective overdose responses).58 Characterizing discrepancies between 
overdose response knowledge and confidence in responding could determine whether overdose 
education that stresses the replacement of prior beliefs is required. 
Our study aimed to inform OEND planning using a sample of 514 PWUO in a residential 
justice diversion addiction treatment program in Michigan. We had three objectives. Our first 
objective was descriptive and sought to add to the literature regarding the characteristics of 
PWUO in justice diversion addiction treatment programs. Specifically, we described 
participants’ prior involvement in the criminal justice system and history of overdose. We 
evaluated these separately by gender to account for potential differences in justice involvement 
and overdose history for men and women. Second, we evaluated whether overdose experiences 
differed by justice involvement history. Finally, we examined the relationship of overdose 
experiences and justice involvement with naloxone knowledge, overdose risk reduction attitudes, 
and confidence in overdose response.  
 
2.4 Methods 
2.4.1 Study Description 
The analytic sample was drawn from a study of 817 adult (≥18 years) patients in a 
residential addiction treatment program in Michigan during October 2014 – January 2016. 
Typical treatment duration for the facility is 60-90 days and treatment populations are separated 
by gender. This facility's clients included those with no justice involvement and clients who were 
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diverted to treatment through their involvement with Michigan's criminal justice system (i.e. law 
enforcement, courts, or corrections, including probation and parole). Clients in justice diversion 
addiction treatment could be diverted at the pre- or post-booking stage or after violating parole or 
probationary supervision agreements.  
Potential study participants were approached by research assistants and asked to complete 
a self-administered survey via paper and pencil. To be eligible for the survey, participants had to 
be ≥18 years, speak English, be able to provide informed consent, and be able to see, speak, and 
hear. We excluded people who were acutely intoxicated, mentally incompetent, or unable to 
provide informed consent for any other reason. The survey took approximately 45 minutes to 1 
hour to complete. Participants were compensated $5. This study was approved by the 
Institutional Review Board at the University of Michigan (HUM00078507). 
 
2.4.2 Inclusion Criteria 
Because the focus of our analysis was justice diversion addiction treatment, we excluded 
36 participants whose treatment was not prompted by the justice system (Figure 2.1). These 
participants answered no to the question “Was this treatment prompted or suggested by the 
criminal justice system (judge, probation/parole officer, etc.)?” An additional four participants 
who skipped this question were also excluded. Participants included in this analysis could be 
diverted at the pre- or post-booking stage after various criminal justice system interactions (e.g. 
arrested, charged, sentenced, or under probationary or parole supervision), and may or may not 
have served time in jail or prison before treatment. 
As the main interest of our study was describing opportunities for OEND and naloxone is 
only relevant to opioid overdose reversal, we restricted the sample to participants who reported 
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lifetime use of heroin or prescription opioids that were not prescribed by a doctor. This criterion 
excluded 238 participants. The most commonly used substances among excluded participants 
were alcohol (n=223), tobacco (n=196), cannabis (n=154), cocaine (n=90), and hallucinogens 
(n=46). An additional 26 participants were removed due to missing responses for demographic 
characteristics (age, gender, race, education and living situation), number of overdoses and 
timing of most recent overdose, number of witnessed overdoses, naloxone and CPR knowledge, 
and self-efficacy to reduce overdose risk for themselves and to respond to a witnessed overdose. 
After these exclusions, a total of 514 participants remained for analysis. 
 
2.4.3 Measures 
2.4.3.1 Justice Involvement 
Five items quantified lifetime and recent justice involvement: age at first arrest (median: 
18, range: 9-59 years), number of past-year arrests (median: 1, range: 0-42 arrests), number of 
lifetime arrests (mode: 6-10, categories: 1-2, 3-5, 6-10, 11-49, 50-99, or 100 or more arrests), 
number of months during the past year spent in jail or prison (median: 5.3, range: 0-12 months), 
and lifetime number of years spent in jail or prison (median: 3.5, range: 0-41.3 years). We 
formed categorical variables using quartile or tertile breaks from distributions in the analytic 
sample, with modifications when appropriate to enhance interpretability (e.g. juvenile versus 
adult age at first arrest). Categorical variables included age at first arrest (9-17, 18-20, or 21-59 
years), past-year arrests (0, 1-2, 3-42 arrests), lifetime arrests (1-5, 6-10, 11 or more arrests), 
past-year time spent in jail or prison (0-1.9, 2-5.9, 6-10.9, or 11-12 months), and total time spent 
in jail or prison (0-0.9, 1-3.4, 3.5-7.4, or 7.5-41.3 years). 
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2.4.3.2 Overdose Experiences 
The survey introduced participants to the definition of an overdose with the following 
statement: “The following questions are about experiences with taking too much drugs or 
medications/pills. This is sometimes called ‘poisoning,’ ‘nodding out,’ or an ‘overdose’ or 
‘OD.’” Participants reported the number of overdoses experienced, timing of their most recent 
overdose, and substances used during the most recent overdose. We formed binary variables for 
any lifetime overdose and any past-year overdose. We also assessed the number of lifetime 
overdoses as a 3-level categorical variable (none, 1-5, or ≥6 overdoses). Finally, we summarized 
whether the participant’s most recent overdose involved heroin or prescription opioids. 
 
2.4.3.3 Witnessed Overdose 
Consistent with previous studies, the following statement introduced participants to the 
definition of a witnessed overdose:  
The following questions are about times you have seen someone else taking too much 
drugs or medications/pills, and/or drinking too much alcohol. This is sometimes called an 
“overdose.” When someone has an overdose, they might have blue skin color, 
convulsions, or difficulty breathing, lose consciousness, collapse, cannot be woken up, or 
have a heart attack or die.14 
Participants reported the number of overdoses they witnessed and drugs used by the victim 
during the most recently witnessed overdose. We formed a binary variable for any witnessed 
overdose and assessed the number of witnessed overdoses (none, 1-5, or ≥6 witnessed 
overdoses). Finally, we summarized whether the most recently witnessed overdose involved 
heroin or prescription opioid use by the victim. 
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2.4.3.4 Naloxone and Cardiopulmonary Resuscitation (CPR) Knowledge 
Participants reported whether they had heard of naloxone and identified its purpose as an 
overdose treatment, drug treatment for opioid dependence, detox, other, or don’t know (multiple 
responses were allowed). For the analysis, participants who had both heard of naloxone and 
identified its purpose as an overdose treatment were defined as having naloxone knowledge, 
while all others had no knowledge. 
Similarly, participants reported whether they had heard of CPR and identified one or 
more purposes (response choices included: used when someone stops breathing, used to help 
someone when their heart stops, used to wake someone up when they’re tired, other, or don’t 
know). Participants were classified as having CPR knowledge if they had heard of CPR and 
identified its purpose as helping when someone stops breathing or when their heart stops. 
 
2.4.3.5 Motivation to Reduce Overdose Risk 
We summarized participant’s motivation to reduce their overdose risk on scales of 1 to 10 
using two items: the importance ([1] not important to [10] very important) and readiness ([1] not 
ready to [10] very ready) to reduce their overdose risk. To identify OEND candidates who were 
ready to change their risk, we created a binary variable for participants with at least neutral (6) 
importance and readiness scores.  
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2.4.3.6 Readiness and Confidence in Responding to a Witnessed Overdose 
Participants reported their readiness to respond to an overdose they witnessed ([1] not 
ready to [10] very ready) and their confidence in responding ([1] not confident to [10] very 
confident) on scales of 1 to 10. We created one binary variable for participants with neutral or 
lower (<6) confidence and readiness and a second binary variable for participants with high 
confidence and readiness (8). The high confidence and readiness measure was based on the 
distribution of scores from the analytic sample. Approximately two-thirds of participants 
reported readiness and confidence scores 8. 
 
2.4.3.7 Demographics and Substance Use 
We examined several demographic characteristics of participants, including age 
(categorized as 18-29, 30-44, 45-67), housing (dichotomized into temporary housing [rooming 
house/hotel, halfway house/group home, inpatient treatment facility/hospital, jail, shelter, or 
homeless] versus stable housing [house/apartment or friend/family member’s house]), education 
(college or higher versus high school/GED or less), race (black, white, other, or multiple races), 
and ethnicity (Hispanic vs. non-Hispanic). In multiple regression models, we collapsed 
race/ethnicity into non-Hispanic white versus non-white participants (regardless of ethnicity) due 
to limited numbers of racial/ethnic minorities in the sample. We also summarized lifetime and 
past-year heroin and illicit prescription opioid use (defined as use not as prescribed by a doctor).  
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2.4.4 Latent Class Analysis 
2.4.4.1 Latent Class Measurement Model 
Latent class analysis (LCA) is a statistical technique used to uncover unobserved (i.e. 
latent) subgroups from patterns (i.e. covariance) of observed variables.59 It is helpful for 
empirically-identifying clusters (subgroups) of individuals who share patterns of characteristics 
in what may otherwise seem to be a homogeneous sample.59 Lorvick et al. previously described 
three classes of justice involvement (low, medium, and high) among women who used drugs in 
California based on their incarceration and community corrections involvement.60  
In this study, we used LCA to identify distinct subgroups defined by involvement in the 
criminal justice system. Based on prior literature, we hypothesized that criminal justice 
involvement history could be a useful means of identifying subgroups that would be more likely 
to benefit from targeted OEND.17,30,53,54,61 To do so, we used five observed justice involvement 
variables: age at first arrest (9-17, 18-20, or 21-59 years), past-year arrests (0, 1-2, 3-42 arrests), 
lifetime arrests (1-5, 6-10, 11 or more), past-year time spent in jail or prison (0-1.9, 2-5.9, 6-10.9, 
or 11-12 months), and total time spent in jail or prison (0-0.9, 1-3.4, 3.5-7.4, or 7.5-41.3 years).  
LCA measurement models provided two types of results. First, we obtained the 
prevalence of each latent justice involvement class in the sample. Second, we obtained item 
response probabilities, which reflect the proportion of participants who endorse each observed 
justice involvement variable within each justice involvement class. Our interpretation of item 
response patterns by class provided the basis for the investigator-assigned class labels that 
summarized the overarching identity of each latent class.  
We selected the number of latent classes using a combination of interpretability and 
model fit indices (Akaike Information Criterion [AIC], Bayesian Information Criterion [BIC], 
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adjusted BIC, and entropy) for latent class measurement models with two to six classes. Smaller 
values of the AIC and BIC, and larger values of entropy indicate better relative model fit. As 
discussed further below, model entropy can also help determine whether latent class assignment 
can be formulated as a categorical (rather than a latent) variable in subsequent analyses.62 After 
selecting the number of classes for the initial model, we ensured convergence to a globally 
optimal solution using 1,000 random start values. We completed LCA analyses in SAS version 
9.4 using PROC LCA.59 
 
2.4.4.2 Justice Involvement by Gender 
Because men and women are treated separately in many residential addiction treatment 
programs, including the facility where these data were collected, we assessed whether the justice 
involvement measurement model operated similarly in groups defined by gender (men versus 
women). We fit the LCA measurement model with and without constraining item response 
probabilities to be equal across genders, testing the null hypothesis that item response patterns 
were the same for men and women.59 We used a likelihood ratio test (LRT) to identify group-
level non-invariance in measurement; rejecting the LRT (p<0.05) implied that the underlying 
measurement model differed by gender and that gender stratified models should be used for the 
remainder of analyses.  
 
2.4.4.3 Assignment of Justice Involvement Class 
Before examining the relationship of justice involvement with outcomes, we formed a 
categorical variable that represented each participant’s most likely latent class membership. 
Posterior probabilities of class assignment were estimated for each participant as part of fitting 
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the measurement model; these reflected the probability that each participant belonged to each 
class and described the uncertainty in their class assignment. We assigned participants to their 
most likely latent justice involvement class using their maximum posterior probability (i.e. the 
modal class assignment approach) and examined pseudo-class draws in sensitivity analyses (see 
details below).63 Both approaches can bias associations towards the null as they fail to 
incorporate uncertainty in class assignment after individuals are classified into a single class.62,64–
66 However, it is generally considered acceptable to use class assignment as a categorical 
variable in further analyses for measurement models with entropy values of >0.8.62 
 
2.4.4.4 Regression Analyses 
After assigning justice involvement class, we examined the prevalence of overdose 
experiences, naloxone knowledge, motivation to reduce overdose risk, and readiness and 
confidence in responding to an overdose by the latent classes of justice involvement. Further, we 
summarized the relationship of overdose experiences (lifetime and past-year), witnessed 
overdose, and justice involvement with naloxone knowledge and self-efficacy outcomes using 
prevalence ratios from quasi-Poisson regression models with robust standard errors.67 Motivation 
to reduce overdose risk and confidence in responding to an overdose were only examined among 
participants without naloxone knowledge to focus the analysis on a population with clear need 
for naloxone training. We summarized results using prevalence rather than odds ratios because 
the high prevalence of many outcomes of interest in this study prevented the odds ratio from 
approximating the prevalence ratio.67,68 We adjusted bivariate prevalence ratios reaching 
statistical significance (p<0.05) for age (18-29, 30-44, and 45-67 years) and race (non-Hispanic 
white vs. other race/ethnicities).  
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2.4.5 Sensitivity Analyses  
To assess whether the relationships between justice involvement and overdose experiences 
and knowledge were robust to the modal class assignment LCA approach, we used a second 
class assignment method, pseudo-class draws.63 We conducted 20 imputations based on the 
posterior probabilities of class assignment (i.e. the pseudo-class approach) using the final LCA 
measurement model to assign class.63 We repeated Poisson regressions for each imputed dataset 
for all associations between justice involvement and overdose outcomes that reached statistical 
significance using the modal class assignment approach. After calculating prevalence ratios for 
each imputed dataset, we pooled results using imputation procedures.69  
 
2.5 Results 
2.5.1 Demographic Characteristics, Overdose Experiences, and Naloxone Knowledge 
The majority of participants were white (74.7%), non-Hispanic (95.3%) and aged 30-44 
years (Table 2.1). Nearly half were arrested for the first time as juveniles (47.9%). Most were 
arrested once or twice in the year before treatment or jail (41.6%); nearly one-third had no arrests 
in the year before treatment. Participants spent a median of 3.5 years in their lifetime and 5.3 
months of the past year incarcerated.  
Most participants had experienced (68.1%) and/or witnessed (79.2%) an overdose, and 
42.7% had an overdose in the past year. Among those who experienced or witnessed an 
overdose, the most recent event often involved opioids (72.6% of most recently experienced 
overdoses, 83.3% of most recently witnessed overdoses). Only 62.1% had heard of naloxone, but 
90.6% of those who had heard of it correctly identified it as an overdose treatment. Only 4 of the 
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195 participants who had not heard of naloxone correctly identified it as an overdose treatment, 
so we conceptualized naloxone knowledge as the combination of hearing of naloxone and 
correctly identifying it as an overdose treatment for the remainder of the analysis. CPR 
recognition was nearly universal (99.4%); 84.3% recognized that it was used to resuscitate 
someone who stops breathing and 56.8% recognized that it was used to help someone whose 
heart stops.  
 
2.5.2 Overdose Risk Reduction and Response Attitudes by Naloxone Knowledge 
Just over half of participants (56.2%) had heard of naloxone and correctly identified it as 
an overdose treatment; knowledge was higher among women than men (66.9% women vs. 
51.8% of men, Table 2.2). Over 90% of women reported neutral or higher importance and 
readiness to reduce their own overdose risk regardless of naloxone knowledge. Women without 
naloxone knowledge had lower confidence and readiness to respond to an overdose they 
witnessed than women who knew about naloxone (p=0.04), though few women (16/151, 10.6%) 
had low confidence and readiness. Conversely, most women (72.2%) reported high confidence 
and readiness (scores ≥8) to respond to an overdose, and this did not differ by naloxone 
knowledge (p=0.11).  
Overall, 81.0% of men reported neutral or higher scores for readiness and importance in 
reducing their overdose risk. Only 12.7% of men reported neutral or lower confidence and 
readiness in responding to an overdose they witnessed while high confidence and readiness 
(scores ≥8) were common (65.0%). No risk reduction or response attitudes differed by naloxone 
knowledge among men.  
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2.5.3 Justice Involvement LCA Measurement Model Fit 
Fit indices for models with two to six latent justice involvement classes are shown in 
Table 2.3. While the BIC and adjusted BIC indicated optimal fit for the three-class model, the 
two-class model had significantly higher entropy, had larger and thus more stable classes, and 
was more interpretable than the models with larger numbers of classes. We therefore chose the 
two-class model for the remaining analysis.62  
 
2.5.4 Justice Involvement by Gender 
Descriptive analysis showed that justice involvement characteristics differed by gender 
(Table 2.1), therefore, we evaluated justice involvement by gender using a multiple group LCA. 
Men had more cumulative justice involvement (i.e., lifetime arrests and time spent in jail or 
prison) than women, although women had more arrests in the year before treatment. Men were 
more commonly arrested for the first time as a juvenile than women.  
We rejected the null hypothesis of measurement invariance using the LRT (2=72.0, 
degrees of freedom: 24, p-value<0.05). This result implied that item response probabilities and 
latent class interpretations differed by gender. To assess whether the solution was sensitive to the 
model’s start values, we repeated the analysis using 1,000 randomly drawn starting values and 
recovered the optimal solution for all values. We used the gender non-invariant model for the 
remainder of analyses.  
The gender non-invariant model recovered two justice involvement classes for each 
gender that we termed “high” and “low” involvement (Figure 2.2). Men with low justice 
involvement (20.3% of men) were characterized by older age at first arrest (median: 19, mean: 
22.2 years), few lifetime arrests (80.6% had 1-5 arrests), and less incarceration time (median 
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past-year: 4.0 months, mean past-year: 4.3 months, median lifetime: 0.8 years, mean lifetime: 1.2 
years); 72.2% had 1-2 arrests in the year before treatment. Men with high justice involvement 
(79.7% of men) were more commonly arrested for the first time as a juvenile (65.3%), had more 
past-year (median: 8, mean: 7.2 months) and lifetime incarceration time (median: 6, mean: 8.3 
years), and had more lifetime arrests (81.4% had 6 or more lifetime arrests). 
Although the classes among women shared similarities with men, the defining features 
and item response probabilities differed. Women with low justice involvement (46.5% of 
women) were more likely to be arrested at an older age at first arrest (84.2% aged 18 years), 
had few lifetime arrests (75.7% with 1-5 arrests) and spent less time incarcerated (lifetime 
median: 0.3, mean: 0.5 years; past-year median: 2.6, mean: 2.8 months). Women with high 
justice involvement (53.5% of women) were younger at their first arrest (70.3% <21 years), had 
more lifetime arrests (50.6% had 11 arrests), and spent more time incarcerated (lifetime 
median: 4.4 years, mean: 2.9 years; past-year median: 4 months, mean: 5.4 months). 
 
2.5.5 Overdose Knowledge, Experience, and Attitudes by Justice Involvement 
Men with high justice involvement had lower prevalence of past-year overdose in 
bivariate associations (34.4% high involvement vs. 50.0% low involvement, Figure 2.3). 
However, prevalence did not differ after adjustment for age and race (Figure 2.4). Past-year 
overdose prevalence was higher among women than men (48.1% high involvement vs. 62.9% 
low involvement, Figure 2.3). Prevalence among women also did not statistically differ by 
justice involvement (Figure 2.4). Men with high involvement were older (76.6% high 
involvement vs. 48.6% low involvement aged 30 years) and less commonly white (69.1% high 
involvement vs. 81.9% low involvement). These patterns were similar among women.  
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2.5.6 Overdose Experience and Naloxone Knowledge 
Across genders, naloxone knowledge was highest among participants who had lifetime 
overdose experience, past-year overdose experience, or who had witnessed an overdose (Figure 
2.5). Only 26.0% of men who had never experienced an overdose were knowledgeable of 
naloxone. Conversely, 65.7% of men with lifetime overdose experience and 73.5% of men who 
overdosed in the past year had naloxone knowledge. Women had similar patterns but higher 
overall prevalence of naloxone knowledge. There was little difference in prevalence of naloxone 
knowledge between women with past year overdose experience (79.5%) and those with lifetime 
overdose experience (77.2%).  
 
2.5.7 Associations of Overdose Experience and Justice Involvement with Naloxone 
Knowledge and Overdose Attitudes 
Experiencing an overdose (lifetime or past year) or witnessing an overdose was associated 
with increased prevalence of naloxone knowledge; these associations remained after adjustment 
for age and race (Figure 2.6). Associations of naloxone knowledge with lifetime overdose 
experience were higher in magnitude than associations with past-year and witnessed overdose. 
Men who experienced an overdose in their lifetime were 2.1-fold more likely to have naloxone 
knowledge than men who had not experienced an overdose after adjusting for age and race (95% 
CI: 1.6-2.9). Similarly, women who experienced an overdose in their lifetime were twice as 
likely to be knowledgeable of naloxone compared to women who had not after adjusting for age 
and race (PR [95% CI]: 2.0 [1.3-3.1]).  
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Next, we compared overdose attitudes among participants without naloxone knowledge. In 
this subset of participants, women who witnessed an overdose were more likely to report high 
readiness and confidence in responding relative to women who had not witnessed an overdose 
after adjustment for age and race (PR [95% CI]: 2.1 [1.0-4.3], p=0.045). The association of 
witnessed overdose with confidence and readiness to respond was attenuated among men without 
naloxone knowledge (PR [95% CI]: 1.3 [0.98-1.7], p=0.07). We found no statistically significant 
differences in prevalence of naloxone knowledge or overdose attitudes by justice involvement 
after adjustment for age and race among men or women.  
 
2.5.8 Sensitivity Analysis: Multiple Imputation of Justice Involvement 
Assigning justice involvement classes with multiple imputation (i.e. the pseudo-class 
approach) yielded similar results to modal class assignment. The lower bivariate prevalence of 
past-year overdose among men with high justice involvement relative to low involvement 
remained statistically significant (PR [95% CI]: 0.69 [0.50-0.95]). The bivariate association of 
justice involvement with naloxone knowledge among men no longer reached statistical 
significance after multiple imputation (PR [95% CI]: 0.79 [0.61-1.0], p=0.08). The attenuation of 
these estimates compared to the modal class assignment approach was consistent with the results 
from a simulation study that compared both approaches.64  
 
2.6 Conclusions 
Using a large sample of adults in a residential justice diversion addiction treatment 
program, this study examined how history of justice involvement related to overdose risk and 
naloxone knowledge. Our primary finding was that nearly all participants had experienced and/or 
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witnessed an overdose, whereas just over half had heard of naloxone and correctly identified it as 
an overdose treatment. In contrast with our expectations, we found no differences in overdose 
experiences, naloxone knowledge, or overdose attitudes by justice involvement. These findings 
suggest that all clients, regardless of their path to treatment, are candidates for diversion-based 
OEND. These elements are described further below. 
Our study identified two subgroups of justice involvement among a sample of PWUO that 
reflect two general pathways to justice diversion addiction treatment. Men with low involvement 
became involved with the justice system at an older age and entered treatment after many recent 
arrests, likely to avoid incarceration. Men with high involvement had more cumulative justice 
involvement and spent much of the year before treatment incarcerated. These individuals likely 
entered treatment after awaiting trial and sentencing in jail or through diversion from a jail or 
prison case manager. Women had similar pathways to treatment, but overall had more past year 
arrests and spent less time incarcerated than men. The sample of women was nearly half high 
involvement and half low involvement, whereas nearly 80% of men had high involvement. 
Patterns of justice involvement in this study reflect both justice involvement patterns in the 
general population and the selection process for diversion programs, such as the one where this 
study was conducted.  
The prevalence of overdose experience history and witnessed overdose experience history 
in our study approached the maximum estimates reported in a 2015 systematic review.10 The fact 
that just over half of participants had heard of naloxone and identified it as an overdose treatment 
highlights the need for overdose and naloxone education as part of OEND conducted in this 
setting. Naloxone knowledge was particularly low among participants who had never personally 
experienced an overdose. While we cannot comment on whether these individuals experienced 
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an overdose post-treatment, the fact that they were in treatment for an OUD and have no 
knowledge of naloxone implies that they would benefit from OEND during treatment. We found 
no differences in overdose experiences, naloxone knowledge, or overdose attitudes by justice 
involvement, supporting that OEND should be provided to all PWUO in justice diversion 
addiction treatment. 
More than 80% of PWUO in this study reported neutral or higher importance and readiness 
to reduce their overdose risk. Clients in justice diversion programs could therefore be engaged 
participants in overdose risk reduction programming. Few (12.1%) participants reported low 
confidence in their overdose response and readiness to respond to an overdose they witnessed. 
While the absence of naloxone knowledge overlapped with low confidence to respond among 
women, we did not find that naloxone knowledge informed response confidence among men. 
Among participants without naloxone knowledge, witnessing an overdose increased confidence 
and readiness to respond, although the estimate among men was only marginally statistically 
significant. Taken together, these results suggest that justice diversion clients in our sample felt 
confident and ready to respond to an overdose even without knowledge of naloxone. OEND 
programs should address discrepancies in knowledge and attitudes by discouraging ineffective 
overdose responses while encouraging uptake of effective responses, such as naloxone, CPR, 
rescue breathing, and involvement of professional medical services. Motivational interviewing, a 
counseling style that addresses discrepancies between beliefs and behaviors, could be applied for 
this purpose.55  
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2.6.1.1 Strengths and Limitations 
This study had several strengths. First, we used LCA to describe overarching patterns of 
justice involvement history. This approach leveraged the covariance of observed justice 
involvement indicators to capture more information than was contained in each single justice 
involvement indicator. Further, we used a large sample of PWUO diverted to addiction treatment 
in both the pre-booking and post-booking stages. This sample therefore included the spectrum of 
potential clients eligible for addiction treatment following their justice involvement. Another 
benefit of the large sample size was our ability to completely stratify our analysis by gender to 
allow for differences in justice involvement, overdose experience history, witnessed overdose 
history, and naloxone knowledge between men and women. Previous studies support that justice 
involvement and overdose risk differ by gender.8,10,11,61  
Our findings are not without limitation. We studied participants from a single addiction 
treatment facility in the mid-Western US. The prevalence of naloxone knowledge, overdose 
experience, and witnessed overdose may reflect levels of OEND implementation specific to the 
Midwest and may not be generalizable to justice diversion addiction treatment programs in other 
regions. Further, our study participants attended treatment because of their involvement with the 
criminal justice system. The patterns of pre-treatment justice involvement we described may 
differ from justice involvement patterns among PWUO seeking treatment for other reasons. In 
addition, we were unable to determine when clients were diverted relative to the time they 
committed the crimes preempting treatment. We therefore cannot comment on specific 
differences between those diverted at the pre-booking, post-booking, or parole/probation stage 
beyond those supported by the LCA results.33 The extent to which the patterns in our study 
reflect characteristics of justice involvement in the general population is unknown and our ability 
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to evaluate this is complicated by the lack of systematic published criteria for diversion program 
eligibility. This lack of objective evaluation criteria further limited our ability to untangle the 
sources of gender and other disparities (e.g. by race) in diversion. In our study population, most 
diversion clients entered treatment after incarceration. Given the variability in diversion 
programs, it is difficult to determine whether the patterns of justice involvement observed here 
would extend to other states.5 
Our study relied on self-reported characteristics from the pre-treatment period to draw 
conclusions and therefore all findings are subject to recall bias. The cross-sectional design 
limited our ability to define the temporal sequence of events (e.g. whether individuals 
experienced or witnessed overdoses before or after their involvement with the justice system and 
when they learned about naloxone relative to their overdose experiences). We also cannot 
comment on post-treatment experienced or witnessed overdoses. Further, we relied on self-
reported scales of motivation to reduce overdose risk and readiness and confidence in responding 
to an overdose. These scales are not validated and cut points for high readiness and confidence to 
witness an overdose were based on distributions from the analytic sample. We therefore cannot 
comment on the sensitivity of these measures to capture motivation, confidence, or actions (i.e. 
overdose risk behaviors or overdose responses).  
Our analytic approach also had several limitations. First, the use of modal class 
assignment and pseudo-class draws to assign participants to a single justice involvement class 
likely resulted in underestimates of the magnitude of associations between justice involvement 
and overdose-related outcomes.62,64–66 While it is generally acceptable to assign class for models 
with entropy values of >0.8, we may have detected a stronger effect if we had used another 
approach.62 The disadvantages of implementing other approaches for this descriptive analysis did 
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not outweigh the benefits of the simpler approaches applied given that our purpose was to 
describe patterns in justice involvement and examine the prevalence of other variables within 
these classes. For example, we could have added our outcomes of interest (e.g. naloxone 
knowledge) into the LCA measurement model as covariates, but this would have changed the 
measurement model’s classes, resulting in different measurement models for each outcome. 
Further, the current implementation of LCA with covariates in SAS estimates odds ratios. The 
high prevalence of outcomes examined in this study presents a challenge where odds ratios do 
not estimate relative changes in prevalence, limiting the interpretability of odds ratios.67,68 Other 
approaches considered (e.g. the inclusive classify-analyze approach) would have also changed 
the formation of latent classes and is recommended for use with only one outcome.64  
 
2.6.1.2 Conclusions 
The low prevalence of naloxone knowledge and high prevalence of overdose experience 
and of witnessing an overdose in our sample of PWUO in a justice diversion addiction treatment 
program in Michigan suggests that OEND should be incorporated into justice diversion addiction 
treatment. Given the low levels of naloxone knowledge, OEND should be provided to all clients, 
regardless of pre-treatment overdose experience or justice involvement. OEND may need to 
address discrepancies between overdose response knowledge and confidence in responding to an 
overdose to minimize ineffective responses to a witnessed overdose.  
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Figure 2.1 Inclusion Criteria for a Sample of 514 People who Use Opioids in Justice Diversion 
Addiction Treatment during 2014-2016 
 
Our study included a sample of 514 PWUO in residential treatment who enrolled in our study, 
affirmed their involvement in justice diversion, used heroin or prescription opioids (not as 
prescribed by a doctor) in their lifetime, and had complete data on covariates of interest.  
 
Completed Survey (n=817)
Treatment associated with 
justice diversion program 
(n=777)
Used heroin or prescription 
opioids not as prescribed 
by a doctor (n=540)
• Was this treatment prompted or suggested by the criminal justice system 
(judge, probation/parole officer, etc.)?
• Excluded n=36 ‘No’ and n=4 missing
• Lifetime use of heroin or prescription opioids (not as prescribed by a doctor) 
• Excluded n=237 with non-opioid substance use
Complete covariate data 
(n=514)
• Reported age, gender, race, education level, housing status before treatment, 
number of witnessed overdoses, number of and time of most recent overdose, 
knowledge of naloxone and CPR, self-efficacy to change own overdose risk, 
respond to an overdose, and talk to others about their overdose risk
• Excluded n=26 with missing responses
• Residential treatment program patient
• Aged ≥18 years
• Provided informed consent
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Table 2.1 Sample Description of 514 People who Use Opioids in Justice Diversion Addiction Treatment during 2014-2016 by Gender 
 Total Women Men 
 n (%) n (%) n (%) 
Total 514 (100) 151 (100) 363 (100) 
Justice Involvementa    
Age at 1st arrest (years)    
Missing 2 (0.4) 0 (0) 2 (0.6) 
9-17 246 (47.9)  46 (30.5) 200 (55.1) 
18-20 138 (26.9) 48 (31.8) 90 (24.8) 
21-59 128 (24.9) 57 (37.8) 71 (19.6) 
Median (IQR) 18 (16-20.5) 19 (17-22) 17 (15-19) 
Lifetime arrests    
Missing 0 (0) 0 (0) 0 (0) 
1-5  173 (33.7) 61 (40.4) 112 (30.9) 
6-10  171 (33.3) 49 (32.5) 122 (33.6) 
11 or more  170 (32.1) 41 (27.2) 129 (35.5) 
Arrests in year before treatment or jail    
Missing 3 (0.6) 0 (0) 0 (0) 
0 167 (32.5) 24 (15.9) 143 (39.4) 
1-2 214 (41.6) 77 (51.0) 137 (37.7) 
3-42 130 (25.3) 50 (33.1) 80 (22.0) 
Median (IQR) 1 (0-3) 2 (1-3) 1 (0-2) 
Time spent in jail or prison in lifetime (years)   
Missing 7 (1.4) 4 (2.7) 3 (0.8) 
0-0.9 107 (20.8) 66 (43.7) 41 (11.3) 
1-3.4 135 (26.3) 47 (31.1) 88 (24.2) 
3.5-7.4 134 (26.1) 23 (15.2) 111 (30.6) 
7.5-41.3 131 (25.5) 11 (7.3) 120 (33.1) 
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Median (IQR) 3.5 (1-7.5) 1.1 (0.3-3) 5 (2.3-9.8) 
Time spent in jail or prison in past year (months)  
Missing 17 (3.3) 8 (5.3) 9 (2.5) 
0-1.9 119 (23.2) 43 (28.5) 76 (20.9) 
2-5.9 134 (26.1) 59 (39.1) 75 (20.7) 
6-10.9 125 (24.3) 28 (18.5) 97 (26.7) 
11-12 119 (23.2) 13 (8.6) 106 (29.2) 
Median (IQR) 5.3 (2-10) 3.1 (1.4-6) 6.5 (2.9-12) 
Overdose Experience    
Experienced an overdose 350 (68.1) 114 (75.5) 236 (65.0) 
Most recent overdose involved heroin and/or prescription opioidsb 254 (72.6) 87 (76.3) 167 (70.8) 
Experienced an overdose in the year before treatment 219 (42.7) 83 (55.0) 136 (37.5) 
Number of experienced overdoses in lifetime    
0 164 (31.9) 37 (24.5) 127 (35.0) 
1-5 225 (43.8) 63 (41.7) 162 (44.6) 
6 or more 125 (24.3) 51 (33.8) 74 (20.4) 
Witnessed Overdose    
Witnessed any overdose 407 (79.2) 127 (84.1) 280 (77.1) 
Most recently witnessed overdose involved heroin and/or prescription opioidsc 339 (83.3) 117 (92.1) 222 (79.3) 
Number of witnessed overdoses in lifetime    
0 107 (20.8) 24 (15.9) 83 (22.9) 
1-5 269 (52.3) 84 (55.6) 185 (51.0) 
6 or more 138 (26.9) 43 (28.5) 95 (26.2) 
Knowledge of Overdose Responses    
Heard of naloxone 319 (62.1) 109 (66.9) 210 (57.9) 
Identified purpose of naloxoned  289 (90.6) 101 (92.7) 188 (89.5) 
Heard of CPR 511 (99.4) 150 (99.3) 361 (99.5) 
Identified purpose of CPR (when someone stops breathing and/or heart stops)e 497 (97.3) 147 (98.0) 350 (97.0) 
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Demographic and Social Characteristics    
Age (years)    
18-29 174 (33.9) 69 (45.7) 105 (28.9) 
30-44  200 (38.9) 57 (37.8) 143 (39.4) 
45-67  140 (27.2) 25 (16.6) 115 (31.7) 
Median (IQR) 34 (27-46) 31 (26-40) 36 (28-48) 
Race    
Black 83 (16.2) 18 (11.9) 65 (17.9) 
White 384 (74.7) 116 (76.8) 268 (73.8) 
Other 13 (2.5) 3 (2.0) 10 (2.8) 
Multiple races 34 (6.6) 14 (9.3) 20 (5.5) 
Hispanic Ethnicity 24 (4.7) 5 (3.3) 19 (5.2) 
College or higher education 184 (35.8) 66 (43.7) 118 (32.5) 
Temporary housing in past 3 monthsf 290 (56.4) 77 (51.0) 213 (58.7) 
Substance Use    
Lifetime heroin use 347 (67.5) 117 (77.5) 230 (63.3) 
Heroin use in the past yearg 249 (71.9) 93 (79.5) 156 (67.8) 
Lifetime prescription opioid use (not as prescribed a doctor) 485 (94.4) 144 (95.4) 341 (93.9) 
Used prescription opioids in the past year (not as prescribed by a doctor)h 271 (55.9) 96 (66.7) 175 (51.3) 
aLatent class analysis allows for missing values in indicators and uses information on available indicators to create classes for 
participants with missing data. Therefore, totals for justice involvement may not add to the full sample size. 
bAmong those who experienced an overdose. Includes most recent experienced overdose events where the participant reported they 
used heroin and/or prescription opioids. An additional 7 participants (5 men, 2 women) did not report substances used. 
cAmong those who witnessed an overdose. Includes most recently witnessed overdose events where the participant reported that the 
victim used heroin and/or prescription opioids. An additional 9 participants (6 men, 3 women) did not know or did not report 
substances used by the victim. 
dAmong those who had heard of naloxone. 
eAmong those who had heard of CPR. 
fIncludes living in a halfway house or group home, inpatient facility, jail, shelter, or homeless. 
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gAmong those who used heroin in their lifetime. An additional 16 participants (10 men, 6 women) reported lifetime heroin use but 
declined to answer questions about past year heroin use. 
hAmong those who used prescription opioids in their lifetime. An additional 19 participants (14 men, 5 women) reported lifetime 
prescription opioid use but declined to answer questions about past year prescription opioid use. 
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Table 2.2 Overdose (OD) Attitudes by Naloxone Knowledge (NK) among Men and Women who Use Opioids in Justice Diversion 
Addiction Treatment during 2014-2016 (n=514) 
OD Attitudes Total Women Men 
 NKa No NK NKa No NK NKa No NK 
Total: n (%) 289 (56.2) 225 (43.8) 101 (66.9) 50 (33.1) 188 (51.8) 175 (48.2) 
Importance of reducing own OD risk: Median (IQR) 10 (9-10) 10 (9-10) 10 (10-10) 10 (10-10) 10 (8-10) 10 (9-10) 
Readiness to reduce own OD risk: Median (IQR) 10 (9-10) 10 (9-10) 10 (10-10) 10 (10-10) 10 (9-10) 10 (9-10) 
Higher than neutral (≥6) importance and readiness in 
reducing own OD risk: n (%) 
246 (85.1) 186 (82.7) 93 (92.1) 45 (90.0) 153 (81.4) 141 (80.6) 
Readiness to respond to an OD: Median (IQR) 10 (7-10) 10 (7-10) 10 (8-10) 10 (7-10) 10 (7-10) 10 (7-10) 
Confidence in responding to an OD: Median (IQR) 10 (7-10) 10 (7-10) 10 (8-10) 9 (7-10) 10 (7-10) 10 (7-10) 
Lower than neutral (≤5) confidence and readiness in 
responding to an OD: n (%) 
31 (10.7) 31 (13.8) 7 (6.9)* 9 (18.0)* 24 (12.8) 22 (12.6) 
High (≥8) confidence and readiness to respond to an 
OD: n (%) 
198 (68.5) 147 (65.3) 77 (76.2) 32 (64.0) 121 (64.4) 115 (65.7) 
aNaloxone knowledge was defined as having heard of naloxone and recognizing its purpose as an overdose reversal agent.  
*Chi-squared test supported statistically significant differences between women with and without NK (p=0.04).  
Abbreviations: NK: naloxone knowledge, OD: Overdose. 
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Table 2.3 Fit of a Latent Class Justice Involvement Measurement Model by Number of Classes 
among a Sample of People who Use Opioids in Justice Diversion Addiction Treatment during 
2014-2016 (n=514) 
Classes Log Likelihood AIC BIC Adjusted BIC Entropy 
2 -2897.1 595.7 701.7 622.4 0.82 
3 -2852.7 532.9 694.1 573.5 0.69 
4 -2841.6 536.7 753.0 591.1 0.71 
5 -2822.0 523.5 795.0 591.8 0.73 
6 -2809.3 524.1 850.8 606.4 0.73 
Bold font indicates optimal fit index value of the tested solutions. 
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Figure 2.2 Patterns of Justice Involvement among Men and Women who use Opioids in Justice Diversion Addiction Treatment during 
2014-2016 (n=363 men and 151 women) 
 
Two justice involvement classes per gender were identified among a sample of 514 PWUO in justice diversion addiction treatment. 
Men with low involvement (20.3% of men) were arrested for the first time at an older age and arrested more often in the past year. 
Men with high involvement (79.7%) had more arrests and incarceration time. Similar classes emerged among women, but women had 
more past year arrests and spent less time incarcerated than men. Women with low involvement comprised 46.5% of the sample and 
high involvement was slightly more common (53.5% of women). 
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Figure 2.3 Prevalence of Overdose Experiences, Response Knowledge, and Attitudes by Justice 
Involvement among People who Use Opioids in Justice Diversion Addiction Treatment during 
2014-2016 (n=363 men and 151 women) 
 
Prevalence of overdose experiences, naloxone knowledge, and overdose attitudes (bars) are 
annotated with the number of participants with each outcome. Prevalence of experiencing an 
overdose and witnessing an overdose was high across justice involvement groups and was 
slightly higher among women than men. Naloxone knowledge was also higher among women 
compared to men and did not differ by justice involvement. In both genders, few participants 
reported low confidence and readiness to respond to an overdose and did not have naloxone 
knowledge, while other overdose self-efficacy outcomes were more common.  
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Figure 2.4 Associations of Justice Involvement with Overdose Experiences among Men and Women who Use Opioids in Justice 
Diversion Addiction Treatment during 2014-2016 (n=363 men and 151 women) 
 
We summarized the association of justice involvement (referent: low involvement) with overdose experiences using prevalence ratios. 
Overdose experiences were not associated with justice involvement among men or women. Past year overdose was slightly less 
common among men in bivariate analyses but this association did not remain after adjustment for age and race.  
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Figure 2.5 Prevalence of Naloxone Knowledge (NK) by Overdose Experiences among People 
who Use Opioids in Justice Diversion Addiction Treatment during 2014-2016 (n=363 men and 
151 women) 
 
Prevalence of naloxone knowledge (bars) for participants with and without overdose experiences 
are annotated with the number of participants with naloxone knowledge in each category. 
Prevalence of naloxone knowledge was higher among men and women who experienced 
overdoses or witnessed an overdose. Naloxone knowledge prevalence differences were largest 
between participants with and without lifetime overdose experience for both men and women. 
Abbreviations: NK: naloxone knowledge.   
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Figure 2.6 Associations of Overdose Experiences and Justice Involvement with Naloxone 
Knowledge and Overdose Attitudes among Men and Women who Use Opioids in Justice 
Diversion Addiction Treatment during 2014-2016 (n=363 men and 151 women) 
 
Naloxone knowledge prevalence was higher among men and women who experienced or 
witnessed an overdose. Readiness and confidence outcomes were only assessed among 
participants without naloxone knowledge. Among women without naloxone knowledge, 
witnessing an overdose increased confidence and readiness to respond. This association was 
attenuated among men (p=0.07). Abbreviations: JI: Justice Involvement.  
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Chapter 3 Hepatitis C Transmission in Young People who Inject Drugs: Insights Using 
a Dynamic Model Informed by State Public Health Surveillance 
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3.1 Author Summary 
Increasing injection drug use arising from the opioid crisis has led to a concurrent increase 
in the incidence of hepatitis C virus (HCV) infections. How best to interrupt HCV transmission 
among young people who inject drugs (PWID) is unknown. We assessed this question in a 
simulation framework informed by HCV trends among young PWID in Michigan. Concurrent 
treatment of currently injecting and formerly injecting PWID could reduce prevalence and 
incidence; however, the predicted case reductions from treatment interventions varied widely. 
High cure rates from HCV treatment could be achieved by integrating HCV treatment into 
addiction treatment or syringe services programs.  
 
3.2 Abstract 
Increasing use of heroin and non-medical use of prescription opioids are major 
contributors to the observed increases in the incidence of hepatitis C Virus (HCV) infections in 
US young adults since the late 1990s. How best to interrupt transmission and decrease HCV 
prevalence in young people who inject drugs (PWID) is uncertain.  
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We developed an age-stratified transmission model of PWID aged 15-64, which we fit to 
Michigan HCV surveillance data among young PWID aged 15-29. We sampled ranges of model 
parameters using 10,000 Latin hypercube samples. We used the best-fitting 10% of simulations 
to predict the potential impact of primary (reducing injection initiation), secondary (increasing 
cessation, reducing injection partners, or reducing injection drug use relapse), and tertiary (HCV 
treatment) interventions on incident and prevalent HCV cases. We summarized these results by 
the predicted median percent reduction in acute and chronic HCV cases and range of predicted 
reductions across the best fitting 10% of simulations. 
Treating both current and former PWID led to the greatest predicted reductions in HCV 
prevalence and incidence. Treating 10% of current and former PWID per year could reduce HCV 
prevalence by 69.8% (range: 47.9-74.0%) and acute cases by 65.8% (range: 24.2-73.2%) among 
PWID aged 15-29 when 90% were cured (i.e. achieved sustained virologic response [SVR] to 
treatment). Treatment results were somewhat sensitive to the proportion cured. Treating 10% of 
current and former PWID with an SVR of 60% predicted a reduction of chronic HCV cases by 
55.0% (range: 36.2-59.5%). Restricting treatment to 10% of former PWID per year with a 90% 
SVR reduced the potential impact of treatment compared to treating both current and former 
PWID (median predicted prevalence decrease: 47.8%, range: 20.5-62.4%, median predicted 
decrease in acute cases: 44.4%, range: 4.1-62.3%).  
Primary and secondary interventions also reduced predicted HCV prevalence and 
incidence. For instance, reducing the number of syringe sharing partners per year by 10% 
predicted a 16.6% (range: 12.7-27.3%) reduction in chronic cases and a 19.7% (range: 13.0-
32.4%) reduction in acute cases. In simulations of combinations of interventions, reducing 
injection initiation, syringe sharing, and relapse rates each by 10% while increasing cessation 
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rates by 10% predicted a 49.1% (range: 40.1-67.3%) reduction in chronic HCV and a 57.7% 
(range: 47.1-77.3%) reduction in acute HCV. 
While these results are specific to Michigan, our approach could be applied in other states 
conducting HCV surveillance to identify local-level intervention opportunities. Our results 
highlight the need for HCV treatment among both current and former PWID. High SVR rates 
could be achieved by integrating HCV treatment into addiction treatment or syringe services 
programs. Further, these results support scaling up both primary and secondary interventions to 
further reduce HCV prevalence and incidence in Michigan. 
 
3.3 Introduction 
The epidemiology of hepatitis C virus (HCV) infections in the United States (US) has 
changed dramatically over the last decade, with notable increases in HCV incidence among 
young people aged approximately 15-29 years.1–5 These changes in incidence have been 
associated with increases in opioid and injection drug use (IDU).1–5 In the US, up to 2.6% of 
adults have injected drugs in their lifetime and more than half of US people who inject drugs 
(PWID) have HCV infection.6–11 IDU is the primary risk factor for new HCV infections in the 
US.5 After decades of asymptomatic chronic infection, HCV leads to liver-associated morbidity 
and mortality (e.g. cirrhosis and hepatocellular carcinoma).12,13 
In the US, transmission modeling studies have shaped HCV screening, treatment, and 
prevention policies by increasing our understanding of HCV transmission dynamics, forecasting 
prevalence of HCV-related liver diseases, and simulating the impact, costs, and benefits of 
highly effective direct-acting antivirals (DAAs) among PWID and other groups disparately 
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burdened by HCV.12,14–19 Multiple studies support the cost-effectiveness of treating PWID with 
DAAs to interrupt HCV transmission, a strategy known as ‘treatment as prevention.’15,16,18,20–43  
To our knowledge, only one modeling study has evaluated the potential impacts of HCV 
treatment among young PWID. In this study, Echevarria et al. suggested that treating just 5 per 
1,000 young PWID (<30 years) in Chicago could halve HCV prevalence in this age group over 
10 years (from 10% to 5%).15 This large predicted reduction from a modest intervention 
stemmed in part from the low baseline HCV prevalence among young PWID in Chicago 
compared with their older counterparts.15,44,45 HCV seroprevalence studies in several US cities 
(Baltimore, Chicago, Los Angeles, New York City, San Diego, and Seattle) suggest that HCV 
prevalence among young US PWID varies widely across the US, with estimates ranging 10-53%; 
however, estimates are unavailable for a majority of states and cities.15,44–49 This absence of local 
HCV seroprevalence estimates limits our ability to evaluate prevalence trends and the potential 
impact of interventions. We demonstrate here that HCV public health surveillance data collected 
as part of nationally notifiable and state-reportable condition surveillance might be used to 
evaluate the potential impact of interventions among young PWID in locations without a 
systematic characterization of HCV prevalence.50  
HCV incidence increases in young adults and adolescents were first identified using HCV 
public health surveillance data.2,51,52 As part of HCV surveillance, laboratories and physicians 
report positive HCV lab results to state health departments, who apply standard case definitions 
to stage HCV as acute or chronic.53–56 Underreporting of HCV cases limits use of surveillance 
data for purposes other than description and outbreak monitoring.2 Klevens et al. estimated the 
magnitude of acute HCV under-reporting at approximately 12.3-16.8 cases per case reported in a 
nationwide study.57 However, Onofrey et al. suggested that the magnitude of under-detection 
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may be even higher: up to 138 acute cases per reported acute case.58 In addition to under-
reporting, there is high variability in capacity to collect risk factor or demographic information, 
trace contacts, and connect people with HCV infection to further testing and treatment.2,5 These 
limitations have discouraged use of public health surveillance data for HCV transmission 
modeling. 
We developed an HCV transmission model fit to HCV surveillance data among 15-29 year 
olds in Michigan that adjusts for case under-reporting. We reviewed the literature to identify 
ranges for model parameters and simulated the model across 10,000 plausible scenarios using 
Latin hypercube sampling, a form of stratified random sampling.50,59 We then evaluated the 
potential impact of several interventions, including primary prevention (reduced injection 
initiation), secondary prevention (behavioral initiatives), and tertiary initiatives (HCV treatment) 
in a counterfactual framework by summarizing the predicted reduction in HCV prevalence 
(chronic cases) and incidence (acute cases). This modeling framework could be applied to HCV 




A detailed discussion of the model structure, parameters, initial conditions, surveillance 
data, and parameter estimation process is available in Appendix 3.1. Matlab (The MathWorks 
Inc, Natick, MA) code for model simulation and R (R Foundation for Statistical Computing, 




3.4.1 Model Structure 
An HCV ordinary differential equation (ODE) transmission model of PWID with 
preferential age mixing was developed and implemented in Matlab R2017b. The model consists 
of 11 states per age group, with age groups of 15-19 years, 20-25 years, 26-29 years, and 30-64 
years (Figure 3.1). Individuals age through groups and transition through a series of 
compartments within age classes: uninfected, non-PWID with substance dependence or abuse 
(Zi), uninfected current or former PWID (Si or SNi, respectively), acutely infected current or 
former PWID (Ai or ANi, respectively), chronically infected current or former PWID (Ci or CNi, 
respectively), immune current or former PWID (Ii or INi, respectively), and treated current or 
former PWID (Ti or TNi, respectively).  
Individuals in our model acquire HCV by injecting drugs; other transmission modes (e.g. 
perinatal acquisition, unregulated tattoos, sexual transmission) are not considered. IDU is the 
primary risk factor for new HCV infections in the US, therefore we focus on this risk factor.5 
Non-PWID initiate IDU at an estimated injection initiation rate, i, calibrated to fit HCV 
surveillance data. Susceptible current PWID acquire new infections at an estimated rate  
through effective contact (i.e. syringe sharing) with an infected (acute [Aj] or chronic [Cj]) or 
treated (Tj) current PWID in any age class. Contact rates between current PWID in each age 
class are parametrized by partitioning each susceptible individual’s (Si) total contacts (i) into 
the number of contacts per each age class. This partitioning of contacts is parametrized by a 
contact matrix, , which is adapted from social contact patterns in eight European countries and 
informed by a study of IDU syringe sharing networks (Appendix 3.1).60,61 Individuals from any 
of the current PWID classes can stop injecting drugs and move to their adjacent former PWID 
class at a cessation rate i while former PWID can begin injecting again after a period of 
 66 
injection abstinence and enter the current PWID class at a relapse rate i. To maintain a realistic 
ratio of current to former PWID during model fitting to data, we calculated age-specific relapse 
rates for each simulation using the sampled cessation rates and prevalence of current and former 
IDU in the US based on national survey data (Appendix 3.1).1,6,62 
 
3.4.2 Surveillance Data, Parameter Estimation, and Parameter Sampling 
The Michigan Department of Health and Human Services (MDHHS) receives reports of 
HCV diagnoses from healthcare providers and laboratories and stages cases as acute or chronic 
using standardized national case definitions.53,54 We obtained the number of newly identified 
acute and chronic HCV cases per year during 2000-2016 (Table 3.1).  
We made three adjustments to the acute case series to facilitate model fitting to data 
(Appendix 3.1). First, we adjusted the number of 2016 cases to the number that would have been 
detected by the 2012 case definition.53,55 We assumed that only 74% of 2016 cases would have 
met the 2012 definition in accordance with an unpublished case series review conducted by 
MDHHS. Second, we substituted the number of acute cases among 15-19 year olds for the 
number of new chronic cases reported to MDHHS during the same period adjusted for under-
reporting to facilitate model fitting (Figure 3.2). Finally, we adjusted for under-detection of the 
acute cases by MDHHS surveillance using a mid-point estimate between the correction factor 
developed by Klevens et al. and an estimate from Onofrey et al. of 1 case detected per 50 acute 
infections.57,58 
To incorporate parameter uncertainty, we drew a stratified random sample of 10,000 
parameter sets across plausible ranges gathered through literature review using Latin hypercube 
sampling (Table 3.2). We used an initial (year 2000) HCV prevalence of 10% among 15-19 year 
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olds, 20% among 20-25 year olds, 30% among 26-29 year olds, and 55.2% among 30-64 year 
olds in alignment with prevalence estimates from several US locations; no data were available 
for Michigan.10,15,44–49 To optimize model fit to data, we estimated four unknown parameters (the 
transmission rate [] and three age-specific injection initiation rates [i]) in each simulation using 
unweighted least squares assuming normally distributed measurement error with equal variances 
for each data point. The rate of injection initiation for 30-64 year olds was not estimated as we 
had no data to fit to for this age group and because the focus of our analysis was on young 
PWID. Instead, we sampled this parameter.  
Residual sum of squares values after parameter estimation were used to select the best-
fitting 10% of parameter sets to data (i.e. 1,000 simulations). To determine if a certain range 
appeared more consistent with data, we plotted histograms by quartile of fit to visualize 
differences in fit along uniformly sampled parameter ranges (Figure 3.3). Parameter estimation 
and simulations were run using fminsearchbnd and the ODE15S solver in Matlab (due to 
stiffness in some simulation runs).63 Appendix 3.1 outlines details for the selection of bounds for 
estimated parameters used in fminsearchbnd and a discussion of our reasons for expanding 
injection initiation rate bounds from values found in the literature.64–74 
 
3.4.3 Intervention Simulations 
We selected the best-fitting 10% of parameter sets (1,000 simulations) to simulate the 
potential impact of interventions on HCV incidence (acute cases) and prevalence (chronic cases) 
among 15-29 year olds in Michigan. The model was re-simulated after scaling one or more 
parameters, which provided counterfactual estimates of the expected percent reduction in acute 
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or chronic HCV cases in the presence of interventions compared to baseline model estimates 
from the model fitting phase (i.e. no intervention).  
We simulated primary prevention interventions (reduced injection initiation [i]), 
secondary prevention interventions (decreased syringe sharing [i], decreased IDU relapse [i], 
and increased IDU cessation [i]), and tertiary prevention interventions (treatment of former [N] 
and current PWID [P]).75 Although parameters cannot be singly classified into primary, 
secondary, and tertiary (e.g. current PWID treatment is tertiary [treatment] and secondary 
[reduces transmission]), these terms classify interventions by their most immediate roles. 
Parameters were scaled at 10%, 20%, and 40%. For treatment, these can be interpreted as 
treating 10%, 20%, or 40% of PWID per year. We first simulated the expected impact of each 
intervention alone. Next, we simulated the expected impact of combinations of interventions, 
specifically to compare the added benefit of secondary interventions on top of primary versus 
tertiary approaches. Intervention results are summarized by comparing the expected percent case 
reduction for acute and chronic HCV cases at the end of the 17-year simulation period (year 
2016) compared to no intervention. 
We conducted three sensitivity analyses for HCV treatment interventions. We first 
examined the impact of sustained virologic response (SVR), a measure of the percentage cured 
by HCV treatment.76 We assumed that approximately 90% of individuals achieved SVR in main 
intervention simulations in alignment with a recent meta-analysis of DAAs by Ferreira et al., and 
examined values of 60-100% in sensitivity analyses to examine the potential impact of treatment 
incompletion among PWID.76–82 We next examined expected case counts when a proportion of 
current PWID in treatment transmitted HCV. We assumed that 50% of treated current PWID 
contributed to transmission in the main results, and compared values of 0-100% in sensitivity 
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analyses. Finally, we simulated a treatment duration of 12 weeks for the main analysis, and 
examined 8 and 16 week durations in sensitivity analyses; all are typical treatment durations for 
currently approved DAAs.13  
 
3.5 Results 
3.5.1 Model Fit to Acute HCV Surveillance Data 
The model fit data well for the 1,000 parameter sets used to simulate interventions 
(Figure 3.4, top). However, under some simulated conditions, case counts were overestimated 
(Figure 3.4, bottom). Chronic HCV prevalence generally increased throughout the period, 
especially among 15-29 year olds; however, there was a wide range in predicted prevalence due 
to the variability of conditions assessed (Figure 3.5). A variety of scenarios across sampled 
parameter ranges fit the data well (Figure 3.3). Better-fitting parameter sets had a slight tendency 
towards a lower transmission rate, injection initiation rates, and total contacts among 26-29 year 
olds, and towards a higher number of total contacts among 20-25 year olds and former PWID 
prevalence among 26-29 year olds. 
 
3.5.2 Intervention Simulations 
We simulated the potential impact of primary (reducing injection initiation), secondary 
(increasing cessation, reducing injection partners, or reducing injection drug use relapse), and 
tertiary (HCV treatment) interventions on incident and prevalent chronic HCV cases among 
young (aged 15-29 years) PWID. Among the best-fitting 1,000 simulations, treating former 
PWID predicted the largest reduction in chronic HCV prevalence (chronic HCV cases) and 
incidence (acute HCV cases) among 15-29 year olds at year 17 of simulation (Figure 3.6). While 
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this represents an ‘on average’ finding (over the 1,000 tested parameter sets), there were some 
scenarios wherein high current PWID prevalence made treating current PWID equally as 
effective as treating former PWID. In general, the predicted percent case reductions from 
treatment were highly dependent on parameter values, and therefore the predicted effectiveness 
of treatment spanned a large range, especially among former PWID.  
Primary and secondary interventions also reduced prevalence and incidence, but less so 
than treatment (Figure 3.6). However, predicted impacts of these interventions were less variable 
than treatment interventions. Reductions in syringe sharing and injection initiation were 
predicted to be more effective than decreasing relapse. For instance, reducing the number of 
syringe sharing partners per year by 10% reduced HCV prevalence by 16.6% (range: 12.7-
27.3%) and acute cases by 19.7% (range: 13.0-32.4%).  
When considered in combination, adding secondary interventions enhanced the predicted 
reductions from primary prevention initiatives (reduced injection initiation) and HCV treatment 
when provided at lower levels (Figure 3.7). Treating former and current PWID together also 
reduced the uncertainty in treatment effect compared to treatment of former or current PWID 
alone. Treating 10% of both current and former PWID per year predicted a reduction in HCV 
prevalence by 69.8% (range: 47.9-74.0%) and incidence by 65.8% (range: 24.2-73.2%) among 
PWID aged 15-29 when we assumed that 90% were cured (i.e. achieved SVR). Reducing 
injection initiation, syringe sharing, and relapse rates each by 10% while increasing cessation 
rates by 10% reduced HCV prevalence by 49.1% (range: 40.1-67.3%) and acute cases by 57.7% 
(range: 47.1-77.3%). These magnitudes of predicted reductions were similar to those predicted 
for treatment of 10% of former PWID per year, but with much less variability. 
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3.5.3 Sensitivity Analyses 
We assessed the impact of three aspects of treatment on predicted reduction of HCV 
incidence and prevalence. Reducing the proportion of treated current PWID who achieved SVR 
(i.e. were cured by treatment) made treatment less effective (Figure 3.8). The magnitude of these 
effects was similar for former PWID (data not shown). Treatment duration and the proportion of 
treated current PWID who shared syringes (and contributed to transmission during treatment) did 
not impact predicted treatment effectiveness. 
 
3.6 Conclusions 
We developed and implemented an HCV transmission model among young PWID 
informed by Michigan HCV surveillance data, and leveraged our model to evaluate the relative 
benefits of primary, secondary, and tertiary interventions for reducing HCV prevalence and 
incidence. The incorporation of state-level surveillance data allowed us to evaluate interventions 
in a framework consistent with the HCV incidence trends in Michigan. Simulation results 
suggested that HCV treatment was the most effective strategy, especially when both former and 
current PWID received treatment. Both singly and in combination with secondary prevention 
measures, such as decreasing relapse, increasing cessation, and decreasing syringe sharing, 
treatment predicted substantial reduction of chronic HCV infections. In line with the concept of 
‘treatment as prevention,’ treatment also yielded reductions to acute HCV. We found no decrease 
in predicted reductions from HCV treatment when PWID continued to share syringes and 
contributed to transmission during treatment, supporting current recommendations that all PWID 
be provided treatment, regardless of their IDU behaviors.13 
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There are several important caveats to our findings about HCV treatment. First, the 
predicted impact of treatment was highly uncertain across scenarios tested, all of which represent 
reasonable approximations to the current HCV epidemic and PWID prevalence, given their 
parametrization using findings from empirical studies. In addition, compartmental HCV models 
that do not account for the dynamic network structure of syringe sharing are known to 
overestimate treatment effects, especially their treatment as prevention potential.83 Incorporating 
network structure was beyond the scope of this model; however, we did incorporate some 
heterogeneity in IDU contact patterns based on age, and modeled contact patterns under a variety 
of scenarios. Further, our model was optimized at low estimates of the transmission rate, , given 
its range of values in the literature.84–86 This may reflect and account for some of the 
exaggeration of contact rates that contribute to the overestimation of HCV treatment’s 
effectiveness in non-network models. Nonetheless, the predicted impacts of treatment should be 
taken as an upper bound of the potential treatment effect and the integration of a network model 
within our current framework is an area for future model development. Finally, treatment results 
were somewhat sensitive to cure rates. Taken together, these results emphasize the importance of 
engaging PWID in treatment until cure, and highlight the need to incorporate behavioral 
interventions that compliment treatment, given the uncertainty about its effects. 
Primary prevention interventions that reduce injection initiation and secondary prevention 
interventions, which reduce syringe sharing, promote injection cessation, and prevent relapse, 
consistently predicted reductions in HCV prevalence and incidence. These results were robust 
across tested scenarios (i.e. parameter sets). Thus, while HCV treatment is a major public health 
priority, primary and secondary interventions should be implemented concurrently. These 
simulated primary and secondary interventions are meant to represent real-world initiatives, such 
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as expanded access to addiction treatment services and medication assisted treatments, which 
help PWID stop using and prevent relapse, or the “Staying Safe,” “Break the Cycle,” or “Change 
the Cycle” interventions, which promote safe drug injection and prevent people who use drugs 
from initiating injection.87,88 With respect to treatment, several studies have found that providing 
HCV treatment within existing addiction treatment or syringe services programs is feasible and 
produces cure rates similar to those seen in randomized controlled trials of DAAs among non-
PWID, even when patients continue to use drugs.76,79,81,82 In addition to reducing the public 
health impacts of HCV directly, interventions that include behavioral risk reduction focused on 
IDU could concurrently reduce the economic costs of HCV, which increase with earlier age of 
infection, and the economic and societal costs of heroin and other opioid use disorders.89,90 Our 
results therefore reinforce the need for an integrated care model. For example, harm reduction 
programs should provide co-located services that include provision of sterile injecting 
equipment, bystander overdose response training, bloodborne virus testing and referral to (or 
coordination of) treatment for HCV and Human Immunodeficiency Virus, and other services, 
such as mental health counseling, addiction treatment, or opioid maintenance therapy.91  
 
3.6.1.1 Limitations 
Like all modeling exercises, we made several simplifying assumptions, and we were 
limited by existing data. Our model only considers HCV acquisition through IDU and we focus 
results on PWID aged 15-29 given available data. Our results may not be generalizable to other 
age or risk groups. Cases with missing risk factor data were assumed to be PWID, consistent 
with PWID being the most common risk factor for HCV.3,5,92 Because surveillance data suffers 
from under-reporting and missing data, we applied a reporting rate to adjust for under-detection 
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of cases by surveillance during the time period under study, although the true number of 
undetected cases is unknown.57,58 We used a scaled version of newly reported chronic cases 
instead of the acute case series among 15-19 year olds due to the high variability in reported 
acute cases in this age group. To address uncertainty in model parameter values, we sampled 
nearly all parameters and used values most consistent with surveillance data to simulate 
interventions.  
Our model assumed homogeneous mixing beyond age and used a contact matrix from 
Mossong et al., a European study of social contacts, that may not reflect the age-related patterns 
underlying syringe sharing.60 We therefore expanded the ranges presented by Mossong et al. in 
an effort to capture many plausible syringe sharing scenarios. However, treatment effects may 
still be overestimated and should be interpreted as the maximum possible impact of treatment.83 
Treatment interventions also assumed a treatment-naïve population in model fitting, however this 
is likely realistic given the historically low treatment rates among PWID during the time period 
under study.93–96 Finally, in some simulations, our model’s estimated injection initiation rates 
exceeded values found in the literature.64–74 This discrepancy in injection initiation rates could be 
for several reasons, including that injection initiation rates were not available for Michigan, that 
available studies were conducted among specific populations (e.g. Canadian street youth), or 
because high estimated values of injection initiation rates were artefacts of poorly fitting 
simulations or ill-suited initial conditions to data. Intervention simulations were conducted on the 
best fitting 10% of simulations, and therefore reflect the potential impact of interventions for 




HCV surveillance data is a valuable source of information for understanding HCV 
transmission and identifying local intervention opportunities among young PWID. In Michigan, 
HCV treatment could reduce prevalence and incidence. The impact of treatment is more certain 
when both former and current PWID are treated and when treatment is combined with behavioral 
interventions that reduce injection drug use initiation or syringe sharing, increase injection 
cessation, and reduce relapse. PWID at all stages of use or recovery should be connected to HCV 
treatment alongside primary and secondary prevention interventions. 
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Figure 3.1 Hepatitis C Transmission Model among People who Inject Drugs: Model States and 
Parameters 
 
This diagram outlines model states and parameters controlling flows between states of an HCV 
transmission model among PWID in Michigan. Non-PWID with substance abuse or dependence 
(Zi) begin injecting drugs (Si) at a rate i and acquire acute infection (Ai) through effective 
contact with an HCV-infected PWID (Aj or Cj or Tj) of the same or discordant age (j,i) at a 
transmission rate (). Chronic infection (Ci) develops at a rate  among a proportion of acute 
cases, (1-), and resolves in the remaining  acute cases, of whom  develop sterilizing immunity 
and the remaining (1-) become susceptible to reinfection. Chronic infection can be treated (Ti) 
at a rate P, for a duration of -1 years, after which point susceptibility to reinfection ensues. 
PWID stop injecting drugs at a rate i and transition to former PWID states (denoted by StateNi). 
Former PWID can begin injecting drugs after a period of abstinence at a rate i. Death occurs at 
a rate i, which is elevated among current PWID by a factor P and among non-PWID by a factor 
Z. Former PWID mortality rates are closer to mortality rates from the general Michigan 
population (i) by multiplying the current PWID mortality increase factor by a protective factor 
N. Subscript i denotes parameter or state age class (1: 15-19 years, 2: 20-25 years, 3: 26-29, 4: 
30-64 years) and subscript j denotes the age group of contacts from whom susceptible current 
PWID (Si) can acquire infection. Individuals move through age groups based on the duration 
predicted by the age range captured in each group (i, not depicted for simplicity) and new 15 
year-olds are added to the non-PWID compartment each year at a rate 0NZ0 (not depicted for 
simplicity). 
 77 
Table 3.1 Acute HCV Cases among 15-29 Year Olds Detected by Viral Hepatitis C 
Surveillance⎯Michigan, 2000-2016 
Characteristic N (%) 
Total 343 (100.0) 






Black or African American 10 (2.9) 
White 286 (83.4) 
Other or Multiple Races 21 (6.1) 
Unknown 25 (7.3) 
Ethnicity  
Hispanic or Latino 11 (3.2) 
Not Hispanic or Latino 195 (56.9) 
Unknown 137 (39.9) 
Injected Drugs in the 2 Weeks to 6 Months Before Symptom Onsetc  
Yes 226 (65.9) 
Unknown or Missing 117 (34.1) 
Case Status  
Confirmed 333 (97.1) 
Probable 10 (2.9) 
aAll remaining cases were male. No cases were unknown or other gender. 
bFor simulations, we used a case series of newly reported chronic infections to MDHHS among 
15-19 year olds, which was scaled for under-reporting (Appendix 3.1). 
c67 cases who reported no IDU in the 2 weeks to 6 months before symptom onset were excluded 
from the present analysis.
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Figure 3.2 Acute and Newly Reported Chronic HCV Cases Detected by Viral Hepatitis Surveillance among PWID Aged 15-
19⎯Michigan, 2000-2016 
 
The acute HCV case series among 15-19 year olds (red) was characterized by few cases with high variability, presenting a challenge 
for model fitting to data, whereas newly reported chronic cases, another case series used to summarize HCV incidence, showed a more 
consistent trend (green). We used the 15-19 new chronic case series (blue) scaled by the under-reporting rate from Klevens et al. 
during model fitting.57
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Table 3.2 Parameters and Sampling Ranges Incorporated through Latin Hypercube Sampling for an HCV Transmission Model among 
PWID in Michigan 




Units Definition Source 
 NA (Intervention) % Percent treated who are cured 
(achieve sustained virologic 
response) 
Intervention sensitivity analysis, 
tested scenarios from Aspinall et 
al.,78 Butner et al.,79 Eckhardt et al.,81 
Ferreira et al.76, Hellard et al.,77 
Saeed et al.,80 Trabut et al.82 
 0.000019 (0-10.0)b % Probability of infection given 
contact with HCV 
Fit to data from CDC,84 Hasan et 
al.,85 Mitsui et al.86 
1 0.42 (0.07-1.2) Years-1 Injection cessation rate (15-19 
years) 
Chang et al.,97 Fazito et al.,98 
Genberg et al.99 
2 0.18 (0.07-1.2) Years-1 Injection cessation rate (20-25 
years) 
Chang et al.,97 Fazito et al.,98 
Genberg et al.99 
3 1.0 (0.07-1.2) Years-1 Injection cessation rate (26-29 
years) 
Chang et al.,97 Fazito et al.,98 
Genberg et al.99 
4 0.08 (0.07-1.2) Years-1 Injection cessation rate (30-64 
years) 
Chang et al.,97 Fazito et al.,98 
Genberg et al.99 
 0.19 (0.15-0.5) Years-1 Probability of spontaneously 
resolving acute HCV 
Chung,100 Heller & Rehermann,101 
Thomas & Seeff,102 Westbook & 
Dusheiko103 
-1 0.5 (NS) Years-1 Duration of acute infection Westbook & Dusheiko103 
1 0.52 (0.15-1.0) % Prevalence of past year injection 
drug use (ages 15-19, year 2000) 
NSDUH (ICPSR)62 & Tempalski et 
al.1 
2 0.30 (0.26-1.0) % Prevalence of past year injection 
drug use (ages 20-25, year 2000 
NSDUH (ICPSR)62 & Tempalski et 
al.1 
3 0.56 (0.19-1.0) % Prevalence of past year injection 
drug use (ages 26-29, year 2000 
NSDUH (ICPSR)62 & Tempalski et 
al.1 
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4 0.59 (0.16-1.1) % Prevalence of past year injection 
drug use (ages 30-64, year 2000 
NSDUH (ICPSR)62 & Tempalski et 
al.1 
N 0.37 (0.18-0.54) Unitless Standardized mortality ratio: 
former vs. current PWID 
Mathers & Degenhardt104 
P 11.7 (2.5-15.3) Unitless Standardized mortality ratio: 
current PWID vs. general 
population 
Degenhardt et al.,105 Evans et al.,106 
Vlahov et al.107 
Z 4.3 (4.3-4.4) Unitless Standardized mortality ratio: non-
PWID who use drugs vs. general 
population 
Veldhuizen & Callaghan108 
1 4.2 (0.05-5.0)b Years-1 Injection initiation rate (ages 15-
19 years) 
Fit to data from Arreola et al.,71 
Bluthenthal et al.,73 Chami et al.,70 
Ompad et al.,66 Parriott et al.,64 
Reddon et al.,74 Roy et al.,65 Roy et 
al.,67 Young & Havens69 
2 1.9 (0.034-5.0)c Years-1 Injection initiation rate (ages 20-
25 years) 
Fit to data from Arreola et al.,71 
Bluthenthal et al.,73 Chami et al.,70 
Lake et al.,72 Ompad et al.,66 Parriott 
et al.,64 Reddon et al.,74 Roy et al.,65 
Roy et al.,67 Young & Havens69 
3 10.0 (0.034-10)b Years-1 Injection initiation rate (ages 26-
29 years) 
Fit to data from Arreola et al.,71 
Bluthenthal et al.,73 Lake et al.,72 
Ompad et al.,66 Stein et al.,68 Young 
& Havens69 
4 0.046 (0.034-1.0)b Years-1 Injection initiation rate (ages 30-
64 years) 
Fit to data from Arreola et al.,71 Lake 




Years-1 Injection drug use relapse rate 
(ages 15-19 years) 
Calculated and checked for 
consistency with previous work 
(Evans et al.,109 HHS,91 Hubbard et 
al.,110 McLellan et al.111) 
2 0.062 (0.00077-
1.7)c 
Years-1 Injection drug use relapse rate 
(ages 20-25 years) 
Calculated and checked for 
consistency with previous work 
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(Evans et al.,109 HHS,91 Hubbard et 
al.,110 McLellan et al.111) 
3 0.16 (0.000046-
1.4)c 
Years-1 Injection drug use relapse rate 
(ages 26-29 years) 
Calculated and checked for 
consistency with previous work 
(Evans et al.,109 HHS,91 Hubbard et 




Years-1 Injection drug use relapse rate 
(ages 30-64 years) 
Calculated and checked for 
consistency with previous work 
(Evans et al.,109 HHS,91 Hubbard et 
al.,110 McLellan et al.,111 Shah et 
al.112) 
1  10 (NS) % Initial HCV prevalence (ages 15-
19 years, year 2000) 
Amon et al.,46 Boodram et al.,44 
Echevarria et al.,15 Garfein et al.,47 
Garfein et al.,45 Garfein et al.,48 
Jordan et al.49 
2 20 (NS) % Initial HCV prevalence (ages 20-
25 years, year 2000) 
Amon et al.,46 Boodram et al.,44 
Echevarria et al.,15 Garfein et al.,47 
Garfein et al.,45 Garfein et al.,48 
Jordan et al.49 
3 30 (NS) % Initial HCV prevalence (ages 26-
29 years, year 2000) 
Amon et al.,46 Boodram et al.,44 
Echevarria et al.,15 Garfein et al.,47 
Garfein et al.,45 Garfein et al.,48 
Jordan et al.49 
4 55.2 (NS) % Initial HCV prevalence (ages 30-
64 years, year 2000) 
Degenhardt et al.10 
1 55.3 (NS) Persons*100,000 
Persons-1*Years-1 
Mortality rate (ages 15-19 years) CDC Wonder113 & Freide et al.114 
2 91.5 (NS ) Persons*100,000 
Persons-1*Years-1 
Mortality rate (ages 20-25 years) CDC Wonder113 & Freide et al.114 
3 119.0 (NS) Persons*100,000 
Persons-1*Years-1 
Mortality rate (ages 26-29 years) CDC Wonder113 & Freide et al.114 
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4 493.0 (NS) Persons*100,000 
Persons-1*Years-1 
Mortality rate (ages 30-64 years) CDC Wonder113 & Freide et al.114 
0-1 1 (NS) Years Rate of entry of new 15-year olds 
per year 
Not applicable 
1-1  5 (NS) Years Duration in 15-19 year old age 
class 
Not applicable 
2-1 6 (NS) Years Duration in 20-25 year old age 
class 
Not applicable 
3-1 4 (NS) Years Duration in 26-29 year old age 
class 
Not applicable 
4-1 35 (NS) Years Duration in 30-64 year old age 
class 
Not applicable 
 42 (0-45) % Probability of developing 
immunity after spontaneous acute 
HCV clearance 
Little data, informed by Mehta et 
al.115 
1 0.93 (0.43-1.0) % Prevalence of formerly injecting 
drugs (ages 15-19, year 2000) 
Lansky et al.6 & NSDUH (ICPSR)62 
2 0.94 (0.71-1.0) % Prevalence of formerly injecting 
drugs (ages 20-25, year 2000) 
Lansky et al.6 & NSDUH (ICPSR)62 
3 2.1 (0.81-2.1) % Prevalence of formerly injecting 
drugs (ages 26-29, year 2000) 
Lansky et al.6 & NSDUH (ICPSR)62 
4 1.9 (1.6-2.7) % Prevalence of formerly injecting 
drugs (ages 30-64, year 2000) 
Lansky et al.6 & NSDUH (ICPSR)62 
1,1 3.0 (1.6-9.3) Contacts*Persons-1 
* Days-1 
Sampled number of 15-19 year 
old contacts aged 15-19 years 
Mossong et al.60 & Williams et al.61 
1,2 0.32 (0.25-1.6) Contacts*Persons-1 
* Days-1 
Sampled number of 20-25 year 
old contacts aged 15-19 years 
Mossong et al.60 & Williams et al.61 
1,3 0.16 (0.12-0.47) Contacts*Persons-1 
* Days-1 
Sampled number of 26-29 year 
old contacts aged 15-19 years 
Mossong et al.60 & Williams et al.61 
1,4 0.42 (0-3.1) Contacts*Persons-1 
* Days-1 
Sampled number of 30-64 year 
old contacts aged 15-19 years 
Mossong et al.60 & Williams et al.61 
2,1 0.84 (0.3-1.2) Contacts*Persons-1 
*Days-1 
Sampled number of 15-19 year 
old contacts aged 20-25 years 
Mossong et al.60 & Williams et al.61 
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2,2 2.5 (0.92-3.7) Contacts*Persons-1 
*Days-1 
Sampled number of 20-25 year 
old contacts aged 20-25 years 
Mossong et al.60 & Williams et al.61 
2,3 0.64 (0.35-2.3) Contacts*Persons-1 
*Days-1 
Sampled number of 26-29 year 
old contacts aged 20-25 years 
Mossong et al.60 & Williams et al.61 
2,4 4.3 (0-4.5) Contacts*Persons-1 
*Days-1 
Sampled number of 30-64 year 
old contacts aged 20-25 years 
Mossong et al.60 & Williams et al.61 
3,1 0.33 (0.16-0.44) Contacts*Persons-1 
*Days-1 
Sampled number of 15-19 year 
old contacts aged 26-29 years 
Mossong et al.60 & Williams et al.61 
3,2 0.63 (0.47-1.8) Contacts*Persons-1 
*Days-1 
Sampled number of 20-25 year 
old contacts aged 26-29 years 
Mossong et al.60 & Williams et al.61 
3,3 1.1 (0.64-2.3) Contacts*Persons-1 
*Days-1 
Sampled number of 26-29 year 
old contacts aged 26-29 years 
Mossong et al.60 & Williams et al.61 
3,4 3.3 (0-6.4) Contacts*Persons-1 
*Days-1 
Sampled number of 30-64 year 
old contacts aged 26-29 years 
Mossong et al.60 & Williams et al.61 
4,1 1.0 (0-2.8) Contacts*Persons-1 
*Days-1 
Sampled number of 15-19 year 
old contacts aged 30-64 years 
Mossong et al.60 & Williams et al.61 
4,2 3.0 (0-4.7) Contacts*Persons-1 
*Days-1 
Sampled number of 20-25 year 
old contacts aged 30-64 years 
Mossong et al.60 & Williams et al.61 
4,3 1.7 (0-5.0) Contacts*Persons-1 
*Days-1 
Sampled number of 26-29 year 
old contacts aged 30-64 years 
Mossong et al.60 & Williams et al.61 
4,4 33 (13-34) Contacts*Persons-1 
*Days-1 
Sampled number of 30-64 year 
old contacts aged 30-64 years 
Mossong et al.60 & Williams et al.61 
-1 50 (NS) True Cases per 
Surveillance-
Detected Case 
Reporting rate Informed by Klevens et al.57 & 
Onofrey et al.58 
1 14.3 (5.0-20) Contacts*Years-1 Syringe sharing partners among 
PWID aged 15-19 years 
Wide range sampled (e.g. Conrad et 
al.,116 Eckhardt et al.,117 Kim et al.,118 
Mackesey-Amiti et al.,119 Williams et 
al.61) 
2 10.1 (5.0-20) Contacts*Years-1 Syringe sharing partners among 
PWID aged 20-25 years 
Wide range sampled (e.g. Conrad et 
al.,116 Eckhardt et al.,117 Kim et al.,118 
Mackesey-Amiti et al.,119 Williams et 
al.61) 
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3 9.9 (5.0-20) Contacts*Years-1 Total number of syringe sharing 
partners among PWID aged 26-29 
years 
Wide range sampled (e.g. Conrad et 
al.,116 Eckhardt et al.,117 Kim et al.,118 
Mackesey-Amiti et al.,119 Williams et 
al.61) 
4 16.2 (5.0-20) Contacts*Years-1 Syringe sharing partners among 
PWID aged 30-64 years 
Wide range sampled (e.g. Conrad et 
al.,116 Eckhardt et al.,117 Kim et al.,118 
Mackesey-Amiti et al.,119 Williams et 
al.61) 
 NA (Intervention) % Proportion of currently injecting 
PWID who transmit during 
treatment 
Intervention sensitivity analysis, 
tested scenarios across full range (0-
100%) 
P NA (Intervention) Years-1 Treatment rate, current PWID Intervention, tested various scenarios 
including Mehta et al.93 & Saeed et 
al.80 
N NA (Intervention) Years-1 Treatment rate, former PWID Intervention, tested various scenarios 
including Mehta et al.93 & Saeed et 
al.80 
1 1.9 (1.6-2.1) % Prevalence of past year 
dependence or abuse without IDU 
(ages 15-19, year 2000) 
NSDUH (ICPSR)62 
2 1.4 (1.1-1.5) % Prevalence of past year 
dependence or abuse without IDU 
(ages 20-25 year 2000) 
NSDUH (ICPSR)62 
3 0.79 (0.37-1.0) % Prevalence of past year 
dependence or abuse without IDU 
(ages 26-29, year 2000) 
NSDUH (ICPSR)62 
4 0.46 (0.24-0.48) % Prevalence of past year 
dependence or abuse without IDU 
(ages 30-64, year 2000) 
NSDUH (ICPSR)62 
N 2.2 (0.81-3.0) % Prevalence of past year 
dependence or abuse without IDU 
(ages 15-19, years 2000-2016) 
NSDUH (ICPSR)62 
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aBest fit value is the parameter’s value for the best fitting single simulation to acute HCV data of 10,000 total simulations. 
b estimates were obtained from an initial value 0.00035 for all 10,000 simulations. 
cInitial values for each injection initiation rate were sampled from the following ranges from the literature prior to parameter 
estimation: 1 (0.05-1.5), 2 (0.034-1.5), and 3 (0.034-1.5) and were bounded by the following ranges: 1 (0.05-5.0), 2 (0.034-5.0), 
and 3 (0.034-5.0) during parameter estimation and fit to acute HCV data. 
dPresented as the best fitting parameter set’s value and range of calculations for 10,000 simulations based on fit to acute HCV data. 
Values of i were not sampled, but rather were calculated from , , N, P, , , , and P, for each parameter set (Appendix 3.1). 
-1 NA (Intervention) Years Treatment duration Sensitivity analysis, tested scenarios 
from AASLD13 
P1 723,319 (NS) Persons Average population of 15-19 year 
olds in Michigan, 2000-2016 
CDC Wonder120 & Freide et al.114 
P2 815,922 (NS) Persons Average population of 20-25 year 
olds in Michigan, 2000-2016 
CDC Wonder120 & Freide et al.114 
P3 483,070 (NS) Persons Average population of 26-29 year 
olds in Michigan, 2000-2016 
CDC Wonder120 & Freide et al.114 
P4 4,605,115 (NS) Persons Average population of 30-64 year 
olds in Michigan, 2000-2016 
CDC Wonder120 & Freide et al.114 
Z0 144,097 (NS) Persons Number of 15 year olds CDC Wonder120 & Freide et al.114 
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Latin hypercube sampling was used to sample 10,000 parameter sets determining model state flows and initial conditions across 
plausible ranges and we summarized each simulation by its quartile of fit (based on the residual sum of squares) to acute HCV data, 
where Q1 (light grey) represents the best fitting 25% of models and Q4 (black) shows the worst fit (residual sum of squares in the 
highest quartile) to data. Parameters fit to data (transmission rate [] and injection initiation rates [i]) or parameters adjusted (N) or 
calculated from other parameters (relapse rate [i], proportion of contacts that occur with each age group [j,i/  j,i for j=1 to 4]) are 
not expected to be sampled uniformly. Most sampled parameters fit well throughout their sampled range. Here we transform the 
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Figure 3.4 Model Fit to Acute HCV Cases Detected by Public Health Surveillance in Michigan among PWID, 2000-2016 
An ordinary differential equation HCV transmission model among PWID was fit to HCV surveillance-detected acute HCV cases aged 
15-29 years reported to the Michigan Department of Health and Human Services during the years 2000-2016. Parameters were 
sampled across plausible ranges using 10,000 Latin hypercube samples. Model fit (colored lines) to data (black points) is shown by the 
residual sum of squares values. Results are shown for the best fitting 10% of simulations (top) and for all 10,000 simulations (bottom) 
for each age group. We did not fit to data for PWID aged 30-64 and instead show predicted acute HCV cases. 
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Figure 3.5 Predicted Chronic Hepatitis C Cases among PWID in Michigan from a HCV Model Fit to HCV Surveillance Data in 
Michigan, 2000-2016 
 
An ordinary differential equation HCV transmission model among PWID was fit to HCV surveillance-detected acute HCV cases aged 
15-29 years reported to the Michigan Department of Health and Human Services during the years 2000-2016. Each graph summarizes 
the predicted number of chronic HCV cases in Michigan among the best fitting 10% to data (n=1,000 simulations) by age and fit to 
data (color of lines).
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Figure 3.6 Counterfactual Simulations of Primary, Secondary, and Tertiary Interventions to Reduce HCV Prevalence and Incidence 
among Young PWID 
 
The distribution of predicted percent reduction in chronic HCV (top) and acute HCV (bottom) for each of 6 interventions among the 
best-fitting 10% of parameter sets to data are depicted as violin plots. Diamonds denote the median percent reduction. Treating former 
PWID and current PWID were associated with the largest predicted reductions to HCV prevalence. Other measures also reduced 
HCV, and generally had less variability across scenarios than treatment interventions. 
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Figure 3.7 Counterfactual Simulation of Combined Interventions to Reduce HCV Prevalence and Incidence among Young PWID 
 
Histograms of the predicted percent reduction in acute (top) and chronic (bottom) among 15-29 year olds after 17-years simulation are 
plotted using the best fitting 1,000 parameter sets. All percent reductions are calculated compared to no intervention and interventions 
are sequentially added from a base of primary (left) versus tertiary (right) interventions. Diamonds denote the median percent 
reduction. Both strategies reduced HCV prevalence and incidence. Combined former and current PWID treatment had the largest 
impact on prevalence and incidence. The precision of predicted reductions grew with higher intensity interventions or when secondary 
interventions were combined with treatment. 
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Figure 3.8 Sensitivity of Predicted Effects of HCV Treatment among Current PWID to Cure 
Rate, Continued Syringe Sharing During Treatment, and Treatment Duration 
 
The distribution of predicted % reduction in HCV prevalence (left) and acute HCV (right) among 
15-29 year olds for several treatment scenarios implemented among current PWID for the best 
10% of parameter sets fitting to data are presented as violin plots. Diamonds denote the median 
percent reduction. We show the potential impact of ongoing syringe sharing during treatment 
(top), cure rates (middle), and treatment duration (bottom). The cure rate (% of treated current 
PWID achieving sustained virologic response) moderately impacted treatment effectiveness, 
whereby lower cure rates decreased the predicted impact of treatment.
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Appendix 3.1 Detailed Methods for Model Fitting and Parameter Estimation for an HCV 
Transmission Model among PWID in Michigan 
 
Model Structure 
An HCV ordinary differential equation (ODE) transmission model of PWID with 
preferential age mixing was developed in Matlab R2017b (The MathWorks Inc, Natick, MA). 
The model consists of 11 states per age group, with age groups of 15-19, 20-25, 26-29, and 30-
64 years (Figure 3.1). We obtained the number of people with substance dependence or abuse 
(non-PWID, Zi), former PWID, and current PWID by multiplying the Michigan population size 
for each age group (Pi) by several US national prevalence estimates described in further detail in 
Table 3.2.1,6,62 Individuals age through groups and transition through a series of compartments 
within age classes: uninfected, non-PWID with substance abuse or dependence (Zi), uninfected 
current or former PWID (Si or SNi, respectively), acutely infected current or former PWID (Ai or 
ANi, respectively), chronically infected current or former PWID (Ci or CNi, respectively), and 
treated current or former PWID (Ti or TNi, respectively).  
Movement through compartments is governed by a set of 44 differential equations shown 
in (1), where subscript i denotes the age class (1: 15-19 years, 2: 20-25 years, 3: 26-29 years, 4: 
30-64 years) moving through compartments and subscript j denotes the age class of effective 
contacts from whom infection is acquired (i.e. by sharing injecting equipment). In the youngest 
age class, non-PWID without HCV infection are added each year to the Z1 compartment based 
on the prevalence of substance abuse or dependence among 15-19 year olds from the National 
Survey on Drug Use and Health (NSDUH) and the average population size of 15 year-olds 
during 2000-2016 in Michigan.62,114,120 These are represented with the term 0NZ0 (omitted 
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from the equations below for simplicity). In other age groups, individuals age to the subsequent 
age class at a rate i. Mortality occurs at a rate i, which is elevated for current PWID and 
moderately elevated for former PWID and non-PWID with substance abuse or dependence (Zi) 
compared to age-specific mortality rates for the general population in Michigan through 
standardized mortality ratios P, N, and Z, respectively. 104–108,113,114 The value of N is scaled 
during model simulation so that the mortality among former PWID cannot fall below general 
mortality rates, i. 
 (1) 
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Individuals acquire HCV by injecting drugs; other transmission modes (e.g. perinatal 
acquisition, unregulated tattoos, sexual transmission) are not considered. Non-PWID flow into 
the susceptible PWID compartment (Si) at an estimated injection initiation rate, i, calibrated to 
fit acute case data from initial values based on empirical studies of injection initiation.64–74 
Susceptible PWID acquire new infections at an estimated rate  through effective contact 
between a susceptible PWID (Si) and an acutely (Aj) or chronically (Cj) infected individual in 
any age class. A proportion () of treated current PWID (Tj) also contribute to transmission 
during intervention simulations, as described further below. We set upper and lower bounds for 
estimated values of  from values in the literature.84–86 Initial model fitting suggested that values 
were optimized at approximately 0.0000035 and we therefore used this value as the initial 
condition of  for each model simulation.  
Contact rates between individuals in each age class are parametrized by a contact matrix, 
, and the total number of contacts per susceptible PWID (Si), i, described in further detail 
below. Newly infected PWID (Ai) have acute HCV infection for an average duration of 6 months 
(-1), at which point 50-85% (1-) develop chronic infection (Ci).100–103 A fraction (, 0-45%) of 
acutely infected individuals who spontaneously clear their HCV infection have sterilizing 
immunity and move to the immune class (Ii) while the remaining individuals (1-) move back to 
the susceptible class (Si) where they can be re-infected at the same rate as infection-naive 
individuals. While there is little data to inform this parameter, we used findings by Mehta et 
al.115 to inform the sampling range for . 
Chronically infected individuals are treated (Ti and TNi) at rates P and N for a duration 
of -1 and become susceptible to HCV re-infection after treatment in the current PWID state by 
returning to the susceptible class (Si). A proportion () of current PWID receiving treatment (Ti) 
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transmit HCV (i.e. share syringes during treatment). Like all former PWID, treated former PWID 
(TNi) do not transmit HCV. Individuals from any of the current PWID classes can stop injecting 
drugs and move to their adjacent former PWID class at a cessation rate i. Former PWID can 
begin injecting again after a period of injection abstinence and enter the current PWID class at a 
relapse rate i. 
 
Surveillance Data 
The Michigan Department of Health and Human Services (MDHHS) receives reports of 
HCV diagnoses from healthcare providers and laboratories. Case status (acute or chronic) is 
determined using standardized national case definitions and cases are recorded in a centralized 
surveillance system.53–56 We obtained the number of newly identified acute HCV cases per year 
during 2000-2016 (Table 3.1). Risk factors (e.g. recent injection drug use) are collected by 
surveillance systems, but not for all cases; however, injection drug use (IDU) is the most 
common mode of acquisition for new HCV cases nationally and in Michigan.3,92 For the 
purposes of the model, we assumed that cases with no known risk factors injected drugs during 
the 2 weeks to 6 months before they were reported to MDHHS, and therefore were infected with 
HCV by IDU.  
Acute and chronic HCV are under-reported in the US for several reasons, including that 
20-30% of cases are asymptomatic, not all cases see a healthcare provider, not all cases who see 
a provider are diagnosed, and some of those diagnosed are never reported to state health 
departments.57,121 CDC developed a correction factor representing the estimated number of acute 
cases occurring for each surveillance-detected acute HCV case (1 surveillance detected case per 
16.8 true cases).57 However, work by Onofrey et al. suggested that case under-detection by 
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surveillance systems was more severe given the stringency of the 2012 acute case definition (1 
surveillance detected case per 138 true cases).57,58 We use the inverse of an approximate middle 
point from these studies (1 surveillance detected case per 50 true cases) as a reporting rate, , to 
scale the number of reported acute cases detected by surveillance during parameter estimation.  
The high variability in the acute case series among 15-19 year olds presented a challenge 
during model fitting (Figure 3.2). However, the series of newly reported chronic cases to 
MDHHS among 15-19 year olds more consistently increased during the time period of interest 
and had significant overlap with the acute case series when scaled by the Klevens et al. estimate 
for under-reporting.57 Therefore, we use the scaled newly reported chronic case series for 15-19 
year olds as a proxy for acute cases and note the high variability in the acute case series as a 
limitation preventing model fitting to the observed acute data. State health departments also use 
newly reported chronic case reports among young PWID as indicators of HCV trends beyond 
those available from the sparse acute HCV surveillance data given their limited funding to detect 
and follow-up on acute cases and the stringency of the case definition before 2016.50,52 This 
assumes that, given their young age, these individuals acquired infection relatively, consistent 
with patterns of substance use and injection drug use in the US.62  
We made a final modification to the number of 2016 cases for all age groups based on a 
change in the case definition.53,55 This change increased the number of acute cases detected by 
surveillance in 2016 by removing the requirement that confirmed cases be free from acute 
hepatitis A or B and introducing a probable class classification with less stringent laboratory 
requirements.55 To maintain consistency throughout the time period of study, we therefore 
assumed that only 74% of 2016 cases (for all age groups) would have met the 2012 definition in 
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accordance with an unpublished case series review conducted by MDHHS and used this scaled 
version of 2016 cases for model fitting. 
 
Initial Conditions 
The initial number of acute HCV cases was set to the number of acute cases detected by 
MDHHS during 2000 who endorsed IDU in the HCV incubation period (2 weeks to 6 months 
before symptom onset) or who had unknown or missing responses regarding IDU multiplied by 
the inverse of the reporting rate (-1). As noted above, this included a scaled version of newly 
reported chronic cases for 15-19 year olds. Because the HCV prevalence in 15-64 year olds in 
Michigan is unknown, we used several HCV prevalence estimates from US empirical studies 
conducted outside of Michigan to inform the initial HCV prevalence.10,15,44–49 We set initial HCV 
prevalence to 10% for 15-19 year olds, 20% for 20-25 year olds, 30% for 26-29 year olds, and 
55.2% for 30-64 year olds.10,15,44–49 
Individuals were designated current or former PWID in all relevant states based on 
published and unpublished estimates of past year and lifetime PWID prevalence.1,6 Upper 
sampling bounds for the prevalence of current PWID came from a meta-analysis of past year 
injection drug use by Tempalski et al. while former PWID prevalence upper sampling bounds 
came from a meta-analysis of lifetime PWID prevalence by Lanksy et al. (Table 3.2).1,6 Lower 
bounds for the sampling ranges of current and former PWID prevalence as well as the entire 
sampling range for the prevalence of non-PWID with substance abuse or dependence were based 
on an unpublished analysis of data from NSDUH (contact first author for more information).62 
We calculated the year 2000 US national prevalence of substance abuse or dependence by age 
group for any of the following substances: heroin, prescription opioids, stimulants and/or cocaine 
 101 
without lifetime IDU, and set the 95% confidence interval bounds as sampling ranges (Table 
3.2).62 The lower bounds for former PWID prevalence and current PWID prevalence were set to 
the point estimates for prevalence of lifetime without past year (former PWID) or past year 
(current PWID) injection of any of the following substances: heroin, prescription opioids, 
stimulants and/or cocaine using NSDUH data from 2000 (Table 3.2).62 These substances were 
chosen because they are commonly injected, meaning that people with abuse or dependence and 
no lifetime IDU history may be at risk for initiating IDU and thus could be at risk for HCV if 
they share syringes.122 
PWID prevalence estimates were applied to the Michigan population and, after 
subtracting the total number of HCV cases, were used as the initial number of uninfected current 
and former PWID (Si and SNi). We assumed that there were no treated current or former PWID 
during parameter estimation, which is reasonable given that changes in treatment availability and 
targeting of treatment to PWID occurred only recently.93–96  
 
Contact Rates between Infected and Susceptible Current PWID 
We sampled the total number of contacts per susceptible individual from 5-20 contacts 
per person; this parameter is known to vary widely in empirical studies.61,116–119 We then adapted 
the contact matrix, , from a study of age-specific physical contacts per day in eight European 
countries, so that it reflected the proportion of total contacts per susceptible PWID that occurred 
with PWID in each age group.60 First, we summed the number of contacts among persons aged 
30-64 years from the original 5-year age groups for each country-specific matrix (both contacts 
by 30-64 year olds to other age groups and contacts by other age groups to 30-64 year olds). We 
used the maximum contacts from the eight matrices as the upper bounds for Latin hypercube 
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sampling. We used the minimum as the lower bound for sampling, with one modification. 
Because Mossong et al. included parent-child contacts in their study, we sampled to a lower 
bound of 0, regardless of the observed minimum value, in all sampling ranges including 30-64 
year-old contacts with other age groups.60 In our study, this allowed us to include the possibility 
of a very low syringe sharing rate of younger individuals with this large and oldest age group, 
which likely reflected parent-child contacts in the original study. We should also note that our 
study did not have perfect overlap with the age groups used in Mossong et al.; however, they 
were approximately similar (e.g. 20-24 in Mossong et al. vs. 20-25 in our study).60 We formed 
age groups for the model that were consistent with the age reporting structure in NSDUH, which 
more directly influenced PWID prevalence than contact rates.62 
After values for the number of contacts were sampled with Latin hypercube sampling, we 
transformed the contact matrix to column-wise proportions, which represent the proportion of 
each age group’s total contacts that occurred with people from each age group. We multiplied 
these proportions by the total number of contacts per year, i, to obtain the number of syringe 
sharing contacts in each age group per susceptible PWID per year. These proportions included 
those reported in a study of PWID age-specific syringe sharing rates.61 
 
Solving Steady-State Equations for PWID Relapse Rates 
During initial model design and fit to data, we noticed that model simulations generally 
produced population-level trends where current PWID outnumbered former PWID. These initial 
findings were inconsistent with empirical studies, which suggest that there are more former 
PWID than people currently injecting drugs.1,6,62 Therefore, to maintain a realistic ratio of 
current to former PWID during model fitting to data throughout the simulation period, we 
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calculated age-specific relapse rates (i) for each simulation using the sampled parameters for 
each simulation. As described in detail below, this procedure rearranged the system of ordinary 
differential equations to solve for i, relying on the assumption that the system of differential 
equations was at steady-state (all derivatives set to equal 0). The assumption of steady-state is 
analogous to the principle that prevalence approximately equals the product of incidence and 
duration when the prevalence, incidence rate, and mortality rate are stable, there is no net 
migration of individuals with the condition, and the condition is rare.123 
We rearranged the ODEs to solve for the four relapse rate parameters (i). The system of 
11 equations per age-group was rewritten as three ODEs per age-group (non-PWID [Zi], current 
PWID [Ci], and former PWID [Fi]) as each state within the three groups had the same net inflows 
and outflows. Each equation was set to 0 and we obtained:  
(2) 
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Rearranging the equations in (2) as a function of the parameter of interest, the relapse rate 
(i), from the equations for dCi/dt gave (3), which are shown directly from above and in terms of 
the additional parameters required to calculate compartment sizes. 
 (3)  
Rearranging from the equations for dFi/dt gave: 
 (4) 
During simulations, we used the sampled values for all parameters shown in (4) to 
calculate the value of i. Negative values from both (3) and (4) were possible given sampling 
ranges. Because more of the i values calculated from (4) were positive, we used the dFi/dt (4) 
instead of (3). When a negative value was calculated given the sampled parameters, we reset the 
value for i to the minimum value for relapse rates found in the literature (0.1).91,109–112 
 
Least Squares Estimation Methods 
We chose an unweighted least squares method, which assumes that all points have 
normally distributed errors of the same magnitude (maximum likelihood with equal variances for 
each data point). Compared with other least squares weights considered, this strategy fit both the 
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smaller and larger case counts, whereas other methods (e.g. weighted least squares with 
variances proportional to the size of each data point) were unable to fit the larger data points that 
occurred later in the case series.  
Although we chose to use one unweighted least squares scheme, the Matlab code 
provided for least squares estimation includes four total least squares methods, each with 
different weighting schemes to minimize the residual sum of squares after fitting to surveillance 
data. These include weights by the data point size, square root of the data point size, maximum 
data point size, and unweighted least squares. 
 
Model Fitting with Latin Hypercube Sampling 
To incorporate parameter uncertainty, Latin hypercube sampling with 10,000 simulations 
was used to draw a stratified random sample of parameter sets across plausible ranges (Table 
3.2). Ranges for the majority of parameters were based on published estimates except when 
described here or used in intervention analyses. To optimize model fit to data, we estimated four 
unknown parameters (the transmission rate [] and three age-specific injection initiation rates 
[i]) in each simulation. Parameters were estimated for each simulation by unweighted least 
squares (equivalent to maximum likelihood assuming normally distributed measurement error 
with equal variances for each data point). Parameter estimation and simulations were run using 
fminsearchbnd and the ODE15S solver in Matlab.63 
We used fminsearchbnd instead of fminsearch so that we could set upper and 
lower limits for the estimated parameters.63 We set upper and lower bounds for estimated values 
of  from values in the literature.84–86 Initial model fitting suggested that values of this parameter 
were optimized at approximately 0.0000035 (by visual inspection of fit to data) and we therefore 
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used this value as the initial condition of  for each model simulation. We also fit three injection 
initiation rates, i, to fit acute case data from 15-29 year olds from initial values based on 
empirical studies of injection initiation.64–74 While we did set upper and lower bounds for 
injection initiation rates to ensure the model provided realistic estimates, we allowed the model 
to fit higher injection initiation rates than were found in empirical studies to improve model fit 
and accommodate the possibility that Michigan’s initiation rates were higher than studies 
conducted in other locations. Initial simulations using bounds from empirical studies produced 
bimodal distributions, where >20% of parameter sets were assigned the maximum value (the 
upper limit from empirical studies). We therefore set upper bounds for parameter estimation that 
prevented the formation of bimodal distributions during simulations across our parameter value 
ranges to allow maximum flexibility during this process. This resulted in upper bounds for i that 
were 3.3 (1, 2) or 6.7 (3) fold higher than the upper bound found in the literature, which was 
approximately 1.5 per year.66  
Residual sum of squares values after parameter estimation identified the best-fitting 10% 
of parameter sets to data (i.e. 1,000 simulations, Figure 3.3). To determine if a certain range 
appeared more consistent with data, we plotted histograms by quartile of fit and examined 
distributions alongside their uniformly sampled ranges. Matlab code for model simulation and R 
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Chapter 4 The Association of Opioid Agonist and Antagonist Use with Gut Microbiota 
Diversity, Genera, and Enterotypes among People in Addiction Treatment 
 
In preparation for publication in a peer reviewed journal 
Gicquelais RE, Bohnert ASB, Thomas L, Foxman B 
 
4.1 Author Summary 
The gut microbiota, the living bacterial community in the gut, is increasingly recognized 
for its influence on health and disease. We explored the relationship between opioid agonist (e.g. 
heroin and prescription opioids) and antagonist use with the gut microbiota of people in 
addiction treatment. We identified several attributes of the gut microbiota that differed between 
people exposed to opioid agonists compared to those with no agonist or antagonist exposure. 
These included lower microbial diversity and lower abundance of bacteria involved in butyrate 
production and bile acid metabolism in people exposed to opioid agonists. These differences 
were not seen in people exposed jointly to opioid agonists and antagonists, suggesting that the 
antagonizing effects of naltrexone and naloxone may offset some of the impacts of agonist 
exposure. This work informs future studies that examine the effects of opioid use on gut health, 
and the relationship of gut-brain-microbiota communication in addiction treatment outcomes. 
 
4.2 Abstract 
The gut microbiota is increasingly recognized as a potential determinant of 
psychopathology and treatment outcomes through its interactions with the brain along the gut-
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brain-microbiota axis. We conducted a pilot study to examine human gut microbiota changes 
associated with use of opioid agonists and antagonists as a first step in understanding how gut 
health might relate to psychological functioning during addiction treatment.  
We recruited 46 patients receiving outpatient addiction treatment at a private addiction 
treatment facility; consenting individuals reported their substance use in the past month and 
provided stool specimens. Analysis of self-reported substance use data and medical record 
review identified opioid agonist (heroin, prescription opioids, and methadone), antagonist 
(naltrexone), or agonist-antagonist combinations (buprenorphine+naloxone or other 
opioid+naltrexone). We sequenced participant stool samples using Illumina MiSeq and examined 
bacterial diversity (Shannon diversity and Chao1 indices), enterotypes (via dirichlet multinomial 
mixture modeling), and differential relative abundance (using ALDEx2) by opioid agonist-
antagonist defined groups. 
Among the 46 participants, 5 used opioid agonists only, 4 used agonist-antagonist 
combinations, 6 used antagonists alone, and 31 used neither. Participants who used only opioid 
agonists had lower bacterial diversity, Bacteroidetes enterotypes, and lower relative abundance 
of Roseburia and Bilophila. These differences were not observed between any other groups, 
including participants who used agonist-antagonist combinations versus participants exposed to 
neither agonists nor antagonists. 
Addiction treatment patients with opioid agonist use had several alterations in the gut 
microbiota relative to other addiction treatment patients. These were consistent with those 
observed in murine models of morphine dependence. These changes were not evident in 
individuals who used both opioid agonists and antagonists. These findings support further 
characterizing the relationships between opioid agonist and antagonist exposure, gut 
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permeability, inflammation, and relapse predictors to inform whether psycho-adjunctive 
treatments for opioid use disorders could improve addiction treatment outcomes. 
 
4.3 Introduction 
Approximately 40-60% of people who receive treatment for substance use disorders 
(SUDs) relapse in the first year following treatment.1 SUD-related morbidity and mortality have 
increased dramatically during the past decade alongside changes in opioid prescribing patterns 
and nonmedical prescription opioid heroin use and overdose.2,3 There is an urgent need to 
improve treatment outcomes to mitigate growing morbidity and mortality from opioid and other 
SUDs.1 
The gut microbiota, the bacterial community living in the intestinal tract, is increasingly 
explored as a determinant of health and disease, and more recently, of psychopathology.4,5 The 
gut microbiota may play a role or be a marker for the development of and/or recovery from 
several psychiatric disorders, including depression, autism spectrum disorders, and 
schizophrenia.4,5 Following this recognition, the microbiota was incorporated into the 
communication pathway that describes the crosstalk between the gut and brain, termed the gut-
brain-microbiota axis.6 
The gut microbiota, and gut barrier function in general, may also influence SUD recovery 
and treatment outcomes.7,8 Previous research supports that stress, anxiety, depression, and 
cravings influence vulnerability to relapse after periods of abstinence, and the microbiota may 
modulate these relapse precursors.7–11 For example, Leclercq et al. found that chronic alcohol use 
alters gut barrier function and promotes gut leakiness compared to healthy controls.12–14 Further, 
intestinal permeability, which was associated with altered levels of Lactobacillus and 
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Bifidobacterium, modulated inflammatory markers and relief from depressive symptoms during 
a three week detoxification.14 Collectively, the authors surmise that alterations to gut leakiness 
from chronic drinking and the release of bacterial products and metabolites into the bloodstream 
promote a neuro-inflammatory state that influences mood and drinking behaviors.15 These results 
highlight the potential role of gut barrier function and the microbiota in alcohol addiction 
treatment outcomes, but less is known about other SUDs.  
Wang et al. used a murine morphine dependence model to characterize the impact of 
opioid exposure on the gut microbiota.16 Mice exposed to morphine exhibited major shifts in 
their gut microbiota within one day of exposure, and by day three had decreased gut microbiota 
richness (i.e. number of species), increased abundance of Enterococcus faecalis, and decreased 
abundance of Flavobacterium, Fusobacteriuam, Suterella, and Clostridium compared to 
placebo-treated mice.16 Further research by this group and others has demonstrated that opioid 
exposure increases intestinal permeability, bacterial translocation to mesenteric lymph nodes and 
the liver, and risk of enteric and septic infections, dysregulates immune responses, disrupts bile 
acid metabolism, promotes inflammation, and may even induce the expression of virulence 
factors in pathogenic bacteria, such as Pseudomonas aeruginosa.16–19  
Interestingly, Wang et al. also showed that the observed expansion of E. faecalis and 
changes to bile acid metabolism in morphine treated mice were not found among mice treated 
with both morphine, an opioid agonist, and naltrexone, an opioid antagonist.16 This and other 
work by Banerjee et al. suggest that observed microbiota alterations relate to the binding of 
opioids to -opioid receptors and that the gut microbiota of mice treated with morphine and 
naltrexone differs from that seen in mice treated with morphine alone.16,18 
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Currently approved medication-based treatments for opioid use disorders (OUDs) involve 
two types of opioid antagonists, which are medications that block the -opioid receptor.20 
Naltrexone is an opioid antagonist used to manage cravings for both alcohol and OUDs. Its 
formulation as methylnaltrexone relieves opioid induced constipation.21–23 A low dose 
formulation of naltrexone is currently debated as a potential treatment for the gut mucosal injury 
and inflammation characteristic of Crohn’s Disease and for other inflammatory conditions.24–26 
These applications suggest that the formulation of naltrexone used for OUDs and alcohol use 
disorders might similarly modulate gut barrier function, which was previously correlated with 
gut microbiota composition and relapse risk among people with alcohol use disorders.14 
A second opioid antagonist used in products with buprenorphine, a partial opioid agonist, 
is naloxone.20 In combination, buprenorphine-naloxone is one of the most commonly used 
medication assisted treatments for OUDs.27 Alone, naloxone is an opioid antagonist that reverses 
the respiratory depressive effects of an opioid overdose. Naloxone’s mechanism of action is 
similar to naltrexone (i.e. blocks the -opioid receptor); it is included in buprenorphine 
formulations to reduce the risk of abuse. Collectively, the impacts of joint administration of 
opioid agonists and antagonists (e.g. buprenorphine+naloxone or opioid agonists and naltrexone) 
and the sole administration of opioid antagonists (e.g. naltrexone) on the human gut microbiota 
are unknown.  
We identified two human studies of people with OUDs that characterized changes to the 
gut microbiota associated with opioid agonists.28,29 Barengolts et al. studied 99 male veterans to 
explore how diabetes, metformin use, and OUDs modulated the gut microbiota.28 They observed 
a positive association between Bifidobacterium and OUDs among men with type 2 diabetes and 
no metformin use.28 Xu et al. compared the gut microbiota’s diversity and composition among 
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45 Chinese men with SUDs to 48 controls without SUD; 26 participants in the SUD group used 
heroin and all used alcohol and smoked daily.29 They observed increased prevalence of Thauera, 
Paracoccus, and Prevotella and a trend towards higher diversity among the SUD group.29  
There are several opportunities to extend the important findings from these studies. First, 
previous studies commented on two measures of the microbiota (diversity and individual taxa); 
however, no studies have evaluated enterotypes, a representation of the entire gut community 
structure, among people or animal models of opioid or other SUDs. A recent review by Costea et 
al. identified three gut microbiota enterotypes found across a variety of settings and populations 
and discussed the overlap of enterotypes with diseases and diets.30 Enterotype characterization 
among people who use opioids could help identify mechanisms underlying dysbioses related to 
opioid use through their overlap with enterotype patterns observed in other conditions. Second, 
the joint and single effects of opioid agonist and antagonist exposure on the human gut 
microbiota remain unknown. These findings could be important for several groups, including 
people using opioid agonists as prescribed, people with OUDs, and people prescribed medication 
assisted treatments for an OUD (buprenorphine+naloxone, methadone, and naltrexone) and/or 
alcohol use disorder (naltrexone). 
In summary, opioid agonist exposure disrupts the gut microbiota in mouse models and 
these changes are incompletely described in humans who use opioids.16,18,19,28,29 While these 
effects are antagonized by naltrexone in a murine model, to our knowledge, there are no gut 
microbiota studies of opioid antagonists among humans.16,18 The ongoing opioid crisis highlights 
the urgent need to identify and improve treatment outcomes for OUDs, and improvements in 
treatment outcomes may be possible through adjunctive treatments that modulate gut microbiota 
dysbioses and improve gut barrier function.1,2,15 A first step in achieving these goals is to 
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describe the gut microbiota’s associations with opioid agonist and antagonist exposure in 
humans. Therefore, we examined the relationship between opioid agonist and antagonist 
exposures with the gut microbiota of 46 patients receiving outpatient SUD treatment. We 
describe differences in microbiome diversity, enterotypes, and bacterial genera abundance by 




We consented 46 patients aged 18-60 years who were receiving treatment in an outpatient 
addiction treatment facility to participate in a gut microbiota and substance use study. We 
surveyed participants about the substances they used in the 30 days prior and reviewed 
participant medical records to characterize their opioid agonist and antagonist use. Participants 
submitted a stool sample and we sequenced the V4 hypervariable region of the 16S ribosomal 
ribonucleic acid (rRNA) gene to characterize the gut microbiota. Each participant’s opioid 
agonist and antagonist use patterns from survey and medical record data were summarized as 
agonist only (Ag), agonist+antagonist (AgAt), antagonist only (At), or neither agonist nor 
antagonist (N). We compared gut microbiota diversity, enterotypes, and genera relative 
abundance between participants in these four opioid agonist and antagonist groups. Details about 
each step of participant recruitment and data analysis are summarized below. 
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4.4.2 Participant Recruitment  
4.4.2.1 Study Site and Substance Use Survey 
The study population was drawn from a sample of adult (≥18 years) patients from a 
private, outpatient addiction treatment facility in Michigan during July 2016 – September 2017. 
The facility provided SUD treatment in both individual and group settings and treatment options 
included psychotherapy and pharmacotherapy for alcohol, opioid, and other SUDs. The facility 
offered medication assisted treatments, including buprenorphine+naloxone and naltrexone, but 
did not offer methadone. Study research assistants approached patients before group and 
individual appointments about their interest in completing a survey about substance use. To be 
eligible to participate, patients had to be ≥18 years, speak English, be able to provide informed 
consent, and able to see, speak, and hear. We excluded people who were acutely intoxicated, 
mentally incompetent, or unable to provide informed consent for any other reason. The study 
was approved by the Institutional Review Board at the University of Michigan (HUM00113964). 
Interested and eligible participants provided informed consent and completed a 45-minute 
survey, which could be completed electronically using Qualtrics (Qualtrics, Provo, Utah) or as 
paper and pencil. The screening survey assessed substance use and demographic characteristics. 
A total of 124 participants provided informed consent and 92 (74.2%) completed the initial 
survey within 4 weeks (Figure 4.1). Participants were compensated $5 for their survey.  
 
4.4.2.2 Microbiota Study Eligibility Criteria 
Research assistants reviewed results of the substance use survey and invited 65 
participants who met eligibility criteria to enroll in a microbiota study. Before enrollment, 
research assistants administered the Mini-Mental State Exam (MMSE) to check cognitive 
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function and ability to consent; a total score 21 was required to enroll.31 Further eligibility 
criteria included age 18-60 years and self-reported use of at least 1 substance in the past 30 days 
or misuse of prescription opioids during the month before beginning treatment.  
We used an abbreviated version of the Alcohol, Smoking, and Substance Involvement 
Screening Test (ASSIST) to assess past 30 day substance use. ASSIST is a 12-item questionnaire 
that asks about use of street opioids, opioid pain medications (with or without a prescription), 
methadone or buprenorphine+naloxone (with or without a prescription), tobacco, alcohol, 
cannabis, cocaine (including crack), amphetamines, inhalants, sedatives or sleeping pills, and 
hallucinogens.32,33 Participants who only endorsed tobacco were not eligible without use of 
another substance. Participants reporting past 30-day use (nonmedical or as prescribed) of 
medication assisted treatments (buprenorphine+naloxone or methadone) were eligible, regardless 
of past 30 day use of other substances. We used the Current Opioid Misuse Measure (COMM) to 
capture self-reported misuse of prescribed opioids.34 The COMM is an eight-item scale that 
assesses self-reported opioid misuse not captured by ASSIST.34 Participants with a score >0 for 
questions 4 and 6-8 were eligible.34  
 
4.4.2.3 Microbiota Study Participants and Stool Sample Collection 
A total of 51 out of 65 eligible participants provided informed consent for the microbiota 
study; the remaining 14 were not enrolled for reasons listed in Figure 4.1. At enrollment in the 
microbiota study, participants completed an additional survey about their dietary habits and were 
compensated $20. Weekly thereafter for three weeks, participants submitted a stool sample 
(described further below) and completed an additional survey reporting their depression, anxiety, 
cravings to use drugs or alcohol, dietary habits, and antibiotic use. Participants were 
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compensated $10 per appointment. All follow-up appointments were completed within one 
month of enrollment in the microbiota study. We received at least one stool sample from 46 of 
the 51 participants who provided informed consent for the microbiota study. 
 
4.4.3 Medical Record Review 
As part of their written informed consent, participants granted the research team access to 
their University of Michigan Health System medical record. We reviewed medical encounters at 
the University of Michigan during the 30 days before completion of the first survey through the 
day of sample collection.  We documented the following items to supplement study survey data: 
1) prescription for naltrexone, and 2) prescription for buprenorphine+naloxone.  
 
4.4.4 Measures: Participant Characteristics 
4.4.4.1 Opioid Agonist and Antagonist Use 
We used a combination of the ASSIST and medical record review to identify any opioid 
agonist use. We defined opioid agonist use as a binary indicator for either of the following: 1) 
self-reported opioid use (heroin, methadone, buprenorphine, or prescription opioids used as 
prescribed or not as prescribed) in the 30 days before study enrollment on the modified ASSIST, 
or 2) buprenorphine+naloxone use during the day of sample collection in the medical record. We 
supplemented the ASSIST data on buprenorphine use with data from the medical record because 
survey questions about medication assisted treatments were added to the modified ASSIST 
during January 2017 and were not available prior. Of note, one participant who was prescribed 
opioids to manage pain was included in the group of participants who used opioid agonists. 
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We also assessed opioid antagonist use. For the purpose of this study, we defined opioid 
antagonist use as either of the following according to the medical record: 1) 
buprenorphine+naloxone use during the day of sample collection, or 2) naltrexone use during the 
day of sample collection. We included any formulation of either opioid antagonist. Finally, we 
created a categorical variable describing the overlap in opioid agonist and antagonist use (i.e. 
agonist only, combined agonist-antagonist, antagonist only, and neither agonist nor antagonist).  
 
4.4.4.2 Depression, Anxiety, and Cravings to Use 
We summarized scores from the Patient Health Questionnaire-9 (PHQ-9), a reliable and 
valid depression severity screening tool (Cronbach’s : 0.86-0.89, Test-retest correlation: 0.84, 
range: 0-27).35 We also summarized scores from the Generalized Anxiety Disorder 7-Item Scale 
(Cronbach’s : 0.92, Test-retest correlation: 0.83, range: 0-21).36 For reference, a sum 10 
indicated possible GAD.36 Finally, cravings to use drugs or alcohol were reported using summed 
scores from a modified version of the Penn Alcohol Craving Scale adapted to capture drug 
cravings (range: 0-30).37–39  
 
4.4.4.3 Microbiota Study Population Characteristics 
We summarized average age, self-identified gender (female, male, and other), race 
(black, white, other, or multiple races), ethnicity (Hispanic vs. non-Hispanic), and self-reported 
days in SUD treatment at the study site. We calculated predicted past month dietary fiber intake 
(grams per day) from food frequency questions completed at enrollment in the microbiota study 
using validated predictive models developed from the National Health and Nutrition 
Examination Survey (Appendix 4.1).40 Dietary fiber intake has previously been associated with 
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the gut microbiota, transit time, and stool water content.30,41–43 We used the ASSIST to describe 
alcohol use during the 30 days before completing the substance use survey.32 Finally, we 
summarized self-reported antibiotic use during the week of sample collection. 
 
4.4.5 Stool Sample Collection and Sequencing 
4.4.5.1 Stool Sample Collection 
We based our stool collection protocols on those from Feigelson et al., Flores et al., and 
Fu et al.44–46 Participants self-collected stool samples by placing two dime-sized scoops of stool 
into a sterile Sarstedt tube with a spoon lid (Sarstedt, Nümbrecht, Germany) containing a 
cryopreservant, RNAlaterTM (Ambion, Austin, TX), and 5-10 glass beads (Walter Stern, 
Washington, NY). Participants then secured the lid, homogenized the sample in RNAlaterTM by 
shaking, and stored the sample at room temperature for up to two days before returning the 
sample to a research assistant. Previous research supported that RNAlaterTM preserved the 
composition of the stool bacterial community at room temperature for up to three days after 
collection.45,46 Stool samples were then frozen in 1 mL aliquots at -80C.  
 
4.4.5.2 Illumina Sequencing and Sequence Processing 
After all participants were enrolled, we thawed a 1 mL aliquot of each stool sample, 
centrifuged at 10,000xg, and resuspended in 1 mL 1X phosphate buffered saline (Gibco, Thermo 
Fisher Scientific, Waltham, MA, pH 7.4). We added 250 uL resuspended stool to each of two 
wells of a bead beating plate so that each sample would be sequenced in duplicate. We provided 
plates to the Microbial Systems Molecular Biology Laboratory at the University of Michigan. 
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They used previously described protocols for deoxyribonucleic acid (DNA) extraction and 
Illumina MiSeq sequencing of the V4 hypervariable region of the bacterial 16S ribosomal 
ribonucleic acid (rRNA) gene (Appendix 4.1).47–49  
We processed sequencing reads using mothur (v1.39.5) and the MiSeq standard operating 
procedure (https://www.mothur.org/wiki/MiSeq_SOP, accessed November 8, 2017) to perform 
quality filtering and align sequences to the V4 region of the 16S rRNA gene.49 We converted 
sequences to the format required for oligotyping and clustered samples into oligotypes using the 
procedures and default parameters described by Eren et al. (Appendix 4.1).50–52  
Two samples with fewer than 1,000 reads were removed from further analysis; however, 
we were able to retain these two participants in the analytic sample using their duplicate 
sequenced sample. We verified that all mock communities resembled their known compositions 
(data not shown) and summed duplicate sequenced samples. For this analysis, we examined the 
first sample submitted per participant, amounting to 46 samples with 2,207,827 sequence reads 
(21,796 – 77,013 reads per participant) and 354 oligotypes. We assigned oligotype taxonomy 
using the Ribosomal Database Project (release 11, update 5).53 We focused this analysis on the 
first sample per participant after observing little change to taxa diversity metrics (described 
further below) during the month-long period of study (Appendix 4.1). 
 
4.4.6 Microbiota Measures 
4.4.6.1 Genus Relative Abundance and Diversity Metrics 
We calculated the relative abundance of genera in each sample (i.e. the number of 
sequencing reads from each genus divided by the total number of sequencing reads per sample). 
We used oligotype counts to calculate Shannon diversity and the Chao1 Index, which 
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summarized within-sample oligotype alpha diversity (number and evenness of oligotypes) and 
richness (number of oligotypes), respectively. Further, we visualized between-sample (beta 
diversity) differences using principal coordinate analysis of the Bray-Curtis dissimilarity index to 
provide a comparable index with other microbiome analyses and of the Morisita index, given its 
adequate performance with low sample sizes.54  
Microbiota sequencing data are compositional; the total number of sequences from each 
sample is bound by an arbitrary depth of sequencing coverage that does not reflect the true 
abundance of bacteria in the participant’s gut.55 Thus, taxa comparisons between samples must 
be analyzed on the relative (not absolute) scale.55 Failure to analyze these data as compositional 
results in spurious correlations between taxa and biases associations of taxa abundance with 
other taxa and covariates.55 We therefore applied two analytic approaches to compare taxa 
distributions by covariates of interest that accounted for the compositional nature of the data: 
Dirichlet multinomial mixture modeling and ALDEx2.56–59  
 
4.4.6.2 De Novo and Reference-Based Enterotyping 
Enterotyping (broadly: community typing methods) distill highly dimensional microbiota 
taxa data into clusters (i.e. groups of samples exhibiting similar taxa distributions) by leveraging 
the information from the covariance structure of taxa.30,57,60 The high dimensionality of 
microbiome data (number of taxa) poses a challenge during analysis, as testing for associations 
of single taxa with metadata requires many tests and results can be difficult to interpret without 
acknowledging co-occurring changes in other taxa. Enterotyping addresses these challenges 
through data reduction and summary by clustering samples with similar bacterial profiles into 
groups based on the distribution of taxa in samples.30 
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We applied two clustering approaches that classified each stool sample’s genus-level read 
counts into enterotypes.30,57 First, we used Dirichlet multinomial mixture (DMM) models, an 
extension of latent profile analysis adapted for microbiota data by Holmes et al.57 Like 
traditional latent profile analysis, this technique recovers unobserved (i.e. latent) subgroups 
based on joint distributions of bacterial genera. DMM-based enterotypes were assigned de novo 
(i.e. based on the data and participants included in our study) using data from all 129 samples 
collected during the study to standardize DMM assignments across all samples. We compared 
model fit using the Laplace approximation of negative log models for DMM models with one to 
five enterotypes and chose the number of enterotypes that optimized model fit (i.e. minimized 
the Laplace approximation).57 We then assigned each sample to its most likely enterotype based 
on posterior probabilities of enterotype assignment. All samples used in this analysis had 
posterior probabilities 90% and were therefore all assigned to an enterotype (minimum 
posterior probability: 95.3%). We examined the average relative abundance of all genera and the 
top 20 taxa that were most influential in distinguishing between enterotypes to summarize taxa 
distributions representative of each enterotype.  
Costea et al. recently reviewed the enterotyping literature and suggested the existence of 
three enterotypes in healthy human populations based on their dominant bacterial taxa: 
Bacteroides, Firmicutes, and Prevotella.30 They also created an online reference-based 
enterotyping tool that assigns uploaded samples to one of these three enterotypes.30 This tool 
compares genera relative abundance in uploaded samples to relative abundance from two studies 
of the healthy human gut microbiota, the Human Microbiome Project (HMP) and the 
Metagenomics of the Human Intestinal Tract (MetaHIT) study. It also applies enterotyping 
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methods described by Arumugam et al. (i.e. partitioning around medoid clustering) to assign an 
enterotype based those observed in HMP and MetaHIT.30,60  
We uploaded genus relative abundance data from our study to http://enterotypes.org and 
obtained enterotype assignments and a binary variable indicating whether each sample had 
similar genera to the observed patterns in reference samples from HMP and MetaHIT. Two of 46 
samples were not comparable to reference samples based on this indicator and were therefore 
assigned as “missing” for their assignment.  
 
4.4.7 Analysis: Association of Microbiota with Opioid Use 
4.4.7.1 Diversity and Enterotypes by Opioid Agonist and Antagonist Use 
We compared all microbiota metrics described below by two indicators of opioid use: 
opioid agonist use (binary, yes/no) and combined opioid agonist/antagonist use in four categories 
(agonist only [Ag], agonist+antagonist [AgAt], antagonist only [At], or neither opioid agonist 
nor antagonist [N]). Using appropriate statistical tests for each exposure and outcome, we 
compared 1) opioid agonist use versus no use, 2) Ag vs. N, 3) AgAt vs. N, and 4) At vs. N and 
other pairwise comparisons where relevant. 
We compared alpha diversity metrics (Shannon and Chao1) by opioid use and tested for 
differences using Wilcoxon rank sum tests. We visualized beta diversity metrics as principal 
coordinate analyses. Next, we compared the distribution of de novo enterotypes by opioid use 
variables with Fisher’s exact test. We also described taxa that were influential in assigning 
enterotypes by their average relative abundance patterns and alpha diversity in de novo assigned 
enterotypes We examined the overlap of de novo and reference-based enterotype assignments. 
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4.4.7.2 Genus Differential Abundance by Opioid Agonist and Antagonist Use 
We compared abundance of specific genera by opioid use status and other covariates of 
interest using ALDEx2, an analysis of variance-like tool for compositional data.58 For each 
genus, ALDEx2 inferred absolute abundance given the observed abundance matrix over 1,000 
Monte-Carlo simulations from a Dirichlet distribution. This simulation-based framework was 
meant to recognize each sample as a single realization from the gut bacterial communities of 
participants. To account for the compositional structure of the data, genera abundances for each 
sample and simulation were transformed to centered log ratios (i.e. log of the ratio of taxai 
abundance for sample j divided by the geometric mean for the abundance of all taxa [i=1:K ] in 
sample j). ALDEx2 then calculated each genera’s median centered log ratio by group (e.g. opioid 
agonist use vs. no use) for each simulation. Within-group variability in each taxa’s log ratios 
reflected sampling variation whereas between-group differences represented the biological 
variation of interest (e.g. by opioid use status). These were used to calculate an effect size for 
each genus as the median difference in centered log ratios between groups across all simulations 
divided by the median of the largest detected difference within groups for each condition (e.g. 
the median of two items: 1) the largest difference in centered log ratios for taxai among opioid 
agonist use group across 1,000 simulations and 2) the largest difference in centered log ratios for 
taxai among people not using opioid agonists across 1,000 simulations). Statistical significance 
for each effect size was summarized as a p-value corrected for the false discovery rate (FDR) 
using the Benjamini-Hochberg procedure. We summarized genera relative abundance for all 
samples as bar charts for taxa with FDR corrected p-values<0.05 identified from the ALDEx2 
Wilcoxon rank sum test. 
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4.4.7.3 Alcohol and Dietary Fiber 
We examined how dietary fiber intake and past 30-day alcohol use varied by both 
microbiota characteristics (diversity, enterotypes, and genera differential abundance) and opioid 
use. These variables are explored as potential alternative explanations for our findings around 




4.5.1 Study Sample Characteristics 
The 46 participants were aged a median of 33.5 years; most were male (56.5%), white 
(84.7%), and non-Hispanic (89.1%, Table 4.1). Nine (19.6%) used opioid agonists (Figure 4.1). 
Five used opioid agonists only (heroin or prescription opioids, Ag), four used agonists and 
antagonists (AgAt, three buprenorphine+naloxone and one prescription opioids and naltrexone). 
Among the 37 who were unexposed to an opioid agonist, 6 used naltrexone, an opioid antagonist 
(At), and 31 were exposed to neither opioid agonists nor antagonists (N).  
Participants using both opioid agonists and antagonists reported receiving treatment at this 
facility for longer periods of time compared with other participants. Depression, anxiety, and 
craving scores were higher in the Ag group compared to others. Antibiotic use was uncommon 
but one participant was exposed to antibiotics during the week of stool sampling. Fiber intake 
and alcohol use are further discussed below. 
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4.5.2 Opioid Agonists Were Associated with Decreased Gut Microbiota Alpha Diversity 
We used the Wilcoxon Rank Sum test to compare species diversity (Shannon Index) and 
richness (Chao1 Index) between opioid agonist vs. no agonist groups and by agonist/antagonist 
combination groups (Figure 4.2). Diversity metrics were, on average, lower in participants who 
used any opioid agonist vs. those who did not use opioid agonists but differences did not reach 
statistical significance (Shannon diversity p=0.055, Chao1 p=0.059). However, diversity 
(p=0.04) and richness (p=0.02) were significantly lower among Ag vs. N individuals. While we 
noted similar patterns between the Ag vs. At groups, differences in Shannon diversity (p=0.08) 
and richness (p=0.13) did not reach statistical significance. We found no statistically different 
differences in diversity or richness between any other groups (all p>0.19). Plots of principal 
coordinates from calculation of two beta diversity metrics (Bray-Curtis and Morisita) showed 
some evidence for clustering in the Ag group (Figure 4.3). However, we avoided further 
statistical testing for differences given the lack of strong clustering by group and small sample 
size.  
 
4.5.3 De Novo Assigned Enterotypes Differed by Opioid Agonist Use 
Fit indices clearly favored a three enterotype model using de novo clustering with DMM 
models (Figure 4.4). Mean relative abundance distributions from samples clustered into each 
enterotype identified two Bacteroides dominated groups and a third dominated by Prevotella 
(23.9% of participants, n=11, Figure 4.5). Prevotella and Bacteroides were also the two most 
influential taxa in assigning enterotypes. Among the 35 participants with Bacteroides dominated 
groups, 24 were assigned to an enterotype with elevated relative abundance of Faecalibacterium 
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(Bacteroides: Faec.) and 11 were assigned to an enterotype with elevated Clostridium cluster 
XIVa (Bacteroides: Clost.).  
No participants exposed to opioid agonists had the Prevotella enterotype, regardless of 
antagonist use (Figure 4.6). The distribution of enterotypes differed for the Ag and N groups, 
likely reflecting that the Bacteroides: Clost. enterotype was common in the Ag group. The 
Bacteroides: Clost. group had reduced alpha diversity (Figure 4.7, Kruskal Wallis test for 
Shannon diversity p-value<0.00001, Chao1 p-value<0.0001). We did not detect any further 
statistically significant differences in the distribution of enterotypes by other groups (e.g. AgAt 
vs. N and At vs. N). 
 
4.5.4 Enterotypes Were Largely Consistent with those from Healthy Human Populations 
We submitted genera relative abundance for each sample to http://enterotypes.org to 
determine whether our samples had overlapping genera distributions with two studies of healthy 
populations (HMP and MetaHIT) and to obtain reference-based enterotype assignments to one of 
three previously described enterotypes: Bacteroides, Prevotella, or Firmicutes.30 The majority 
(95.7%, 44 of 46 samples) were similar to the genera distributions observed in HMP and 
MetaHIT and therefore able to be assigned to reference-based enterotypes (Table 4.2). Among 
these, all 11 Prevotella samples from the DMM method were assigned the Prevotella reference 
enterotype. Nearly all (91.7%, 22 of 24 samples) of the samples assigned to the Bacteroides: 
Faec. enterotype from DMM were assigned to the Bacteroides reference enterotype. The 
remaining were assigned Prevotella. Fewer of the Bacteroides: Clost. samples were assigned to 
the Bacteroides reference enterotype (81.8%, 9 of 11 samples) and the remaining two samples 
were unable to be assigned as the algorithm determined that they were outside of the sample 
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space of enterotypes observed in HMP and MetaHIT. The two methods agreed that the majority 
of samples were Bacteroides enterotype(s); 11 or 13 of 46 samples were assigned Prevotella 
depending on the method used. Regardless of method, the Prevotella enterotype never included 
participants who used opioid agonists, even with concurrent antagonist use.  
 
4.5.5 Opioid Agonist Use was Related to Specific Genera  
We used ALDEx2 to compare genera abundance by opioid agonist (vs. no agonist) and 
between agonist/antagonist combination groups while accounting for the compositional data 
structure and adjusting for multiple comparisons (i.e. 77 genera tested) using the FDR. Roseburia 
abundance was reduced (FDR p-value: 0.017) and Clostridium cluster XIVa (FDR p-value: 
0.045) abundance was increased in samples from participants who used opioid agonists (vs. no 
agonist use). We identified nine differentially abundant genera between Ag and N participants 
(Figure 4.8). Unclassified Enterobacteriaceae (FDR p-value: 0.026), Lactobacillus (FDR p-
value: 0.031), Clostridium cluster XIVa (FDR p-value: 0.033), Faecalicoccus (FDR p-value: 
0.037), Anaerostipes (FDR p-value: 0.040), and Streptococcus (FDR p-value: 0.045) abundances 
were higher in Ag vs. N participants while unclassified Firmicutes (FDR p-value: 0.031), 
Bilophila (FDR p-value: 0.037), and Roseburia (FDR p-value: 0.043) were less abundant in Ag 
vs. N participants. We found no statistically significant differences between other opioid 
agonist/antagonist groups. 
 
4.5.6 Fiber Intake and Alcohol 
Nearly all participants used alcohol in the 30 days before the substance use survey (Table 
4.1). Alcohol use prevalence was lower among Ag participants (60%) but there were no 
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statistically significant differences between opioid agonist exposure (Fisher exact p-value=0.68) 
or Ag and N groups (p=0.60). Shannon diversity was marginally lower among participants with 
no alcohol use (Wilcoxon rank sum p=0.052, Figure 4.9). Visually, the Bacteroides: Faec 
enterotype was more common in people who used alcohol in the past 30 days (Fisher exact p-
value=0.11, Figure 4.10). Using ALDEx2, we were unable to identify any taxa that were 
statistically significantly associated with alcohol use in this sample of participants (all FDR 
Wilcoxon rank sum p>0.12). 
Average fiber intake was lowest among the Ag group but there were no statistically 
significant differences by opioid agonist exposure (Wilcoxon rank sum p-value=0.81) or between 
Ag and N groups (p=0.32, Table 4.1). Gut microbiota richness was positively and linearly 
associated with fiber intake (Pearson correlation: 0.41, p=0.005, Figure 4.9).  Although there 
were visual differences in fiber consumption by de novo assigned enterotypes, they did not reach 
statistical significance (Kruskal Wallis p-value=0.12, Figure 4.10). We used ALDEx2 with a 
four-level categorical variable formed from quartiles of fiber intake among participants. No 
genera were statistically significantly associated with fiber intake; however, we found marginally 
significant associations with Collinsella (FDR Kruskal Wallis FDR p-value=0.051) and 




In our pilot study of 46 individuals receiving SUD treatment, exposure to opioid agonists 
was associated with variations in the human gut microbiota. Consistent with results from a 
murine model by Wang et al., we observed decreased alpha diversity among participants 
 139 
exposed to opioid agonists only (Ag) vs. neither agonist nor antagonist (N) exposed 
participants.16 Opioid agonist exposure was also associated with Bacterioides enterotypes and 
variations to several bacterial genera, whose metabolic and functional roles are discussed below. 
While decreased alpha diversity was associated with opioid agonist exposure in our study 
and in a murine model, Xu et al. found that alpha diversity was higher among participants with 
SUDs relative to healthy controls.16,29 These conflicting results may be explained by differences 
in study design.29 We recruited a sample of participants who all had SUDs to help control for 
lifestyle and dietary factors associated with being in recovery from addiction and so that all 
participants compared had the possibility for an opioid antagonist prescription. However, Xu et 
al. compared 45 Chinese men with SUDs to and 48 Chinese men without SUDs and did not 
evaluate antagonist exposure.29  
Participants exposed to agonists were more likely to have the Bacteroides enterotype with 
higher relative abundance of Clostridium cluster XIVa. This enterotype also had the lowest 
diversity, which was consistent with Costea et al.’s comment that Bacteroides enterotypes are 
generally the least diverse.30 However, in our study, a second Bacteroides enterotype appeared to 
have similar diversity to the Prevotella enterotype.  
No participants exposed to opioid agonists, including those with concurrent antagonist 
exposure, had the Prevotella enterotype. Prevotella has previously been associated with a fiber-
rich diet.30 As such, this association could reflect the lower fiber consumption among the opioid 
agonist only (Ag) group, or could reflect underlying processes common to both low fiber diets 
and opioid agonist exposure, including slowed transit time, constipation, and reduced stool water 
content.19,42,43 Given our study design, we were unable to disentangle the effects of fiber and 
opioid agonist exposure and our data supported a positive association between fiber and gut 
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microbiota richness. However, we also observed consistent associations between opioid agonist 
exposure and three aspects of the gut microbiota (diversity, enterotypes, and genera relative 
abundance). Murine models suggest that the impacts of low fiber diet and opioid agonist 
exposure differ.18 In particular, Banerjee et al. showed that the gut barrier compromise and 
bacterial translocation observed in morphine exposed mice were not observed in mice 
constipated due to a low fiber diet.18 Future studies will need to further differentiate the impacts 
of fiber and opioids on the gut microbiota in humans. We did not detect the Firmicutes 
enterotype among study participants; however, we cannot determine whether this was a true 
absence in our population or a reflection of sampling variability and random error. The 
Firmicutes enterotype has the highest alpha diversity of the three known enterotypes, and is 
associated with low inflammation, making its complete absence from our study population an 
interesting finding worth further research.30,61  
We also observed differences in the relative abundance of several bacterial genera by 
opioid agonist exposure, including decreased Roseburia and Bilophila and increased Clostridium 
cluster XIVa, Lactobacillus, Faecalicoccus, Streptococcus, and Anaerostipes. Roseburia 
abundance was decreased among the opioid agonist group, with or without concurrent antagonist 
exposure. Species in this genus produce butyrate, a short chain fatty acid associated with colon 
health.62 Butyrate’s beneficial properties include reduced inflammation, the reduction of colon 
oxidative stress, and improvement of gut barrier health.62 Interestingly, this genus is considered 
part of the Clostridium XIVa cluster, a functionally related group of bacteria that spans many 
genera. Seemingly contrary then, is the association of increased Clostridium XIVa cluster 
abundance with opioid agonist use. A search of the Ribosomal Database Project, the 
phylogenetic reference assignment tool used in this study, suggested that Roseburia and 
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Clostridium XIVa were distinct genera for the purposes of taxa assignment and that the 
Clostridium XIVa genera assigned corresponds to three Clostridium species of unknown butyrate 
production status, rather than a reflection of the full breadth of the Clostridium XIVa 
cluster.53,63,64 Wang et al. observed an increase in the relative abundance of Clostridium in mice 
exposed to morphine relative to placebo; however, we are unable to determine whether the 
species detected in their study are the same as those detected in our study due to limitations of 
current species identification capabilities from 16S rRNA sequencing.16  
The association of opioid agonist exposure with Bilophila relative abundance may relate to 
a disruption in bile acid metabolism observed in morphine exposed mice.18,19 Decreases in 
Bilophila, a bacterial genera known to use bile as a nutrient source, may correlate with the 
reduced intestinal primary and secondary bile acid levels observed in morphine exposed mice.18 
Reductions in bile acid levels were accompanied by gut microbiota changes, gut barrier 
disruption and systemic inflammation.18 The temporal sequence of metabolic and inflammatory 
changes occurring after morphine exposure and their relationship to the gut microbiota have not 
yet been determined.18,65 Interestingly, reductions in Bilophila abundance were also observed in 
inflamed intestinal samples from ulcerative colitis patients and in the gut microbiota of people 
with autism spectrum disorders vs. healthy controls.66,67  
The remaining bacteria that were differentially abundant in participants exposed to opioid 
agonists are less well described. Faecalicoccus, a rare taxa in our study (<1.4% abundance 
across all participants), was elevated in three of five participants in the opioid agonist group. 
Faecalicoccus is largely undescribed in the literature, but is known to produce moderate amounts 
of butyrate.68 Graphically, the associations detected among Anaerostipes, Streptococcus, and 
Lactobacillus were difficult to interpret and may have been overly influenced by outliers. As 
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such, we reserve discussion of these genera and point to them as genera that could be explored in 
future work. Overall, the differential abundances we observed may reflect differences in bacterial 
metabolism associated with opioid agonist exposure, and could be directions for study in future, 
larger studies. 
We also identified that microbiota diversity, enterotypes, and taxa were similar for 
participants with combined agonist and antagonist (AgAt) exposure, antagonist only exposure 
(At), and neither agonist nor antagonist exposure (N). To our knowledge, these similarities have 
not been previously described in a human study and they align with the observed antagonism of 
morphine’s effects by naltrexone in mice.16 Taken together, these results suggest that 
combinations of agonists and antagonists may have benefits beyond their intended application 
(e.g., naloxone reducing the abuse potential and risk of overdose from the buprenorphine portion 
of the combination product). These benefits may include those observed in other applications of 
naltrexone, including its use as a laxative for opioid induced constipation, its potential promotion 
of gut mucosal healing in Crohn’s disease, and its anti-inflammatory applications for treating 
chronic pain.21–26 It is important to note that the mechanisms of naltrexone’s action in Crohn’s 
disease are the subject of some debate, and that the formulations for use in these applications 
differ from those used for craving management in alcohol and OUDs.24,26 However, these 
applications suggest the possibility that naltrexone improves gut barrier function and this action 





This study was limited by the small sample size (n=46), especially the small number of 
agonist and antagonist exposed individuals. Despite this, we found several biologically plausible 
associations that deserve follow-up in larger studies. We were not able to adjust for confounding 
(e.g., by fiber or alcohol use) given our small sample size, and instead presented descriptive 
statistics that showed the potential extent of confounding by fiber and alcohol use. Larger studies 
will need to evaluate the potential for confounding further. We did not include healthy controls, 
but we compared our samples to two large studies to determine whether our samples were in the 
sample space observed in healthy human gut microbiota studies. While it is encouraging that our 
samples were within the sample space of HMP and MetaHIT, we must acknowledge that 
differences in sample collection, processing, and sequencing, and differences in target 
populations limit inferences that might be made from this comparison.  
Nearly all measures were self-reported (except prescriptions for naltrexone or 
buprenorphine+naloxone that were identified through medical record review) and are therefore 
subject to recall bias. We had missing data on two important variables, including one dietary 
measure quantifying cheese intake, which we imputed (Appendix 4.1), and self-reported 
buprenorphine or methadone use in the past 30 days, which we were able to gather through a 
medical record review. Nonetheless, this process could have introduced bias into our results.  
Several participants were lost to follow-up after consenting for the first substance use 
survey, and five did not submit stool samples after consenting for the microbiota study. This 
opens the potential for selection bias if participants who dropped out had more severe substance 
use disorders or systematically differed from retained participants in some other way. We 
qualitatively observed that increased hardness of stool samples among participants using opioids 
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made these samples more difficult to homogenize in RNAlaterTM but did not measure stool 
consistency or hardness. We expect that participants who used opioid agonists had harder stool 
and slowed transit time, but are unable to comment on how stool hardness and transit time affect 
the variation observed in the non-opioid agonist groups. Nonetheless, the strong biological 
plausibility of the present findings suggest that they are worthwhile to explore further and 
validate using other more comprehensive methods. 
Our study had several offsetting strengths. Methodologically, previous studies did not 
describe enterotypes or evaluate associations of microbial taxa with opioid exposure using 
analytic tools appropriate for compositional data, and therefore previous findings may include 
spurious or biased associations.55 We were able to evaluate the impact of two factors that could 
alternatively explain the associations observed between the microbiota and opioids, which were 
alcohol and dietary fiber. Neither exhibited as strong a relationship as the results for opioids, 
pointing to opioids as a future direction for further research, yet still highlighting the importance 
of measuring these potential confounders. 
 
4.6.1.2 Conclusions 
Individuals exposed to opioid agonists had differences in gut microbiota diversity, 
enterotypes, and bacterial genera compared to individuals who used neither an agonist nor 
antagonist. We observed decreased diversity and richness, an absence of the Prevotella 
enterotype, and decreases in Roseburia, a butyrate producer, and Bilophila, which may reflect 
the bile acid dysregulation observed in murine models of morphine dependence.18,19 Individuals 
who concurrently used an opioid agonist and antagonist, and individuals who only used 
naltrexone, an opioid antagonist, did not differ in gut microbiota diversity, richness, or genera 
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relative abundance compared to individuals who used neither an agonist nor antagonist. These 
findings suggest that the effects of opioids on the gut microbiota might be antagonized by 
naltrexone or naloxone. Overall, this study supports conducting future work that further 
characterizes the relationships between opioid agonist and antagonist exposure, gut permeability, 
inflammation, and relapse predictors to inform whether psycho-adjunctive treatments for opioid 
and alcohol use disorders could improve addiction treatment outcomes. 
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Figure 4.1 Inclusion Criteria and Opioid Use among 46 Participants Enrolled from an Outpatient 
Addiction Treatment Facility into a Study of the Gut Microbiota and Opioid Use, 2016-2017 
 
We included 46 participants who were eligible and provided informed consent for both study 
stages and provided stool samples in the present analysis. Among the 9 using opioids, 5 used 
only agonists (prescription opioids and heroin) and 4 used an agonist and antagonist combination 
during the time their sample was provided. Among the 37 not using opioids, 6 used an opioid 
antagonist and 31 were exposed to neither opioid agonists nor antagonists during the time they 
provided their stool sample. 
• 5 lost to follow-up or declined to participate after consent
• 4 did not attend Part II enrollment appointment
• 2 stopped treatment
• 3 were unable to return for study enrollment
• 5 declined to participate
• 27 participants ineligible 
• aged >60 years and/or no past 30 day substance use
• 32 did not complete survey
• Outpatient addiction treatment patient
• Aged ≥18 years
• Provided informed consent
Completed Substance Use Survey 
(n=92)
Eligible for Microbiota Study 
(n=65)
Provided stool sample 
(n=46)
Consented for Substance Use 
Survey (n=124)







• 3 prescription opioids
• 2 heroin
Agonist + Antagonist (n=4)
• 3 buprenorphine + 
naloxone




No Agonists or Antagonists
(n=31)
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Table 4.1 Characteristics of 46 Participants Enrolled from an Outpatient Addiction Treatment Facility into a Study of the Gut 












Total 46 (100) 5 (100) 4 (100) 6 (100) 31 (100) 
Age, Median (IQR) 33.5 (26.3-47.5) 38 (31-46) 27.5 (23.5-35.8) 34 (27.5-44.3) 36 (25.5-48) 
Gender      
Female 26 (41.3) 1 (20.0) 2 (50.0) 1 (16.7) 15 (48.4) 
Male 19 (56.5) 4 (80.0) 2 (50.0) 5 (83.3) 15 (48.4) 
Other 1 (2.2) 0 (0) 0 (0) 0 (0) 1 (3.2) 
Race      
Black 2 (4.3) 0 (0) 0 (0) 0 (0) 2 (6.5) 
White 39 (84.7) 3 (60.0) 4 (100.0) 5 (83.3) 27 (87.1) 
Multiple Races 2 (4.3) 1 (20.0) 0 (0) 0 (0) 1 (3.2) 
Other 3 (6.5) 1 (20.0) 0 (0) 1 (16.7) 1 (3.2) 
Hispanic ethnicity 5 (10.9) 1 (20.0) 0 (0) 1 (16.7) 3 (9.7) 
Used alcohola 34 (73.9) 3 (60.0) 3 (75.0) 5 (83.3) 23 (74.2) 
Antibiotic use 1 (2.2) 0 (0) 1 (25.0) 0 (0) 0 (0) 
Days in Treatment, Median (IQR) 34 (5-74) 12 (3-1,171) 549 (123-949) 23 (6-53) 19 (6-67) 
Fiber (grams/day), Median (IQR)b 15.7 (14.1-18.4) 13.5 (12.7-17.0) 17.9 (14.9-19.0) 16.9 (13.2-18.3) 15.6 (14.3-17.7) 
Depression Score, Median (IQR)c 9.5 (6.0-12.8) 13 (12-18) 7 (6.5-8.8) 9 (6.3-11) 9 (5.5-11.5) 
Anxiety Score, Median (IQR)d 8 (4-10) 13 (9-14) 4.5 (1.5-8) 8 (7-9.8) 7 (3-9.5) 
Craving Score, Median (IQR)e 9 (5-16) 16 (9-19) 5.5 (6.5-13) 12 (6.8-17.3) 8.5 (5-13.8) 
aParticipants self-reported alcohol use in the 30 days before the substance use survey (before enrolling in the microbiota study).  
bFiber intake data were available for 45 of 46 participants (30 of 31 participants who used neither opioid agonists nor antagonists). 
cScore from the Patient Health Questionnaire (PHQ)-9 (range: 0-27). 
dScore from the Generalized Anxiety Disorder 7-Item scale (range: 0-21). 
eScore from the modified Penn Craving Scale (range: 0-30). Data were available for 45 of 46 participants (30 of 31 participants who 
used neither opioid agonists not antagonists).  
Abbreviations: Ag: Opioid agonist only (heroin [n=2] or prescription opioid [n=3]), AgAt: Opioid agonist+antagonist use 
(buprenorphine+naloxone [n=3] or prescription opioids+naltrexone [n=1]), At: Opioid antagonist use only (naltrexone [n=6]), N: 
Neither opioid agonist nor antagonist use (n=31), IQR: interquartile range. 
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Figure 4.2 Gut Microbiota Alpha Diversity among 46 Participants Enrolled from an Outpatient Addiction Treatment Facility by 
Opioid Agonist and Antagonist Use, 2016-2017 
 
We compared alpha diversity between opioid agonist vs. no agonist groups and between groups using agonists and antagonists versus 
no use (N) using two metrics. Ag participants had lower diversity compared to N for both Shannon diversity (Wilcoxon rank sum 
p=0.04) and richness (Chao1 index, p=0.02). No other groups statistically differed, including AgAt vs. N and At vs. N.
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Figure 4.3 Gut Microbiota Beta Diversity among 46 Participants Enrolled from an Outpatient Addiction Treatment Facility by Opioid 
Agonist and Antagonist Use, 2016-2017 
 
We summarized two beta diversity metrics, Bray-Curtis Distance and the Morisita Index, using a principal components analysis. We 
observed some clustering of the Ag group using Bray-Curtis. Strong clustering was not observed by opioid agonist-antagonist groups 
using the Morisita index. For this reason, we avoided further statistical testing. 
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Figure 4.4 Dirichlet Multinomial Mixture Model Fit (Laplace Approximation) for Models with 
1-5 Enterotypes 
 
We fit Dirichlet multinomial mixture models with one to five enterotypes. Model fit was 
optimized by a three enterotype model given the minimization of the Laplace approximation, a 
measure of model fit. 
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Figure 4.5 Enterotypes Recovered from De Novo Clustering of Gut Microbiota Samples among 
46 Participants Enrolled from an Outpatient Addiction Treatment Facility, 2016-2017 
 
The relative abundance of the top 20 genera that were most informative in partitioning samples 
into three enterotypes accounted for >70% of sequencing reads (top). We identified two 
Bacteroides enterotypes, one with increased Faecalibacterium and a second with increased 
Clostridium cluster XIVa. The third enterotype was dominated by Prevotella. Twenty-four 
participants assigned to the Bacteroides: Faec. enterotype had higher Faecalibacterium (mean 
Faecalibacterium relative abundance of 8.9% Bacteroides: Faec., 2.1% Bacteroides: Clost., 
7.2% of Prevotella). Faecalibacterium was the third most influential genera in assigning 
enterotypes. Eleven participants assigned to the Bacteroides: Clost. enterotype had higher 
Clostridium cluster XIVa (mean Clostridium cluster XIVa relative abundance of 4.0% 
Bacteroides: Clost., 0.86% Bacteroides: Faec., and 0.63% Prevotella enterotype). Clostridium 
cluster XIVa was the fifth most influential genera in assigning enterotypes. The fourth most 
influential genera in assigning enterotypes was Blautia, which distinguished the Prevotella and 
two Bacteroides enterotypes (mean Blautia relative abundance of 8.5% Bacteroides: Faec., 8.6% 
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Figure 4.6 De Novo Assigned Gut Microbiota Enterotypes among 46 Participants Enrolled from an Outpatient Addiction Treatment 
Facility by Opioid Agonist and Antagonist Use, 2016-2017 
 
The prevalence of three enterotypes identified through Dirichlet multinomial mixture modeling differed by opioid agonist-antagonist 
exposure groups. No individuals who used opioid agonists had the Prevotella enterotype and 4 of 5 participants who used only opioid 
agonists (Ag) had a Bacteroides enterotype with elevated Clostridium cluster XIVa. The distribution of enterotypes differed by opioid 
agonists vs. no agonists (Fisher exact p-value=0.0036) and between the agonist only group (Ag) vs. the group that used neither opioid 
agonists nor antagonists (N, Fisher exact p-value=0.0060). 
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Figure 4.7 Alpha Diversity in De Novo Assigned Gut Microbiota Enterotypes among 46 Participants Enrolled from an Outpatient 
Addiction Treatment Facility by Opioid Agonist and Antagonist Use, 2016-2017 
 
We used Dirichlet multinomial mixture modeling to identify three enterotypes. A hallmark feature of the Bacteroides: Clost. group 
was reduced alpha diversity by both the Shannon diversity (Kruskal Wallis p-value<0.00001) and Chao1 (Kruskal Wallis p-
value<0.0001) metrics. We did not detect any statistically significant differences in the distribution of enterotypes by other groups 
(e.g. AgAt vs. N and At vs. N).
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Table 4.2 Reference-Based and De Novo Enterotype Assignments among 46 Participants Enrolled from an Outpatient Addiction 
Treatment Facility, 2016-2017 
 De Novo Assigned Enterotypes (Method: DMM)  
Reference-Based Enterotypes 
(Method: PAM) 








Bacteroides 22 (91.7) 9 (81.8) 0 (0) 31 (67.4) 
Firmicutes 0 (0) 0 (0) 0 (0) 0 (0) 
Prevotella 2 (8.3) 0 (0) 11 (100) 13 (28.3) 
Unable to be assigned 0 (0) 2 (18.2) 0 (0) 2 (4.3) 
Total 24 (100) 11 (100) 11 (100) 46 (100) 
Abbreviations: DMM: Dirichlet multinomial mixture model, PAM: Partitioning around medoid clustering, n: number.
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Figure 4.8 Genera Selected by ALDEx2 as Differentially Abundant by Opioid Use among 46 
Participants Enrolled from an Outpatient Addiction Treatment Facility, 2016-2017 
 
We used ALDEx2 to identify nine genera that were differentially abundant between participants 
who used opioid agonists (Ag) vs. participants who used neither agonists nor antagonists (N) 
using a false discovery rate (FDR) corrected p-value<0.05 threshold for the Wilcoxon rank sum 
test. Unclassified Enterobacteriaceae (FDR p-value: 0.026), Lactobacillus (FDR p-value: 0.031), 
Clostridium cluster XIVa (FDR p-value: 0.033), Faecalicoccus (FDR p-value: 0.037), 
Anaerostipes (FDR p-value: 0.040), and Streptococcus (FDR p-value: 0.045) abundances were 
higher in Ag vs. N participants while unclassified Firmicutes (FDR p-value: 0.031), Bilophila 
(FDR p-value: 0.037), and Roseburia (FDR p-value: 0.043) were less abundant in Ag vs. N 
participants. We found no statistically significant taxa abundance differences between other 
opioid agonist/antagonist groups. *Taxa were also differentially abundant in a comparison of 
opioid agonists (Ag or AgAt) vs. no agonist (At or N) use. 
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Figure 4.9 Gut Microbiota Alpha Diversity by Alcohol Use and Fiber Intake among 46 
Participants Enrolled from an Outpatient Addiction Treatment, 2016-2017 
 
We compared alpha diversity using the Shannon diversity and Chao1 metrics by past 30-day 
alcohol use (top) and dietary fiber (bottom). Shannon diversity was marginally lower among 
participants who did not use alcohol in the past 30 days (Wilcoxon rank sum p=0.052). Gut 
microbiota richness was positively associated with fiber intake and the Pearson correlation (0.41) 
between richness and fiber intake reached statistical significance (p=0.005).
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Figure 4.10 De Novo Assigned Enterotypes by Alcohol Use and Dietary Fiber Intake among 46 
Participants Enrolled from an Outpatient Addiction Treatment Facility, 2016-2017 
 
We examined whether enterotype prevalence differed by past 30-day alcohol use (top) or dietary 
fiber consumption (bottom). The Bacteroides: Faec enterotype was more common in people who 
used alcohol in the past 30 days (Fisher exact p-value=0.11). Bacteroides: Clost had the lowest 
median fiber intake (Kruskal Wallis p-value=0.12). 
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Appendix 4.1. Supplementary Methods 
 
 
Dietary Fiber Intake Estimation 
 
Upon enrollment in the microbiota study, participants completed a validated food 
frequency questionnaire about general past month intake of 25 food and drink items.69 Due to a 
skipped question on the survey, participants did not report their cheese intake. We therefore 
assigned participants the survey weighted mean values of cheese intake using age and race-
specific values from the 2009-2010 cycle of the National Health and Nutrition Examination 
Survey (NHANES), which included the food frequency questionnaire used in our study. We did 
not use sex-specific values as cheese intake did not differ by sex in NHANES. We calculated 
predicted past month dietary fiber intake (predicted grams per day) from reported dietary item 
intake and validated predictive models developed from the National Health and Nutrition 
Examination Survey.40 
 
DNA Extraction and Illumina MiSeq Sequencing 
After all participants were enrolled, we thawed a 1 mL aliquot of each stool sample, 
centrifuged at 10,000xg, and resuspended in 1 mL 1X phosphate buffered saline (Gibco, Thermo 
Fisher Scientific, Waltham, MA, pH 7.4). We added 250 uL resuspended stool to each of two 
wells of bead beating plates and provided samples to the Microbial Systems Molecular Biology 
Laboratory at the University of Michigan. They used standard protocols for deoxyribonucleic 
acid (DNA) extraction and Illumina MiSeq sequencing of the V4 hypervariable region of the 
bacterial 16S ribosomal ribonucleic acid (rRNA) gene.47–49  
 First, DNA was extracted using the Qiagen MagAttract PowerMicrobiome kit (Qiagen, 
Hilden, Germany). DNA libraries for the V4 region of the 16S rRNA gene were generated and 
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16S DNA was amplified using polymerase chain reaction (PCR) and barcoded dual-index 
primers for the V4 hypervariable region.49 Reactions included 5 uL of 4 uM equimolar primer 
set, 0.15 uL AccuPrime Taq DNA High Fidelity Polymerase, 2 uL 10X AccuPrime PCR Buffer 
II (Thermo Fisher Scientific), 11.85 uL PCR-grade water, and 1 uL DNA and used the following 
cycling conditions: 2 min at 95°C, 30 cycles of 95°C for 20 s, 55°C for 15 s, and 72°C for 5 min, 
and finally 72°C for 10 min. PCR reactions were normalized, pooled, and quantified. The pooled 
amplicon library was sequenced using Illumina MiSeq with the 500 cycle MiSeq V2 Reagent kit 
(Illumina, San Diego, CA) with modifications to the primer set (custom read 1/read 2 and index 
primers were added to the reagent cartridge). Two types of mock communities were included 
with samples to assess sequencing error rates. Mocks included a community of 10 species (added 
as bacterial DNA, Zymo Research, Irvine CA, catalog no. D6300) and a mock community of two 
species added as suspended overnight cell culture in brain heart infusion broth (equal ratios of 
Escherichia coli and Staphylococcus aureus). All samples were sequenced in duplicate and 
mocks were sequenced on each of four DNA extraction plates. 
We processed sequencing reads using mothur (v1.39.5) and the MiSeq standard operating 
procedure (https://www.mothur.org/wiki/MiSeq_SOP, accessed November 8, 2017) to perform 
quality filtering and align sequences to the V4 region of the 16S rRNA gene.49 We converted 
sequences to the format required for oligotyping and clustered samples into oligotypes using the 
procedures and default parameters described by Eren et al.50,52 Oligotyping uses minimum 
entropy decomposition methods to identify highly variable nucleotide positions and clusters 
sequences based on Shannon entropy.50 Compared with operational taxonomic units, an 
alternative way to cluster sequences based on distance-based metrics, oligotyping improves 
identification of taxa at the species or strain level.50  
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Two samples with fewer than 1,000 reads were removed from further analysis; however, 
we were able to retain these two participants for analysis using their duplicate sequenced sample. 
We verified that all mock communities resembled their known compositions (data not shown) 
and summed duplicate sequenced samples. For this analysis, we examined the first sample 
submitted per participant, amounting to 46 samples with 2,207,827 sequence reads (21,796 – 
77,013 reads per participant) and 354 oligotypes. We assigned oligotype taxonomy using the 
Ribosomal Database Project (release 11, update 5).53 We chose to focus on the first sequenced 
sample per participant after observing little change to taxa diversity, relative abundance and 
other microbiota characteristics during the month-long period of study (further described below). 
 
Gut Microbiota Diversity Among 129 Samples Collected over a 1 Month Follow-Up Period 
from 46 Participants Enrolled from an Outpatient Addiction Treatment Facility 
 
We examined microbiota diversity among 129 samples collected in our study (up to 3 per 
participant over a maximum of 1 month study enrollment). As shown in Figure 4.11, we found 
that sample replicates clustered strongly by participant using the Bray-Curtis distance metric, a 
measure of beta diversity. We also found little difference in alpha diversity over time (Figure 
4.12). Stool sample relative abundance and enterotypes also changed minimally during the study 
period (data not shown). These findings supported the restriction applied for the present analysis 
to the first sample received per participant. Below we include plots of microbiota diversity by 
participant and study visit. Note that study visit indicates the sample number (1-3). Participant 
identification numbers are withheld to maintain participant confidentiality.
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Figure 4.11 Principal Coordinate Analysis of Bray-Curtis Distances by Participant and Study 
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Chapter 5 Summary and Conclusions 
 
In this chapter, I review some of my experiences during the PhD, and discuss how both 
my successes and challenges helped me develop independence and embrace interdisciplinary 
research. I end the chapter with a discussion of several avenues for future research. 
 
5.1 A Reflection on My Successes and Challenges 
5.1.1 Learning Methodology Early and Often 
When I interviewed for the PhD program, I expressed an interest in becoming more 
proficient in statistics. To achieve this goal, my advisor suggested that I complete linear algebra 
and multivariable calculus courses before beginning the PhD and take several advanced 
biostatistics courses during my first year of the PhD program. At first, I struggled to make sense 
of this new material and could not see its applications to my research. As I moved through my 
first year, however, my skills improved, my confidence grew, and I developed a new interest in 
learning and applying new methods. These new skills were the foundation that let me learn about 
compositional data analysis and use latent variables across seemingly disparate applications. 
Over the past four years, I’ve learned that it’s important to push myself through those first few 
papers or courses and that the process of digging through the details of a new method is 
something I enjoy.  
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5.1.2 Starting Over 
I completely switched dissertation projects during my second year. It was difficult to admit 
to myself that I needed to make a change and to have the conversations necessary to switch 
projects. However, I found my voice after some encouragement from my mentors, and took a 
few decisive steps to transition my research to an area I had long been interested in: substance 
use and its intersection with infectious disease epidemiology. Switching focus to this area of 
research has kept me motivated, passionate, and productive through these past two years in the 
PhD program. Speaking up and having a few difficult conversations in year two were more than 
worth the discomfort I felt at the time. In addition, watching my mentors handle and embrace this 
situation taught me a lot about my own responsibilities as a mentor in the future. I was only able 
to make a big change because of their support. Mentorship, especially to a PhD student, is not a 
small responsibility.   
 
5.1.3 Meeting New Mentors 
Part of starting over meant that I had to find two new research projects, so I set out to find 
a third mentor with an interest in substance use epidemiology. I was so fortunate to meet Dr. 
Amy Bohnert, who graciously integrated me into her research team in Psychiatry, just a few 
weeks after I had decided to switch gears. My timing in meeting Amy was perfect – she was 
looking for a research assistant to get a microbiota project running and I was looking for data 
collection experience, so I was very motivated to take on this challenge. This experience taught 
me to put myself out there – sending a cold email to a professor I read a newspaper article about 
gave me a new mentor and colleagues and led to a complete change in my dissertation research.  
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5.1.4 Data Collection Challenges 
I was a research assistant on the microbiota study team and was therefore involved with 
study setup, participant recruitment, lab work, data entry and cleaning, and analysis. It was 
incredibly rewarding to see the study grow and I learned so much from interacting with the 
participants and my colleagues in psychiatry. I’m incredibly thankful to have been this involved 
in a project for my dissertation. 
 However, the process of data collection was one of the most laborious tasks during my 
PhD. Going to the clinic to recruit almost every day, and sometimes walking away with no new 
participants, left me feeling like I wasn’t progressing on some days. An additional challenge was 
the process of doing risk assessments for participants with thoughts of self-harm or suicide. 
While I knew our protocols well from the beginning, it took me time to feel comfortable and 
confident about conducting risk assessments while taking whatever steps necessary to make sure 
our participants were safe. I was so lucky to be able to rely on the support of my supervisors in 
Psychiatry, who checked in often and really helped me learn this process.  
Although it took time, collecting data taught me so many valuable lessons about research. 
One of these lessons was about the value of piloting studies. The microbiota study was a pilot, 
but participant recruitment was slow and we had to reduce the planned size of the study after a 
few months. We recruited few participants with opioid use disorders, and later learned that many 
of the clinic’s patients who had opioid use disorders only came to the clinic once per month. In 
addition, patients’ late evening appointments often made it challenging for them to stay even 
later to participate in research. These are exactly the reasons why studies are piloted. Even when 
a study site seems like a good fit and protocols and surveys are developed beforehand, the pilot 
phase provides time to really get a feel for the flow of things before doing a larger study.  
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5.1.5 The Benefits of Interdisciplinary Research 
My dissertation research is spread across a couple of topic areas. I have really enjoyed 
being an interdisciplinary scientist, and often I think about a new way to look at data from one of 
my projects while working on another.  
My best example of this was when I attended a community meeting to learn more about 
opioid overdose in Washtenaw county, Michigan. I was hoping that attending this meeting would 
help me plan the overdose research aims I discuss in chapter two. However, the meeting had a 
speaker, a pharmacologist who outlined the applications of low dose naltrexone for pain 
management (in combination with opioids). She briefly mentioned naltrexone’s potential 
mucosal healing benefits for Crohn’s disease. My mind immediately made a connection to the 
microbiota project (naltrexone is also used to manage cravings among people with alcohol or 
opioid use disorders). I took four pages of notes and tried to reason through this idea for months. 
I was excited when I came across a murine model that supported pursuing this idea further and 
was able to relate the findings from the murine model to our microbiota study in chapter 4.1 It 
was not what I expected from a meeting I attended to learn about overdose but was nonetheless 
influenced my work in an important way.  
 
5.2 Future Directions for Research 
5.2.1 Overdose Education and Naloxone Distribution 
As drug overdoses continue to rise, a major research priority must be to determine who is 
at risk for overdose and who could benefit from overdose education and/or naloxone distribution 
programs.2,3 While investigating questions about overdose in chapter 2, we found additional 
potential avenues for future research with implications for overdose education and naloxone 
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distribution. A subset of people who use prescription opioids initiate heroin, but we do not yet 
know how naloxone knowledge differs for individuals with different opioid use initiation 
patterns.4 Using the dataset I described in chapter two, we observed lower naloxone knowledge 
among people who only used prescription opioids compared to participants who transitioned 
from using prescription opioids to heroin. A deeper exploration of the overdose experiences, 
healthcare interactions that may have influenced how these individuals initiated their opioid use 
(e.g. after experiencing pain and receiving a prescription), and criminal justice system 
interactions could point to missed opportunities for overdose education and/or could support 
prescribing naloxone in the context of pain treatment or upon release from incarceration.  
 
5.2.2 Substance Use Trends 
During chapter 3, I mentioned that we used data from the National Survey on Drug Use 
and Health (NSDUH) to help parametrize the model. During model development, we examined 
time trends for substance abuse and dependence and injection drug use but could not explore 
these trends further for the purposes of model development. An age-period-cohort analysis could 
provide insight into the drivers of prescription opioid, heroin, and injection drug use changes 
over time.  
  
5.2.3 Injection Initiation 
Injection drug use carries several risks beyond other methods of drug use, including 
increased overdose risk and the potential for bloodborne viral infections if syringes are shared.5–7 
The initiation period of injection drug use is a particularly risky period for bloodborne viral 
infections and overdose.8 Only a handful of interventions have been shown to decrease the 
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initiation of injection drug use.9 Some of these interventions encourage people who are 
experienced injecting drugs to refuse when asked to help initiate their less experienced peers.9 In 
the short term, I would like to conduct a meta-analysis to understand the rates of injection drug 
use initiation we used in chapter three for the purposes of model fitting. There are only a few 
studies on this topic and summarizing these would be helpful for future transmission models. In 
the long-term, I hope to develop novel interventions that prevent injection drug use initiation and 
reduce the harms associated with injection drug use among people who inject drugs.   
 
5.2.4 Microbiome and Recovery from Opioid Use Disorders 
We are only beginning to understand how the interactions between our gut, brain, and gut 
microbiota impact psychopathology. Expanding our pilot study to consider the gut microbiota, 
and gut health more generally, as a potential support for recovery from opioid use disorders 
would be a first step. We need further research into how opioid agonists and antagonists interact 
with the gut microbiota, gut permeability, and dietary patterns, and how these factors could 
affect inflammatory markers, neuro-inflammation, mood, cravings, psychopathology, substance 
use behaviors, and other aspects of mental and physical health. Limited research suggests the 
potential that opioid antagonists could mitigate some of the negative impacts of opioid agonists 
on the gut microbiota, but this work needs to be replicated in a larger study of humans and to be 
studied further in murine models.1 Nonetheless, the possibilities for this research are exciting, 
and could have major implications for adjunctive treatments among people who take opioids as 
prescribed, people in recovery from opioid use disorders, and in the context of medication 




In conclusion, this dissertation examined three priorities related to the opioid crisis: 
injury, infection, and recovery. Our results suggest that all participants in justice diversion 
addiction treatment should receive overdose education and be provided naloxone given the high 
prevalence of overdose experience and that only half knew about naloxone’s application as an 
overdose treatment. Further, we found that reductions to hepatitis C prevalence and incidence 
among young people who inject drugs in Michigan could be achieved through HCV treatment, 
and that these reductions could be strengthened by behavioral interventions. Finally, we found 
that opioid agonist exposure was associated with several alterations to the gut microbiota, 
including the promotion of a Bacteroides dominated enterotype, lower microbiota diversity, and 
lower abundance of Roseburia, a genus that produces a short chain fatty acid (butyrate) known to 
promote gut health. Collectively, these findings point to strategies to address three major public 
health priorities associated with the opioid crisis: injury, infection, and recovery.
 176 
5.4 References 
1.   Wang F, Meng J, Zhang L, Johnson T, Chen C, Roy S. Morphine induces changes in the 
gut microbiome and metabolome in a morphine dependence model. Sci Rep. 
2018;8(1):3596. doi:10.1038/s41598-018-21915-8 
2.   Centers for Disease Control and Prevention, National Center for Injury Prevention and 
Control, Division of Unintentional Injury Prevention. Understanding the Epidemic | Drug 
Overdose | CDC Injury Center. https://www.cdc.gov/drugoverdose/epidemic/index.html. 
Published August 30, 2017. Accessed May 22, 2018. 
3.   Lagisetty P, Bohnert A, Fendrick A. Meeting the Opioid Challenge: Getting Naloxone to 
Those who Need it Most. Health Aff Blog. May 2018. 
https://www.healthaffairs.org/do/10.1377/hblog20180510.164285/full/. Accessed May 22, 
2018. 
4.   Muhuri P, Gfroerer J, Davies M. Associations of Nonmedical Pain Reliever Use and 
Initiation of Heroin Use in the United States. CBHSQ Data Rev. 2013:17. 
5.   Bohnert ASB, Roeder K, Ilgen MA. Unintentional overdose and suicide among substance 
users: A review of overlap and risk factors. Drug Alcohol Depend. 2010;110(3):183-192. 
doi:10.1016/j.drugalcdep.2010.03.010 
6.   Martins SS, Sampson L, Cerdá M, Galea S. Worldwide Prevalence and Trends in 
Unintentional Drug Overdose: A Systematic Review of the Literature. Am J Public Health. 
2015;105(11):2373. doi:10.2105/AJPH.2015.302843a 
7.   Centers for Disease Control and Prevention. Viral Hepatitis Surveillance - United States, 
2016. April 2018:75. 
8.   Frank D, Mateu-Gelabert P, Guarino H, et al. High risk and little knowledge: overdose 
experiences and knowledge among young adult nonmedical prescription opioid users. Int J 
Drug Policy. 2015;26(1):84-91. doi:10.1016/j.drugpo.2014.07.013 
9.   Werb D, Bluthenthal RN, Kolla G, et al. Preventing Injection Drug use Initiation: State of 
the Evidence and Opportunities for the Future. J Urban Health. September 2017:1-8. 
doi:10.1007/s11524-017-0192-8 
